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Described herein is the total synthesis of neopeltolide and eleven analogs with modifications to 
its macrolactone and side chain. Preliminary biological assays showed neopeltolide and its 
analogs are not general cytotoxins as demonstrated by notable cell line selectivity. The 
introduction of different polar groups to the macrolactone at C8 and C9 positions is tolerated to 
variable extent, while alternations to the side chain generally lead to significantly diminished 
potency with the exception of using a furan ring to replace the oxazole ring. Experimental data 
also indicated p53 to play an auxiliary role in the potent antiproliferative activity of these 
compounds.  
 
DDQ mediated oxidative C-H bond cleavage has been established as an effective and 
stereoselective method to prepare sulfur containing six- or five- member rings. The moieties for 
generating thiocarbenium ions are unsaturated sulfides including allyl sulfides and preferably 
vinyl sulfides, while the appended nucleophiles include enol acetates, enol carbamates and 
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allylsilanes. Most cyclization reactions rapidly afford sulfur containing heterocycles with high 
stereocontrols and in good to excellent yields under very mild conditions.  
 
Also described herein is an enantioselective addition reaction that employs DDQ-mediated 
carbon-hydrogen bond cleavage. 2H-Chromene can undergo oxidative carbon-hydrogen bond 
cleavage and, in the presence of a chiral Brønsted acid, the resulting acetal intermediate is 
converted to a chiral ion pair that reacts with intermolecular nucleophiles to prepare 
enantiomerically enriched products. While the scope of this process is still very limited, we were 
able to conduct reactions with good enantiocontrol at reasonable catalyst loadings in non-polar 
aromatic solvents. 
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1.  TOTAL SYNTHESIS OF NEOPELTOLIDE AND ANALOGS 
1.1 INTRODUCTION 
1.1.1 Discovery and Biological Activities of Neopeltolide 
Secondary metabolites from marine sponges have been found to be rich sources of structurally 
diverse and biological active compounds largely due to the unique and harsh habitats of the 
sponges.1 Among them, marine macrolides having potent cytotoxic properties are especially 
promising anticancer agents.2 Unfortunately, these macrolides are typically scarce or even no 
longer available. This makes further investigation of their mechanism of action and structure-
activity relationship difficult, and hinders their potential growth into important lead compounds. 
Total synthesis of these macrolides and their analogs are thus indispensable for research in 
cancer research community. 
 
In 2007, Wright and co-workers isolated a new macrolide designated as neopeltolide (1.1) from 
the deep-water sponge Daedalopelta belonging to the family Neopeltidae off the north Jamaican 
coast (Figure 1.1).3 It is a 14-membered macrolide featuring a tri-substituted 2,6-cis-
tetrahydropyran ring and a highly unsaturated oxazole-containing side chain at C5-position, 
which is identical to what was found in leucascandrolide A 1.3.4 However, the structure 1.1 
 2 
originally proposed by Wright based on spectroscopic studies contained several stereochemical 
misassignments,3 which were later corrected to be structure 1.2 by Panek5a and Scheidt5b through 
their independent work in total synthesis.  
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Figure 1.1 Structures of neopeltolide and leucascandrolide A. 
 
Neopeltolide was found to be an extremely potent toxin against a series of tumor cell lines, 
including P388 murine leukemia, A-549 human lung adenocarcinoma, and NCI-ADR-RES 
(formerly MCF7/ADR) human ovarian sarcoma (IC50 values of 0.56, 1.2, and 5.1 nM, 
respectively).3 For PANC-1 pancreatic and DLD-1 colorectal cell lines, neopeltolide also showed 
strong inhibitory effects but with only 50% cell death over an extended dose range, suggesting a 
cytostatic effect on these two cell lines. Additionally, neopeltolide is a potent inhibitor of the 
fungal pathogen Candida albicans (MIC value of 0.625 µg/mL in liquid culture), which often 
poses a severe threat to the health of AIDS patients. In comparison, the structurally more 
complex leucascandrolide A showed sub-micro molar inhibitory potency on P388 murine 
leukemia (IC50 value of 0.35 µM) and comparable potency on A549 cells and Candida albicans.4  
 
The structural overlap and similar biological activities between neopeltolide and 
leucascandrolide suggest the possibility that a common mechanism is responsible for the 
 3 
inhibition of cellular proliferation by the two compounds. In 2008 Kozmin and co-workers 
reported a simplified congener 1.4 of leucascandrolide A with the removal of C12, C21 methyl 
groups and C18-C19 alkene group (Figure 1.2)5c. Cellular studies demonstrated this congener 
and neopeltolide effectively inhibited yeast cell growth, which was substantially enhanced by 
substituting glucose with galactose or glycerol. Subsequent genetic analysis of determinants of 
drug sensitivity and suggested these compounds may inhibit mitochondrial ATP synthesis, and 
evaluation of the activity of the four mitochondrial electron transport chain complexes in yeast 
and mammalian cells revealed their principal cellular target was the cytochrome bc1 complex.  
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Figure 1.2 Kozmin’s design of a simplified congener. 
 
Besides neopeltolide and leucascandrolide, other similar natural macrolides of this class include 
callipeltosides,6 lyngbouilloside,7 auriside8 and lyngbyaloside,9 which contain a C-3 hemiketal 
instead of an ether functionality. However, these compounds exhibit moderate cytotoxicity in 
comparison to neopeltolide and leucascandrolide.  
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1.1.2 Reported Syntheses of the Macrolactone 
Inspired by the potent cytotoxic activities of neopeltolide, several elegant total and formal 
synthesis have emerged since its discovery in 2007.5,10 Nearly all total syntheses used a 
Mitsunobu reaction to connect the macrolactone alcohol and the oxazole side chain acid, while a 
major difference is the manner of constructing the tetrahydropyran ring (Scheme 1.1). A 
common approach uses the Prins reaction or its derivations. Syntheses from Scheidt,5b Lee10a and 
Yadav10k employed the Prins reaction to prepare the macrolactone and the tetrahydropyran in one 
step. As shown in Scheme 1.1, Scheidt et al. prepared the dioxinone compound 1.7 and treated it 
with Sc(OTf)3 to give a cyclized intermediate, which released the tetrahydropyrone 1.8 upon 
heating in DMSO. 
 
Scheme 1.1 Scheidt’s synthesis of the macrolactone by Prins macrocyclization reaction. 
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Several syntheses assembled the tetrahydropyran ring before the closure of the macrolactone. 
The synthesis from Panek5a used a triflic acid promoted [4+2] annulation to combine aldehyde 
1.9 and allylsilane 1.10. The following oxymercuration installed the hydroxyl group at C5 with 
the correct stereochemistry (Scheme 1.2). This strategy was also used by Maier10b and Kozmin5c 
in similar ways in their syntheses of the macrolactone. 
 
 Scheme 1.2 Panek’s synthesis of the macrolactone. 
 
Paterson et al. utilized a hetero Diels–Alder reaction to assemble the tetrahydropyran core from 
siloxydiene 1.14 and aldehyde 1.13 (Scheme 1.3).10d The reaction proceeded as expected under 
the catalysis of chiral tridentate chromium (III) salt 1.15 to provide the cis-tetrahydropyrone 1.16 
in 78% yield. Two years later Oestreich designed a more flexible route to prepare the linear 
intermediate 1.13, facilitating the synthesis of different diastereomeric analogs of neopeltolide.10p 
nPr
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O
O
OMenPr
PMBO
N Cr
O
O
Cl10%
4Å M.S., then
acidif ied CHCl3
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O
O
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O
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Scheme 1.3 Paterson’s synthesis of the macrolactone featured by a hetero-Diels-Alder reaction. 
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Fuwa reported two syntheses of the neopeltolide macrolactone in 2008 and 2010.10c,10m The 
reported optimized route afforded the macrolactone via a concise 12-step synthetic sequence 
(Scheme 1.4). The key step, an intramolecular oxa-conjugate addition, was accomplished by 
treatment of 1.17 with DBU in toluene at 100 °C to close the tetrahydropyran ring 1.18 with a 
20:1 stereoselectivity and 73% yield, and subsequently olefin metathesis with 30% Grubbs-II 
catalyst closed the macrolactone ring 1.20. Similar retro-synthetic strategy was used by Taylor10e 
in a 14-step route utilizing ether transfer methodology and a radical cyclization reaction to 
establish the requisite stereochemistry of the tetrahydropyran core. 
 
Scheme 1.4 Fuwa’s synthesis of macrolactone by oxa-conjugate addition and metathesis. 
 
Hong finished the formal synthesis of the macrolactone featuring a tandem allylic oxidation/oxa-
Michael reaction to form the 2,6-cis tetrahydropyran ring 1.22 with a 20:1 d.r. and 78% yield 
(Scheme 1.5).10i Roulland utilized a [CpRu(MeCN)3]PF6-catalyzed tandem alkyne-enal 
coupling/Michael addition sequence to close the tetrahydropyran ring, finishing the macrolactone 
in 15 steps.10h 
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Scheme 1.5 Hong’s Synthesis by a tandem allylic oxidation/oxa-Michael reaction. 
 
The Floreancig group became interested in neopeltolide for the opportunity of applying our 
recently developed methodology of oxidative carbenium formation mediated by DDQ. Previous 
work by Dr. Tu, published in 2009, accomplished the formal synthesis of the macrolactone 
(Scheme 1.6).11 The sequence featured the use of Brønsted acid-mediated etherification and 
Sonogashira reactions to assemble the fragments, an intramolecular hydrosilylation-Tamao 
oxidation to effect a regioselective alkyne hydration, and a stereoselective hydrogenation to 
establish the C-9 stereocenter.  
 8 
 
Scheme 1.6 Previous work by Dr. Tu in the Floreancig group. 
 
Based on the conformation of the macrocycle as illustrated by the X-ray structure of 1.30, the 
sterically more-accessible convex face is the one that should react with H2 to provide the desired 
stereoisomer 1.8 (Figure 1.3).11 Indeed, subjecting 1.30 to H2 and Pd/C provided 1.8 in 74% 
yield with a negligible amount (<10%) of C-9 diastereomer. 
 9 
 
Figure 1.3 Crystal structure of Compound 1.30 in Tu’s synthesis. 
1.1.3 Reported Syntheses of the Oxazole Side Chain 
The first synthesis of the oxazole side chain was reported by Leighton in 2000, though in his 
synthesis of leucascandrolide A he actually chose a different retro-synthetic strategy instead of 
using the Mitsunobu reaction as the last step.12a Since then, several syntheses have emerged with 
the most efficient probably being a 9-step route reported by Roulland in 2009 with an estimated 
overall yield of 18% from commercially available reagents.10f-h,12b-e 
 
The challenges involved in the synthesis of the side chain include the formation of the oxazole 
ring and selective reduction of unsaturated bonds. The methods available for direct cyclization to 
the oxazole ring typically afford low or moderate yields, and the intermediates involved are often 
unstable and may cause reproducibility problems (Scheme 1.7).12b An alternate route is to make 
oxazolone 1.34 first, use triflic anhydride to convert it into oxazole triflate, and then perform a 
Sonogashira reaction.12c These routes may give better yields than direct cyclization, but the 
oxazole triflate must be well protected from moisture, and reproducibility is also a problem 
based on our experience. 
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Scheme 1.7 Typical examples to the oxazole side chain. 
1.1.4 Reported Approaches to Neopeltolide Analogs 
Several research groups have prepared neopeltolide analogs and studied their cytotoxicity to 
understand the structure-activity relationships of neopeltolide analogs. Scheidt et al. explored the 
potencies of the macrolactone, the oxazole side chain and two simplified analogs with the 
modification of oxazole side chain to benzoyl ester 1.37 and octanoyl ester 1.38 against MCF7 
and P-388 cells (Figure 1.4).10g The macrolactone and side chain alone only show nominal 
growth inhibition, and the elimination of the oxazole side chain abolishes the vast majority of 
potency. These results indicate the full potency may rely on a cooperative interaction of the 
macrolactone and the oxazole side chain. 
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Figure 1.4 Neopeltolide analogs reported by Scheidt. 
 
Fuwa et al. confirmed the above cooperative interaction by measuring the potencies of slightly 
different macrolactone structures and the oxazole side chain.10j An additional interesting result in 
his report was that removing the C9 methyl group 1.39 or the C11 methoxy group 1.40 did not 
dramatically alter its antiproliferative potency (Figure 1.5). The C-9-desmethyl analog 1.39 has 
slightly better potencies against P388 cells, while C-11-demethoxy analog 1.40 is 80% less 
potent against P388 cells.  
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Figure 1.5 Neopeltolide analogs reported by Fuwa. 
 
Maier et al. prepared 5-epimer 1.41 and 11-epimer 1.42 of neopeltolide by slight modifications 
to their synthetic route, and these two analogs yielded a 4~50 fold loss of potency on L929 and 
A549 cells (Figure 1.6).10f Furthermore, Maier investigated the structure-activity relationship on 
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the side chain. The length of the side chain was found to be very important to maintain its 
potency, with a loss of potency by 6000 fold when two methylene groups were removed (1.44), 
and even greater loss when the homoallyl chain was removed (1.43). Additionally, (E)-isomers 
1.45 or 1.46 lead to a 10~30 fold loss of potency compared with the corresponding Z isomers. 
The best result is the Z,(E)-analog 1.47 with an additional double bond, which is equally potent 
to neopeltolide. 
OMeO
O
OPr
O
O
N
O
H
N
OMe
O
OMeO
O
OPr
O
O
N
O
H
N
OMe
O
OMeO
O
OPr
O R
O
5-epimer 1.41 11-epimer 1.42
R= N O
H
N
OMe
O
N
O
H
N
OMe
O
N
O
H
N
OMe
O
N
O
H
N
OMe
O
N
O
H
N
OMe
O1.43 1.44 1.45 1.46 1.47
 
Figure 1.6 Neopeltolide analogs reported by Maier. 
1.2 SYNTHESIS OF NEOPELTOLIDE 
1.2.1 Completion of Neopeltolide Synthesis 
The conversion from the macrolactone to neopeltolide has been reported, but we completed the 
synthesis to have the natural product for subsequent biological studies. Reduction of 1.8 with 
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NaBH4 in MeOH at 0 °C followed by Mitsunobu esterification13 with 1.6 (prepared according to 
the protocol of Wipf and Graham12b) provided the natural product 1.2 (Scheme 1.8). All spectral 
data matched those reported by the Scheidt group.5b 
 
Scheme 1.8 Completion of the neopeltolide synthesis. 
1.2.2 Modifications to the Macrolactone 
The alkene group in 1.30 gave us a good opportunity to introduce functional groups onto the 
macrolactone and investigate the potency of the resulting products. These functional groups 
could alter the physical properties of neopeltolide, hopefully leading to different absorption and 
distribution profiles as well as providing possibilities to control the drug delivery in future 
studies. We also believe these studies could further our understanding on the structure-activity 
relationship of these macrolides. 
I. Synthesis of Dehydro-Neopeltolide 
 
Since 1.30 was easily accessed through the sequence, we reduced it with NaBH4, and then 
appended the oxazole side chain to obtain dehydro-neopeltolide 1.49 (Scheme 1.9). Although 
this analog is not likely to differ much from neopeltolide, the removal of one step in the sequence 
makes the macrolide more accessible. 
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Scheme 1.9 Synthesis of dehydro-neopeltolide. 
II. Synthesis of C9-Epi-Neopeltolide 
We then subjected 1.30 to hydrogenation in the presence of [Ir(Cod)py(PCy3)]PF6 (Crabtree's 
catalyst).14 The reaction proceeded fast with the catalyst promoting reduction preferably from the 
concave face where the tetrahydropyranyl oxygen rests closer to coordinate the iridium atom 
(Scheme 1.10 and Figure 1.7). The desired C9-epimer 1.50 was isolated in a reasonable 54% 
yield, while the diastereoselectivity for this reaction was 1.4:1 based on crude NMR. Reduction 
with NaBH4 followed by Mitsunobu esterification14 with 1.6 provided C9-epi-neopeltolide 1.51. 
O
O
O
O
O
Ir
H
H
 
Figure 1.7 Inversion of facial selectivity by utilizing oxygen coordination. 
 
 
Scheme 1.10 Synthesis of C9-epi-neopeltolide. 
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III. Synthesis of Dihydroxy Neopeltolide 
 
Next we tried to introduce polar groups that could bring useful alterations in the physical 
properties of the molecule. Exposing 1.30 to OsO4, followed by osmate ester cleavage with 
NMO15 yielded diol 1.52 in 75% yield as a single diastereomer, as expected from the analysis of 
crystal structure of compound 1.30 (Scheme 1.11). This reaction required stoichiometric OsO4 to 
proceed at a reasonable rate on our scale, though when scaled up the OsO4 loading could 
conceivably be lowered. After reduction with NaBH4, Mitsunobu esterification with 1.6 provided 
dihydroxy neopeltolide 1.53 in a moderate 50% yield. This reaction was performed at slightly 
lowered temperature with a controlled amount of the side chain acid 1.6 to ensure the 
regioselectivity over the more hindered secondary and tertiary alcohols. 
 
Scheme 1.11 Synthesis of dihydroxy neopeltolide. 
 
 
IV. Synthesis of Two C8-Hydroxy Neopeltolides 
 
Introducing one hydroxyl group instead of two is also desirable. Under standard reaction 
conditions with borane, two separable diastereomers 1.54 and 1.55 were obtained from 1.48 with 
a ratio of nearly 1:1 (Scheme 1.12). The stereochemical assignments for these compounds were 
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confirmed by NOESY experiments. Lowering the reaction temperature for the borane addition 
had no effect on the ratio of the two diastereomers. Commonly employed bulkier reagents such 
as thexylborane and dicyclohexylborane were unreactive toward 1.48,16a but diethylborane 
reacted efficiently to form 1.54 as a single stereoisomer.16b Both diastereomers were coupled 
regioselectively with 1.6 under Mitsunobu conditions to give two mono-hydroxy neopeltolides 
1.56 and 1.57. 
 
Scheme 1.12 Synthesis of mono-hydroxy neopeltolides. 
 
V. Synthesis of Epoxy Neopeltolide 
We were also interested in introducing an epoxide group to neopeltolide. To avert a potential 
competitive Bayer-Villiger reaction, we first reduced 1.30 with NaBH4, and then subjected the 
alcohol 1.48 to m-CPBA oxidation (Scheme 1.13). The desired epoxide 1.58 was obtained in a 
moderate yield as a single diastereomer, as expected from the analysis of crystal structure of 
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compound 1.30. Mitsunobu esterification with 1.6 provided epoxyneopeltolide 1.59 in 66% 
yield. 
 
Scheme 1.13 Synthesis of epoxyneopeltolide. 
 
VI. Synthesis of an Amide Analog 
 
Amide bonds are considerably more stable than ester bonds under normal physiological 
conditions, and amides have better solubility in aqueous solution compared with esters.17 We 
were curious about whether replacing the ester linkage with an amide linkage in neopeltolide 
would bring a significant variation in terms of potency. Compound 1.5 was treated with MsCl 
and then sodium azide in DMF,18 affording the desired azide 1.61 with inverted C5 stereocenter 
in a moderate yield (Scheme 1.14). Standard hydrogenation provided amine 1.62, followed by 
coupling with PyBOP to obtain the desired amide 1.63 in 77% yield.19 
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Scheme 1.14 Synthesis of amide analog. 
 
1.2.3 Simplification to the Side Chain 
Results from previous work explain that oxazole-containing side chain is important for the 
antiproliferative potency of neopeltolide, though it shows no potency on its own.10g Changing to 
benzoate and octanoate esters oversimplifies the structure and diminishes potency,10g and 
shortening the length of the side chain significantly lowers its potency.10f However, there has 
been no attempt to investigate the role of the oxazole ring and the carbamate to our knowledge. 
Considering the challenges of synthesis posed by the oxazole ring, we tried to use simpler and 
more accessible aromatic rings to substitute the oxazole ring and investigate the antiproliferative 
activities of the resulting products (Figure 1.8). 
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Figure 1.8 Simplification to the side chain of neopeltolide. 
 
I. Simplification with Phenyl Group 
 
The phenyl-containing side chain acid was accessed starting from commercially available, 
inexpensive 3-(3-bromophenyl)propionic acid 1.68 (Scheme 1.15). An esterification was effected 
in quantitative yield using two equivalents of thionyl chloride in methanol. The carbamate group 
was introduced through a Sonogashira reaction in an excellent yield in the presence of 
bis(triphenylphosphine)palladium(II) dichloride, triphenylphosphine and copper(I) iodide.20 
Without the presence of triphenylphosphine, there was no coupling even at an elevated 
temperature. A possible explanation was that the alkyne group in 1.70 could not reduce the 
Pd(II) to form the effective Pd(0) catalyst.  
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To convert the alkyne 1.71 to the cis-alkene 1.72, a standard Lindlar hydrogenation was initially 
used. Although the desired cis-alkene was obtained in 44% yield, the reaction also produced 
trans-alkene and over-reduced alkane products that caused some difficulties in the purification 
process. Later experiments revealed P2-nickel catalyst could perform this reduction to provide 
1.72 in a very clean and efficient manner.21 The colloidal P2-nickel catalyst was easily prepared 
from nickel(II) acetate tetrahydrate and sodium borohydride, and had to be used immediately 
after preparation. Sometimes the P2-nickel reaction stalled before complete conversion, and 
another batch of freshly prepared catalyst had to be added. The ester group was selectively 
reduced with 1.3 equivalents of DIBAL-H to form aldehyde 1.73 in 64% yield along with a 
minor amount of over-reduced alcohol. A Still-Gennari condensation22 followed by hydrolysis 
afforded the phenyl-containing side chain acid 1.74, which was coupled with 1.5 to provide 1.64 
under Mitsunobu conditions. 
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Scheme 1.15 Synthesis of the phenyl analog. 
 
II. Simplification with Pyridyl Group 
 
We chose commercially available 6-bromo-2-pyridinecarboxaldehyde 1.75 as our starting 
material to prepare the pyridine-containing analog 1.65 (Scheme 1.16). Chain extension through 
a Horner-Wadsworth-Emmons reaction23 proceeded nearly quantitatively. Initially we used 10% 
palladium on charcoal to reduce the newly-formed double bond in compound 1.76. 
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Unfortunately, the palladium catalyst led to a significant debromination. Suppressors previously 
reported to be effective in eliminating debromination, including diphenyl sulfide24 and zinc 
bromide,25 were tried but with little improvement. Finally, sodium borohydride in the presence of 
CuCl26 effected a chemoselective reduction of the newly-formed double bond to provide 1.76 in 
75% yield, and no debrominated product was found in this reaction. 
 
A Sonogashira coupling was then performed to afford 1.78 in an excellent yield. Standard 
Lindlar hydrogenation on 1.78 led to complete over-reduction in 3 hours. Samarium(II) iodide in 
the presence of bis(triphenylphosphine)cobalt(II) dichloride27 led to an undesired dimerized 
product in 78% yield. Again the P2-nickel catalyst reduced the alkyne group in 1.78 to provide 
the cis-alkene group in 1.79 in 65% yield with no trans-isomer. DIBAL-H was used to reduce 
1.78 to provide the aldehyde 1.79 in a moderate 42% yield along with 37% of an over-reduced 
alcohol. Still-Gennari condensation afforded the desired ester 1.80 in 71% yield, which was then 
hydrolyzed by lithium hydroxide. However, the zwitterionic nature of the hydrolytic product 
made its purification and characterization difficult, so it was used directly into the next 
Mitsunobu reaction to form the pyridine-containing analog 1.65.  
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Scheme 1.16 Synthesis of the pyridine-containing analog. 
III. Simplification with Furanyl Group 
The sequence for furanyl analog started from commercially available reagent 5-bromo-2-
furaldehyde 1.81 (Scheme 1.17). Chain extension through a Horner-Wadsworth-Emmons 
reaction produced 1.82 nearly quantitatively. While the newly-formed conjugated double bond 
could be easily reduced with the NaBH4-CuCl system, a significant amount of debromination 
occurred. We thought the NaBH4-CuCl system would preferably occur on a trans-alkene and we 
might evade this problem by first performing a Sonogashira reaction. Thus a Sonogashira 
coupling was performed to introduce the carbamate fragment in 82% yield. Much to our surprise, 
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treatment of the Sonogashira product 1.83 with NaBH4-CuCl led to a complete reduction from 
the alkyne to an alkane before the reduction of the desired trans-alkene. Considering the result 
reported by Maier10f that the analog 1.47 with an additional trans-double bond was equally 
potent to the natural product, we decided to retain this double bond. 
Thus, the Sonogashira product 1.83 was reduced with the P2-nickel catalyst to afford the desired 
cis-alkene 1.84 in 65% yield. DIBAL-H reduction led to a complete reduction of the conjugated 
ester to the corresponding alcohol, which was then oxidized with Dess-Martin reagent28 to afford 
the aldehyde 1.84. Still-Genarri condensation followed by hydrolysis yielded the conjugated side 
chain acid 1.86, which went through a Mitsunobu esterification to provide the final furanyl 
analog 1.66. 
 
Scheme 1.17 Synthesis of the furanyl analog. 
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IV. Simplification with Des-Carbamate Side Chain 
The sequence to prepare the shortened oxazole side chain without the carbamate group was 
smoothly completed in 5 steps (Scheme 1.18). The commercially available starting material, 2-
methyloxazole-4-carboxaldehyde 1.87, underwent a Horner-Wadsworth-Emmons reaction to 
prepare the chain extended product 1.88 in 77% yield. Hydrogenation with 10% Pd/C followed 
by a selective reduction provided the aldehyde 1.89 in good yield. Still-Genarri condensation 
afforded the cis-alkene 1.90 in 71% yield, which under hydrolysis produced the shortened 
oxazole side chain acid 1.91 in 80% yield. Finally a Mitsunobu reaction with the macrolactone 
alcohol 1.5 furnished the des-carbamate analog 1.67 in a good yield. 
 
Scheme 1.18 Synthesis of the des-carbamate analog. 
1.3 BIOLOGICAL STUDIES 
Next we sought to explore the potency of neopeltolide 1.2, the macrolactone modified analogs 
(1.49, 1.51, 1.53, 1.56, 1.57, 1.59 and 1.63) and the side chain modified analogs (1.64-1.67). The 
biological assays were conducted by Dr. Balachandran in the research group of Professor Billy 
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Day from School of Medicine, University of Pittsburgh. Human colon carcinoma cell line 
(HCT116) and an isogenic p53 knock-out control of HCT116 cells with p53 knock-out were 
used to evaluate the antiproliferative potency of these compounds. An MCF-7 breast carcinoma 
cell line obtained from Georgetown University was also studied, and this cell line is known to be 
more resistant than the commonly used MCF7 (ATCC® HTB-22™). The obtained GI50 values 
are listed in Table 1.1.  
 
To confirm that the synthetic neopeltolide 1.2 is the same as previously reported, we evaluated 
its potency against the HCT116 cell line. Compound 1.2 inhibited growth of HCT116 cells with 
a GI50 of 0.77 nM, which is in close agreement with the data reported by Kozmin (0.50 nM).5c  
 
Next we analyzed the effect of macrolactone modifications to their potencies. The two 
structurally closest analogs, the alkene analog 1.49 and C9-epi analog 1.51, were slightly less 
potent than neopeltolide. The C8-hydroxy analogs 1.56 and 1.57, epoxy analog 1.59 and amide 
analog 1.63, showed 20~100 fold loss of potency against HCT116 cells, while the dihydroxy 
analog 53 showed 1000 times less potency against HCT116 cells. Interestingly, the profile of 
potency against HCT116-P53KO cells was different from against HCT116 cells. Neopeltolide 
1.2 and analogs 1.49 and 1.51 were roughly 10 times less potent when P53 was knocked out, 
which suggests an important role of P53 in their mechanism against HCT116 cells. On the other 
hand, more polar analogs 1.53, 1.56, 1.57, 1.59 and 1.63, showed little loss of potency in P53KO 
cells, or even some gain.  
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In the MCF-7 cell line obtained from Georgetown University, neopeltolide 1.2 showed an 
effective inhibition with a GI50 of 6.96 µM, indicating a significant loss of potency when 
compared with the nanomolar potency in the commonly used MCF7 cells from ATCC. The C9-
epi analog 1.51 and dihydroxy analog 1.53 were found to be more effective than the natural 
product. The sharp contrast of relative potencies between HCT116 and MCF-7 for the dihydroxy 
analog 1.53 might be additional evidence suggesting the selectivity of this class of macrolides 
against different cell lines, and this selectivity may be highly dependent on their subtle structural 
differences.  
Table 1.1 Biological activities of neopeltolide and the analogs. 
Compound 
HCT116 
GI50 [nM] 
HCT116-P53KO 
GI50 [nM] 
MCF-7 
GI50 [nM] 
Description 
1.2 0.77 9.9 6960 neopeltolide 
1.49 5.4 49 30000 alkene analog 
1.51 6.6 50 1180 C9-epi analog 
1.53 4300 4300 2770 dihydroxy analog 
1.56 17 13 43600 C8-hydroxy analog 
1.57 48 49 >50000 
C9-epi-C8-epi-hydroxy 
analog 
1.59 24 48 >50000 epoxy analog 
1.63 66 68 >50000 amide analog 
1.64 100 73 >50000 phenyl analog 
1.65 2900 2300 4480 
pyridine-containing 
analog 
1.66 24 52 34800 Furanyl analog 
1.67 730 550 >50000 des-carbamate analog 
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When analyzing the modification on the side chain, we found that for HCT116 cells phenyl 
analog 1.64 and furanyl analog 1.66 showed roughly 20~100 fold less potency than neopeltolide, 
but comparable potency when p53 was knocked out. The pyridine-containing analog 1.65 
showed a significant loss against HCT116 cells, but better potency against MCF-7 cell line than 
the natural product. The des-carbamate analog 1.67 showed significant loss of potency in all the 
cell lines tested, suggesting the essential role of the carbamate group for the full potency of 
neopeltolide. 
1.4 SUMMARY 
The total synthesis of neopeltolide was completed, together with the synthesis of eleven analogs 
with modifications focusing on the macrolactone and the side chain (Figure 1.9). Preliminary 
biological assays showed the selectivity of these analogs against different cancer cell lines. The 
potent antiproliferative activity of neopeltolide was found to be at least partly related to P53. The 
introduction of polar groups to the macrolactone and the introduction of simplified aromatic ring 
to the side chain led to different profiles of antiproliferative potencies against different cell lines, 
ranging from significant loss to appreciable gain.  
 
The changes to C9 stereocenter (1.49 and 1.51), and the introduction of polar functional groups 
to the macrolactone (1.56, 1.57, 1.59 and 1.63), are both tolerated. Considering the overall 
antiproliferative potency and ease of modification, the C8-hydroxy analog 1.56 may be a good 
start point for further research of targeted drug delivery. The analog with two vicinal hydroxyl 
groups 1.53 is essentially inactive to HCT116 cells. The substitution of the oxazole ring with 
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simpler aromatic rings 1.64, 1.65 and 1.67 is tolerated to a certain extent, and five-membered 
furan ring 1.67 provides antiproliferative GI50 values closest to those of the natural product 1.2. 
The removal of the carbamate group 1.67 leads to a significant loss of potency. This clearly 
underscores the importance of the carbamate group to the potency of neopeltolide. 
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Figure 1.9 Neopeltolide and analogs. 
top GI50 against HCT116; below GI50 against HCT116 with p53 knock-out 
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2.  SYNTHESIS OF SULFUR-CONTAINING HETEROCYCLES THROUGH 
OXIDATIVELY GENERATED THIOCARBENIUM IONS 
2.1 INTRODUCTION 
2.1.1 Previous Methods for Synthesis of Sulfur-Containing Heterocycles 
Organic sulfides are widely recognized as versatile functional groups in organic chemistry. 
Compared with theire oxygen counterparts, organic sulfides are more nucleophilic and less basic, 
and can be easily transformed into a variety of derivatives via hydrogenolysis, oxidation, 
olefination and rearrangement,29 thus providing additional opportunities for structural 
diversification. The versatility of sulfur has been demonstrated in the construction of a number of 
synthetic targets.30 Sulfur is also among one of the most abundant elements of life, primarily 
being an essential component in many proteins and cofactors.31 In some other cases, sulfur exists 
in heterocycles that are important structural subunits in many biologically active molecules.32 
 
In contrast to ethers,33 methods for the synthesis of sulfur containing heterocycles are relatively 
limited. Of various methods reported for the synthesis of sulfur containing heterocycles,34-36 the 
two most successful strategies utilize the nucleophilic nature of thio species35 and the 
intermediacy of thiocarbenium ions36 (Scheme 2.1). 
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Scheme 2.1 Two major synthetic strategies for sulfur containing heterocycles. 
Thiocarbenium ions are attractive intermediates for the synthesis of sulfur-containing 
compounds.37 Traditionally, the Pummerer reaction has been utilized to generate thiocarbenium 
ions (Scheme 2.2)38. The classic Pummerer reaction involves an acylation of a sulfoxide by an 
anhydride, followed by elimination to form the thiocarbenium ion and thus to expose the reactive 
site on the adjacent carbon. The thiocarbenium ion is then trapped with acetate or other 
nucleophiles where applicable. The classic Pummerer reaction generally requires harsh acidic 
initiators, and in most cases forms exo product when appended nucleophiles are used.39 
 
Scheme 2.2 Pummerer reaction. 
Another way to generate thiocarbenium ion strategy is via thia-Prins-type reactions in which ring 
formation occurs through homoallylic mercaptans with aldehydes in the presence of an acid 
catalyst (Scheme 2.3). This method was first described by Li,36a and further developed by other 
research groups.36b-i 
 
Scheme 2.3 Thia-Prins type reaction. 
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2.1.2 Oxidative C-H Bond Cleavage  
Selective and efficient oxidative activation of the C-H bond adjacent to a heteroatom (such 
as N or O) has been widely investigated and successfully used in the synthesis of a number of 
natural products and pharmaceuticals.40 Dr. Tu and Dr. Liu in the Floreancig group have 
developed a stereoselective synthetic route for the preparation of tetrahydropyrones, whereby 
allylic or benzylic ethers are oxidized with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) to 
generate oxocarbenium ions that react with appended enol acetate nucleophiles(Scheme 2.4).41 In 
the postulated chair transition state, the substituent R assumes an equatorial position and the α,β-
unsaturated oxocarbenium ion exists in (E)- geometry. Therefore, the reaction generates 2,6-cis 
disubstituted tetrahydropyrones with excellent stereocontrol. 
 
Scheme 2.4 Six-membered heterocycle synthesis through oxidative C-H bond cleavage. 
 
By a simple analogy to their oxygen counterparts, the desired thiocarbenium ions may also be 
oxidatively generated from corresponding allyl sulfides. Sulfur is larger than oxygen, so the 
orbital overlap between sulfur and the adjacent carbon in thiocarbenium ions may not be as good 
as the orbital overlap between oxygen and carbon in oxocarbenium ions. On the other hand, 
sulfur atom is less electronegative. A few studies have shown that the energetic difference 
between thiocarbenium ions and oxocarbenium ions is small.42 With respect to stereoselectivity, 
due to the fact that carbon-sulfur bonds are significantly longer than carbon-oxygen bonds,43a the 
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energy penalty of (Z)-geometry of the thiocarbenium ions over (E)-geometry 43b may be smaller 
than the corresponding oxocarbenium geometries. Therefore it is reasonable to assume lower 
stereoselectivities from thiocarbenium ions intermediates. 
 
In 2007, Zhiping Li and coworkers 44 attempted a similar approach, whereby o-chloranil instead 
of DDQ was utilized to effect a C−H bond oxidation on benzyl sulfides to generate 
thiocarbenium ions, followed by an intermolecular nucleophilic attack (Scheme 2.5). Though 
limited by the scope of substrates and nucleophiles, this method sheds light onto the feasibility of 
synthesizing sulfur containing heterocycles via DDQ mediated oxidative C-H bond cleavage. 
 
Scheme 2.5 C-H bond oxidation of benzyl sulfide with o-chloranil.44 
 
2.2 SYNTHESIS OF SULFUR CONTAINING HETEROCYCLES THROUGH DDQ 
MEDIATED OXIDATIVE C-H BOND CLEAVAGE 
To provide a new alterative in addition to the limited number of synthetic methods for sulfur 
containing heterocycle synthesis, we decided to approach tetrahydrothiopyrones and 
tetrahydrothiophenes through oxidatively generated thiocarbenium ions and appropriate 
appended nucleophiles. We investigated the types of sulfides that are used to generate 
 34 
thiocarbenium ions and the types of appended nucleophiles, and synthesized a series of 
substrates for the development of this synthetic methodology. 
2.2.1 Synthesis of Tetrahydrothiopyrone Using Thiocarbenium Ions Generated from 
Allylic and Benzylic Sulfides 
Our initial approach was to mimic our route to the formation of tetrahydropyrones developed by 
former group members Dr. Wang and Dr. Liu. The strategy involved the oxidative C-H bond 
cleavage of allylic or benzylic ethers with DDQ to yield oxocarbenium ions, and the 
incorporation of an enol acetate as an appended nucleophile that had been proved to be 
compatible with DDQ mediated oxidative cyclization. Thus, substrate 2.2 was prepared and 
subjected to the DDQ oxidation conditions (Scheme 2.6). A simple nucleophilic substitution of 
(E)-1-bromohex-2-ene with but-1-yn-4-yl thioacetate 2.1 afforded the allyl sulfide intermediate 
in an excellent yield. The alkynyl group was then converted to the enol acetate 2.2 in 57% yield 
via a ruthenium-catalyzed Markovnikov addition with AcOH.45 Substrate 2.2 was then treated 
with DDQ in 1,2-dichloroethane (DCE) in the presence of 4Å molecular sieves as the water 
scavenger and 2,6-dichloropyridine as the base. The cyclization was complete within 2 hours at 
room temperature, providing the desired tetrahydrothiopyranone 2.3 in 50% yield and over-
oxidation side product 2.4 in 4% yield. The addition of LiClO4 to the reaction mixture is believed 
to help reducing the formation of 2.4, presumably due to the stabilization of the radical anion of 
DDQ that forms from the initial single electron transfer. Besides LiClO4, Mg(ClO4)2 was also 
found to be as effective in this role. 
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Scheme 2.6 Synthesis of a simple allyl sulfide and its cyclization reaction. 
 
To investigate the stereoselectivity of the reaction, secondary allyl sulfide 2.6 was synthesized in 
a very similar route as illustrated in Scheme 2.7. It should be noted that the ruthenium-catalyzed 
Markovnikov addition afforded the desired internal enol acetate in only 27% yield, while the 
major products were terminal enol acetates. Substrate 2.6 reacted with DDQ to yield 2.7 as a 
diastereomeric mixture at 10:1 ratio with cis-product being preferred, confirming that the (E)-
thiocarbenium ion is the dominant reactive species in the reaction process. The over-oxidation 
side product 2.8 was also isolated from this reaction. 
 
 
Scheme 2.7 Synthesis of substituted allyl sulfide and its cyclization reaction. 
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Benzyl sulfide 2.10 was similarly synthesized and subjected to the cyclization reaction (Scheme 
2.8). The cyclization reaction with benzyl substrate 2.10 afforded the desired cis-
tetrahydrothiopyranone 2.11 in higher yield (60%) than the reaction with allyl sulfide substrate 
2.6, with an excellent diastereomeric ratio of 25:1. No over-oxidation was observed even after 
the reaction was allowed to proceed at room temperature overnight. We postulate that the 
benzylic carbonhydrogen bond in the product does not overlap the p-orbitals of the aromatic ring, 
thereby greatly slowing further oxidation of the desired product. 
 
  
Scheme 2.8 Synthesis of substituted benzyl sulfide and its cyclization reaction. 
2.2.2 Synthesis of Tetrahydrothiopyrone Using Thiocarbenium Ions Generated from 
Vinyl Sulfides 
The over-oxidation problem observed with allyl sulfide substrates is believed to be related to the 
similar oxidation potentials between the substrates and the desired products, and thus comparable 
oxidation rates of the two species to form thiocarbenium ions. Previous mechanistic studies in 
the Floreancig group and other groups revealed that vinyl substrates have lower oxidation 
potential than allyl substrates, and usually lead to faster generation of corresponding 
oxocarbenium ion intermediates.46 Therefore we postulated that vinyl sulfides would overcome 
the over-oxidation problem and improve the efficiency of the reaction. Additionally, vinyl 
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sulfides are attractive substrates because these structures can be accessed through a number of 
new metal mediated protocols.47  
 
Vinyl substrates 2.13 and 2.15 were synthesized and subjected to the DDQ oxidation reactions as 
illustrated in Scheme 2.9. An efficient palladium-mediated coupling reaction48 between but-3-
yne-1-thiol 2.12 and (E)-1-iodohex-1-ene led to the formation of a vinyl sulfide structure, which 
was subjected to the ruthenium catalyzed Markovnikov addition conditions to afford the desired 
substrate 2.13. Exposing 2.13 to DDQ provided 2.3 in 58% isolated yield within 5 min at 0 °C 
with no observable formation of the over-oxidation side product 2.4. Secondary vinyl sulfide 
2.15 was prepared from 2.14 and subjected to the DDQ mediated reaction conditions to afford 
the desired cis- cyclization product 2.7 in 71% yield with an excellent 25:1 dr. Compared with 
the aforementioned allyl sulfides, both of these vinyl sulfides substrates require lower reaction 
temperature and much shorter reaction time, yet afford the desired products in better yields and 
higher stereoselectivity when secondary sulfides are used. 
 
Scheme 2.9 Synthesis of vinyl sulfides and their cyclization reactions. 
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2.2.3 Synthesis of Tetrahydrothiopyrone with 2,3-Stereoselectivity Using Enol Silane and 
Enol Carbamates 
Employing substituted nucleophiles instead of unsubstituted enol acetates may lead to the 
formation of 2,3-disubstituted cyclization products, thus expanding the scope and versatility of 
this method. Initially we demonstrated this concept by using substituted enol silanes as a Z/E 
mixture, as shown in Scheme 2.10. Commercially available 3-bromopropanoyl chloride 2.16 was 
reacted with N,O-dimethylhydroxylamine hydrochloride to form a Weinreb amide, followed by a 
nucleophilic replacement with potassium thioacetate to obtain intermediate 2.17. The thioacetate 
group was hydrolyzed and coupled with (E)-1-iodohex-1-ene to yield vinyl sulfide 2.18. The 
Weinreb amide group was then converted to enone by reacting with vinyl magnesium bromide at 
low temperature, followed by a cupper(I) mediated silylation reaction to afford the desired 
substituted enol silanes 2.19 with 1.2:1 Z/E ratio. The cyclization reaction of this Z/E substrate 
mixture afforded the desired 2,3-disubstituted tetrahydrothiopyranone in good yield as an 
inseparable mixture with a 1:0.6 trans:cis ratio. 
 
Scheme 2.10 Synthesis of vinyl sulfide with appended enol silane as a Z/E mixture  
and its cyclization reactions 
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To precisely control the stereochemical outcome of the 2,3-disubstituted cyclization product, the 
substituted nucleophiles in the substrates need to be prepared with a high degree of geometrical 
control. The geometries of internal enol acetates and internal enol silanes are difficult to control. 
Several different approaches to achieve the desired geometry on these two species were tried, but 
none of them afforded satisfactory geometrical selectivity. Finally we were able to solve this 
problem by preparing the desired (Z)- and (E)- enol carbamates through two different routes 
(Scheme 2.11 and 2.12).  
The preparation and cyclization of (Z)-enol carbamate 2.24 is shown in Scheme 2.11. A Grignard 
reaction between aldehyde 2.21 and vinyl magnesium bromide at low temperature, followed by a 
straightforward acylation, led to the formation of allyl carbamate 2.22. Upon treatment with 
LDA in the presence of HMPA at low temperature,49 the allyl carbamate 2.22 isomerized to the 
desired (Z)-enol carbamate 2.23. The silyl ether protecting group was cleaved with TBAF 
(buffered with acetic acid), replaced with thioacetic acid under Mitsunobu conditions,50 and 
coupled with (E)-1-iodo-1-hexene under the catalysis of copper(I) iodide and potassium 
hydroxide51 to form 2.24. Although the coupling reaction conditions were originally developed 
for thiols, we found thioesters could be used with similar efficiency, presumably due to in situ 
cleavage of thioesters with potassium hydroxide. Therefore the necessity of converting thioesters 
to thiols was eliminated. Treatment of the (Z)-enol carbamate substrate 2.24 with DDQ rapidly 
afforded the cyclization product 2.25 in 80% yield with 25:1 dr favoring 2,3-trans product. 
When branched substrate 2.26 was used, the reaction also ran very smoothly with high 
stereocontrol favoring 2,3-trans and 2,6-cis stereochemical outcome. 
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Scheme 2.11 Synthesis of vinyl sulfides with (Z)-enol carbamate and cyclization reactions. 
 
For the (E)-enol carbamate substrate 2.31, a different synthetic route was designed as illustrated 
in Scheme 2.12. Vinyl iodide 2.29 with the desired geometry was prepared by exposing alkynyl 
carbamate 2.28 to Marek’s carbocupration/iodination sequence.52 The following Kumada 
coupling, hydroboration, Mitsunobu reaction and copper catalyzed coupling reaction provided 
the (E)-enol carbamate substrate 2.31. Exposing 2.31 to DDQ oxidation afforded 2,3-cis-product 
2.32 in 88% yield as a single stereoisomer (as determined by NMR) within a few minutes at 0 °C. 
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Scheme 2.12 Synthesis of vinyl sulfide with (E)-enol carbamate and cyclization reaction. 
2.2.4 Synthesis of Tetrahydrothiopyran Derivatives with 2,3-Stereocontrol Using 
Allylsilane 
Another way to achieve 2,3-stereoselectivity is through using π nucleophiles such as allylsilanes, 
which were shown to be efficient nucleophiles in similar reactions.53 Palladium catalyzed 
coupling between thiol 2.33 and (E)-1-iodo-1-hexene afforded the common intermediate 2.34 for 
preparing both trans- and cis- allylsilane substrates. Treatment of the alkynyl group with in situ 
prepared Schwartz's reagent followed by iodine quenching54 and a subsequent palladium 
catalyzed Kumada coupling with trimethylsilyl methylmagnesium chloride,55 afforded trans- 
allylsilane 2.35 in high yields. For cis-allylsilane substrate 2.36, the alkynyl group was first 
converted to an alkynyl iodide, then reduced with in situ generated diimide to obtain the desired 
cis- geometry and coupled under Kumada conditions to introduce the allylsilane moiety. 
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Scheme 2.13 Synthesis of vinyl sulfides with allylsilane nucleophile. 
 
Oxidative cyclization with allylsilanes nucleophiles are greatly affected by the choice of solvent. 
When methylene chloride was used, dienyl sulfide 2.38 was the major product of the reaction, 
probably resulting from the deprotonation of thiocarbenium ion 2.37 (Scheme 2.14). When more 
polar solvent MeNO2 was used, the oxidation of trans-allylsilane substrate 2.35 led to the 
formation of 2,3-trans tetrahydrothiopyran derivatives 2.39 in 68% yield with a 7.7:1 dr. With 
cis-allylsilane substrate 2.36, the cyclization reaction also led to the formation of 2,3-trans 
tetrahydrothiopyran 2.39 as the main product but with only 1.9:1 dr. 
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Scheme 2.14 Cyclization reaction of vinyl sulfides with allylsilane nucleophile. 
 
To further derivatize the cyclization products and expand the scope of the reaction, several other 
substituted allylsilane substrates were prepared and investigated. Scheme 2.15 shows a modified 
synthetic route for substituted trans allylsilane substrates. The allylsilane group was first 
installed in 2.42/2.43 using hydrozirconation/iodination 54 and Kumada coupling,55 followed by 
deprotection of the silyl ether, mesylation and thiolation to obtain intermediate 2.44/2.45. 
Reduction with lithium aluminum hydride and subsequent palladium catalyzed coupling reaction 
afforded the desired trans-substrates 2.46/2.47. 
 
Scheme 2.15 Synthesis of secondary vinyl sulfides with trans-allylsilane nucleophiles. 
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For the preparation of substituted cis- allylsilane substrates 2.54/2.55 (Scheme 2.16), the desired 
cis- geometry in 2.50/2.51 was installed by a partial hydrogenation of the corresponding 
propargyl silane catalyzed with in situ prepared P2 nickel.21 The silyl protected alcohol was then 
converted to vinyl sulfide 2.54/2.55 by deprotection, mesylation, thiolation, reduction and 
palladium catalyzed coupling reaction. 
 
Scheme 2.16 Synthesis of secondary vinyl sulfides with cis-allylsilane nucleophile. 
The results of oxidative cyclization in MeNO2 on the substituted trans-/cis- allylsilanes in 
Scheme 2.15 and 2.16 are summarized in table 2.1. The additional n-butyl or i-propyl 
substituents in these substrates led to the formation of four diastereomeric products as shown in 
Figure 2.1 denoted as o-trans-m-cis 2.58, o-trans-m-trans 2.59, o-cis-m-cis 2.60 and o-cis-m-
trans products 2.61. The cyclization of substituted trans- allylsilanes afforded good 
stereoselectivities, with the expected o-trans-m-cis products being major products. However, the 
cyclization of substituted cis- allylsilanes led to the formation of a mixture of o-trans-m-cis and 
o-cis-m-trans products in a nearly 1:1 ratio and other minor diastereomers. The stereo structures 
of these products were determined by NOESY and coupling constant analysis. Also note that 
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increasing the size of the substituent on the cis- allylsilanes from n-butyl to i-propyl has no effect 
in improving o-selectivity.  
Table 2.1 Cyclization of substituted allylsilane substrates. 
Substrate Major product Total yield (%) 
dr ( o-t-m-c:  o-t-m-t:  
o-c-m-c: o-c-m-t) 
 
 
68 1.0: 0.18:0.09:0.05 
 
 
79 1.0: 0.14: 0.09: 0.04 
 
 
87 1.0: 0.17 : 0.17 : 0.80 
 
 
72 1.0: 0.14 : 0.12 : 1.0 
 
 
Figure 2.1 Four diastereomeric products resulting from substituted allylsilanes. 
R: n-butyl, iso-propyl 
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Tri-substituted allylsilane 2.63 was prepared in two steps from 2.62 (Scheme 2.17). The 
following cyclization reaction led to the formation of 2.64 in a 72% yield with a 2:1 dr favoring 
2,3-trans product. The diastereomeric ratio was fairly close to the (Z)-allylsilane substrate 2.36 
as described in Scheme 2.14. 
 
Scheme 2.17 Cyclization of tri-substituted allylsilane. 
2.2.5 Synthesis of Tetrahydrothiophene 
Tetrahydrothiophenes could also be accessible through the present oxidative cyclization reaction 
with one less carbon atom in the substrate structures. We investigated their synthesis by only 
choosing substrates with vinyl sulfide and allylsilane functionalities. As shown in Scheme 2.18, 
(Z)-allylsilane substrate 2.67 was synthesized and oxidatively cyclized in a very similar route. 
Homopropargyl silyl ether 2.65 was deprotonated and reacted with trimethylsilyl methyl iodide, 
followed by a partial hydrogenation of the triple bond catalyzed with in situ prepared P2 nickel 
catalyst21 and deprotection of the silyl ether to afford 2.66. A standard sequence of mesylation, 
reduction and coupling reaction led to the formation of the desired substrate 2.67. The 
cyclization reaction rapidly afforded tetrahydrothiophene 2.68 in a 20:1 diastereomeric ratio 
favoring 2,3-cis stereochemistry. The 2,3-cis stereochemistry was confirmed by further 
hydrogenation to 2.69 and compared with literature reported NMR data.56 
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 Scheme 2.18 Synthesis of tetrahydrothiophene through cis-allylsilane. 
 
2.3 DISCUSSION 
2.3.1 Proposed Mechanism for Reactions with Allyl and Vinyl Sulfides 
The approach of extending the DDQ mediated oxidative C-H bond cleavage strategy from allyl 
or vinyl ether substrates to their sulfur counterparts has proved to be very successful. Under 
similar reaction conditions to allyl ethers or vinyl ethers, the cyclizations on allyl sulfides and 
vinyl sulfides proceed smoothly as expected with moderate to good yields and, in many cases, 
excellent stereoselectivities. 
A proposed mechanism for the cyclization of allyl sulfide 2.2 and the formation of side product 
is shown in Figure 2.2. A single electron transfer reaction on 2.2 generates the radical cation 2.70, 
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followed by a hydrogen atom abstraction by the DDQ radical anion 2.71 to form the α,β-
unsaturated thiocarbenium ion 2.72. An intramolecular nucleophilic attack from the enol acetate 
group, via a chair transition state, leads to the formation of the cyclization product 2.3. The 
resulting acylium ion (not shown) was quenched by 2,6-dichloropyridine, thus facilitating the 
cyclization process. During the reaction, LiClO4 presumably stabilizes the radical anion 2.70 and 
acts as a catalyst. Due to comparable oxidation potentials of the starting material 2.2 and the 
desired product 2.3, 2.3 may be further oxidized by DDQ under the reaction conditions to form 
undesired thiocarbenium ion 2.74 and eventually afford the side product 2.4. 
 
Figure 2.2 A proposed mechanism of DDQ-mediated cyclization of allyl sulfide 2.2. 
 
Compared with allyl sulfide 2.2, the reaction of vinyl sulfide 2.13 is much faster even at lower 
temperature with a higher yield of 2.3 and a negligible amount of side product 2.4. This indicates 
the same α,β-unsaturated thiocarbenium ion intermediate 2.72 is formed in the reaction pathway 
(Figure 2.3). A plausible explanation for the reactivity difference is that vinyl sulfide 2.13 has 
much lower oxidation potential than the substrate allyl sulfide 2.2 and the desired product 2.3 
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(also an allyl sulfide). Therefore at lower temperature the oxidation reaction on vinyl sulfide 2.13 
is much faster than on allyl sulfide 2.2 and the desired product 2.3 (which leads to the formation 
of undesired over-oxidation product 2.4). This observation is in agreement with the conclusions 
from previous mechanistic studies.45 
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Figure 2.3 A comparison between allyl sulfide 2.2 and vinyl sulfide 2.13. 
2.3.2 Stereocontrol with Enol Acetate and Enol Carbamate Nucleophiles 
For secondary sulfides substrates 2.6, 2.10 or 2.15, 2,6-cis cyclization products are the major 
products with satisfactory to excellent diastereomeric ratios. In the postulated chair transition 
states, the substituent R assumes an equatorial position, and the (E)-thiocarbenium ion 2.75 is the 
dominant reactive species in the reaction mechanism (Figure 2.4), thus favoring the formation of 
2,6-cis product 2.76. In the less favored (Z)-thiocarbenium ion 2.77 greater steric hindrance is 
expected, and therefore 2,6-trans product 2.78 is formed as a minor product. Compared with 
their oxygen counterparts, the stereoselectivities from the cyclization reactions with sulfides are 
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generally lower, indicating the longer bonds between carbon and sulfur have an adverse affect to 
the preference of the (E)-geometry of thiocarbenium ions. It should be also noted that though the 
(Z)-thiocarbenium ion explains the minor 2,6-trans product nicely, we cannot exclude the 
possibility of the minor product arising from a possible less favored boat transition state. 
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Figure 2.4 Stereocontrol of 2,6-disubsituted tetrahydrothiopyranone. 
 
For secondary sulfides substrate 2.24 with a (Z)-vinyl carbamate, the 2,3-trans cyclization 
product 2.25 is the major product with an excellent ratio of 25:1. Similar to the mechanism of 
2,6-disubstitution products, the substituents at the 2- and 3-positions assume equatorial 
orientations in the postulated chair transition states, and the (E)-thiocarbenium ion 2.79 is the 
dominant reactive species in the reaction mechanism (Figure 2.5), thus favoring the formation of 
2,3-trans product 2.25. The less favored (Z)-thiocarbenium 2.80 presumably leads to the 
formation of the minor product 2.81. We have also demonstrated that complementary 
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stereocontrol result can be accessed through (E)-vinyl carbamate 2.31, leading to 2,3-cis product 
2.32 as the major product through the same mechanism. 
 
Figure 2.5 Stereocontrol of 2,3-disubsituted THTP from (Z)-vinyl carbamate. 
2.3.3 Mechanisms and Stereocontrols with Allylsilane 
Allylsilanes have also proved to be very efficient nucleophiles in these oxidative cyclization 
reactions, but the solvent of choice is the more polar MeNO2 instead of dichloromethane to avoid 
the formation of diene product 2.38. Presumably allylsilanes are slightly weaker nucleophiles 
than enol acetates and enol carbamates, and therefore the thiocarbenium ion 2.37 has a longer 
life in the reaction system. The use of more polar solvent greatly helps to stabilize 2.37 and 
suppress the unwanted deprotonation pathway to form the diene product 2.38. 
Both (E)- and (Z)- unsubstituted allylsilane afford 2,3-cis products as the major products which 
may be explained by the same mechanism as illustrated in Figure 2.6 (only (E)-allylsilane 
structures are illustrated), where (E)-thiocarbenium 2.37 is more favored than (Z)-thiocarbenium 
2.82. It should be noted that the trans:cis stereoselectivities from (E)-allylsilane 2.35 (7.7:1) and 
 52 
(Z)-allylsilane 2.36 (1.9:1) are lower than those from the enol carbamate substrates. A reasonable 
reason which may explain the lower stereoselectivity of (E)-allylsilane 2.35 is solvent effect due 
to the necessary replacement of dichloromethane with MeNO2, however it cannot explain the 
difference between (E)- and (Z)-allylsilanes. 
 
Figure 2.6 Formation of 2,3-trans products from (E)-allylsilanes. 
 
When secondary allyl sulfides are used, four diastereomeric products are formed (Figure 2.1, 
2.58 to 2.61), again with the (E)-allylsilane substrates reacting with much higher levels of 
stereocontrol than the corresponding (Z)-allylsilane substrates. For (Z)-allylsilane substrates, o-
trans-m-cis product 2.58 and o-cis-m-trans product 2.61 are formed in a nearly 1:1 ratio (Figure 
2.7). Our experimental data revealed that the ratios of four diastereomeric products are not very 
relevant to the size of the R- substituents (Table 2.1), indicating a boat transition state is unlikely 
to be responsible for the much lower stereoselectivity from the cyclization of (Z)-allylsilanes. 
The most plausible pathway is through the (Z)-thiocarbenium ion intermediate 2.85 with the 
conjugated alkenyl group occupying a pseudoaxial orientation. 
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Figure 2.7 Formation of the two major diastereomeric products from (Z)-allylsilanes. 
 
The oxidative cyclization from cis-allylsilane 2.67 to tetrahydrothiophene 2.68 is also very 
efficient with excellent stereoselectivity (dr 20:1) (Scheme 2.18). Carbon-sulfur double bonds 
are known to be longer than carbon-oxygen double bonds,43a which may explain this unusual 5-
endo cyclization reaction. The strong preference towards 2,3-cis product from (Z)-allylsilane 
may be related by the lower energy of the (E)-thiocarbenium ion 2.86 compared with the (Z)-
thiocarbenium 2.87, but we do not fully understand the origin of the stereochemistry (Figure 2.8).  
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Figure 2.8 Formation of the two diastereomeric THT products from (Z)-allylsilanes. 
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2.4 SUMMARY 
We have discovered DDQ mediated oxidative C-H bond cleavage to be an effective and 
stereoselective method to synthesize sulfur containing six- or five- member rings. The moieties 
for generating thiocarbenium ions are unsaturated sulfides including allyl sulfide and preferably 
vinyl sulfide, both of which can be easily accessed, while the appended nucleophiles include enol 
acetate, enol carbamate and allylsilane.  
With vinyl sulfides these cyclization reactions rapidly afford sulfur containing six-membered 
rings with high stereocontrol and in good to excellent yields under very mild conditions. Enol 
acetates and enol carbamate nucleophiles tend to afford tetrahydrothiopyranones with the best 
stereochemical outcomes. With unsubstituted enol acetates as the nucleophiles, cis-2,6-
disubstituted tetrahydrothiopyranones are the preferred products from cyclizations of secondary 
sulfides. With substituted enol carbamates as the nucleophiles, trans-2,3-disubstituted 
tetrahydrothiopyranones are the preferred products from cyclizations of (Z)-enol carbamates, and 
cis-2,3-disubstituted tetrahydrothiopyranones are the preferred products from cyclizations of (E)-
enol carbamates. Allylsilane nucleophiles afford slightly inferior stereocontrols, and the 
stereochemical outcomes are also affected by the geometry of the nucleophiles. While the exact 
explanation for different stereocontrol from (E)- and (Z)- allylsilanes remains to be explored, the 
experimental studies tend to indicate the possibility of a concerted interaction between the 
thiocarbenium ion and the allylsilane moiety. In the meanwhile, we have also demonstrated that 
(E)- and (Z)- allylsilanes could be used to prepare tetrahydrothiophenes with moderate to high 
stereocontrol in good yields under very mild conditions. 
The combination of unique synthetic approach, good functional group compatibility and 
excellent diastereoselectivity highlights this oxidative cyclization methodology from other 
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common synthetic strategies for approaching sulfur containing six- or five- member rings. The 
synthetic methodology described here may also find applications in accessing complex 
molecules in pharmaceutical and special chemical industry. 
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3.  ASYMMETRIC BIMOLECULAR COUPLING REACTIONS THROUGH 
OXIDATIVELY GENERATED AROMATIC CATIONS: SCOPE AND LIMIT 
3.1 INTRODUCTION 
Fragment-based screening has become increasingly popular to design high-affinity ligands and 
sub-units in search of biologically active molecules.57 This protocol generally requires the rapid 
preparation of libraries of low molecular weight compounds with diverse structures. Access to 
these libraries would be facilitated by the development of new fragment coupling reactions that 
allow structural variability and, preferably, incorporation of one or more heteroatoms and 
stereocenters. One strategy to generate these fragments is through oxidative carbon-hydrogen 
bond cleavage, which is characterized by the oxidative formation of stabilized carbocations 
followed by intermolecular nucleophilic attack to accomplish the bimolecular coupling process.58 
A significant challenge in this strategy is the stabilized carbocations must have sufficient lifetime 
to accommodate the addition rates of the intermolecular nucleophile. For this reason, most 
bimolecular coupling reactions through oxidative carbon-hydrogen bond cleavage are based on 
readily oxidized substrates, such as tetrahydroisoquinolines, electron-rich alkenes, isochromans 
and xanthenes.59  
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The Floreancig group has developed a number of stereoselective cyclization reactions based on 
the oxidation of ethers, amides, and sulfides with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
(DDQ) as the oxidant.11,41,46 These processes proceed through oxidative carbon-hydrogen bond 
cleavage to form stabilized carbocations followed by intramolecular additions of appended π-
nucleophiles. Recently, Clausen and Villafane in the Floreancig group have successfully 
extended this approach to bimolecular coupling reactions, and  prepared a number 2H-chromene 
derivatives (Scheme 3.1).60  
 
Scheme 3.1 Achiral bimolecular coupling on chromene substrates. 
 
A plausible pathway for these bimolecular coupling reactions are shown in Scheme 3.2. The 
incorporation of aromatic ring lowers the oxidation potential of these substrates and assures 
easier access to the intermediate 3.4. On the other hand, the aromatic ring also leads to higher 
stability of the oxidation intermediate, and thus necessitates a catalyst to promote its dissociation 
to form an intermediate with higher reactivity. Lithium perchlorate has been found to greatly 
improve the efficiency of the reaction, presumably by promoting the dissociation of the acetal 
3.4 and the formation of a more reactive ion pair 3.5, which reacts with an intermolecular 
nucleophile to afford 3.6. 
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Scheme 3.2 The formation of ion pairs in achiral bimolecular coupling. 
 
The possible formation of an achiral ion pair in the reaction mechanism encouraged us to explore 
the potential of replacing LiClO4 with a chiral Brønsted acid. Thus a chiral ion pair 3.7 may be 
generated and available for further nucleophilic addition to afford enantiomerically enriched 
products (Scheme 3.3). Chiral phosphoric acids were selected for their catalytic activities to 
promote asymmetric additions through oxocarbenium ion intermediates.59i,j The  association  
between  the  oxocarbenium  ion  and phosphoric acid has been attributed to C—HˑˑˑˑX hydrogen 
bonds rather conventional hydrogen bonds.61 Though there are a few examples of asymmetric 
additions into oxidatively generated carbocations in the literature, all of these examples employ 
chiral nucleophiles to achieve enantioselectivity.59g,62 To the best of our knowledge, this 
postulated strategy is very unique in generating a chiral center from oxidatively generated 
carbocations and achiral nucleophiles.  
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Scheme 3.3 Chiral ion pair from an oxidatively generated intermediate. 
 
3.2 ASYMMETRIC BIMOLECULAR COUPLING REACTIONS THROUGH 
OXIDATIVELY GENERATED AROMATIC CATIONS 
In the postulated strategy, the co-existence of the racemic acetal 3.4 and the chiral iron pair 3.7 
dictates the competition between the uncatalyzed background reaction which leads to racemic 
products, and the postulated catalyzed reaction which leads to enantiomerically enriched 
products. Our first approach was to identify the reaction conditions that may suppress the 
background reaction. We anticipated the choice of solvent may have a significant impact on the 
background reaction rate as well as the distance of the counterions in the chiral pair. So we 
performed the bimolecular coupling reaction between 3.3 and allyltrimethylsilane in the absence 
of LiClO4 in different solvents, expecting the disappearance of intermediate 3.4 on TLC to 
reflect the background reaction rate (Table 3.1). Compared with acetonitrile and 
dichloromethane, the background reaction rate was considerably slower in toluene presumably 
due to its lower polarity. So toluene was selected for further screening experiments. 
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Table 3.1 Initial solvent screening results (without LiClO4). 
Solvent Nucleophile Temperature °C TLC Consumption 
acetonitrile AllylTMS 0 1.5 hours 
dichloromethane AllylTMS 0 2 hours 
toluene AllylTMS 0 12 hours 
 
To screen for the optimal catalyst, several BINOL-based phosphoric acids and phosphoryl 
triflimides 3.9-3.12, as well as their thio counterparts 3.13-3.14, were synthesized according to 
literature procedure and screened for optimal enantioselectivities.63 Specifically, substrate 3.3 
was exposed to DDQ oxidation in the presence of stoichiometric amounts of catalysts at 0°C to 
generate the relatively stable acetal intermediates in approximately 30 minutes, followed by the 
addition of allyltrimethylsilane to consume the intermediates and finish the coupling process. 
After disappearance of the stable intermediates on TLC, the crude reaction mixture was purified 
by column chromatography, and the enantiomeric excess was measured by chiral HPLC using a 
Lux Cellulose 3 column. The screening results were summarized in Table 3.2 (entry 1 to 6 for 
catalyst screening). Triisopropylphenyl (TRIP) substituted phosphoryl triflimide 3.11 was found 
to be the optimal catalyst, affording 3.15 in 62% ee at stoichiometric loading (entry 3). The 
absolute stereochemistry of 3.15 was determined through an independent synthetic approach 
(discussed later in Scheme 3.4),65 and confirmed with optical rotations and HPLC retention times. 
Phosphoryl triflimide groups were superior to phosphoric acid groups presumably due to their 
higher acidity. Thiophosphoric acid 3.13 and thiophosphoryl triflimide 3.14 afforded very low ee. 
Replacement of toluene with dichloromethane led to 34% ee (entry 7), while replacement with 
α,α,α-trifluorotoluene further improved the stereocontrol to 77% ee (entry 8). α,α,α-
Trifluorotoluene was usually believed to behave similarly as dichloromethane, so the sharp 
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difference in stereocontrol between these two solvents further suggests the presence of aromatic 
interactions between the chiral ion pair 3.7 and the aromatic solvent, which are beneficial to the 
stereochemical outcome. 
 
Table 3.2 Screening results with stoichiometric loading of catalysts. 
 
Entry Catalyst Ar X Y Solvent ee % 
1 3.9 2,4,6-Triisopropylphenyl O O Tol 26 
2 3.10 3,5-Ditrifluoromethylphenyl O O Tol 4 
3 3.11 2,4,6-Triisopropylphenyl O NTf Tol 62 
4 3.12 2,6-Diisopropyl-4-(9-anthracenyl)phenyl O NTf Tol 31 
5 3.13 2,4,6-Triisopropylphenyl S O Tol 4 
6 3.14 2,4,6-Triisopropylphenyl S NTf Tol 13 
7 3.11 2,4,6-Triisopropylphenyl O NTf DCM 34 
8 3.11 2,4,6-Triisopropylphenyl O NTf PhCF3 77 
 
To further improve the enantioselectivity of the reaction, we screened several other nucleophiles 
besides allyltrimethylsilane (Table 3.3). These reactions were conducted in α,α,α-trifluorotoluene 
with stoichiometric amount of 3.11 at 0 °C. Allyl phenyl dimethylsilane and allyltriphenyltin 
provided 92% ee and 89% ee respectively (entry 1 and 3), while allyltributyltin provided 48% ee 
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(entry 2). While nucleophilicity difference seems to be a reasonable explanation, it should be 
noted allyltriphenyltin is more nucleophilic than allyl trimethylsilane.64 Again we believe the 
higher enantioselectivities may be resulting from possible aromatic interactions between the 
chiral iron pair 3.7 and those nucleophiles containing phenyl groups. 
 
Table 3.3 Screening results at stoichiometric loading of catalysts. 
 
Entry Catalyst M ee % 
1 3.11 SiMe2Ph 92 
2 3.11 SnBu3 48 
3 3.11 SnPh3 89 
 
To test the efficiency of the catalyst, we performed a series of reactions with allyltriphenyltin and 
allyl phenyl dimethylsilane with substoichiometric amount of catalyst 3.11 (Table 3.4). Lowering 
catalyst 3.11 from stoichiometric amount to 20% at 0 °C resulted in nearly 30% drop in 
enantioselectivity, with both nucleophiles affording 62% ee (entry 1 and 5). Lowering the 
nucleophilic reaction temperature from 0 °C to -25 °C (the freezing point of α,α,α-
trifluorotoluene is -29 °C) improved the enantioselectivity significantly, with allyltriphenyltin 
adding in 81% ee and 66% yield (entry 2), and allyl phenyl dimethylsilane adding in 86% ee and 
56% yield (entry 6). It should be noted the lower yields were partially affected by the scales of 
these reactions and the evaporation loss of the products. 
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Table 3.4 Screening results at one equivalent loading of catalysts. 
 
Entry R 
Temperature 
(°C) 
Cat loading 
(mol%) 
Ee (%) Yield (%) 
1 Ph3Sn 0 20 62 - 
2 Ph3Sn -25 20 81 66 
3 Ph3Sn -25 10 68 66 
4 Ph3Sn -25 5 31 57 
5 PhMe2Si 0 20 62 - 
6 PhMe2Si -25 20 86 56 
7 PhMe2Si -25 10 79 52 
8 PhMe2Si -25 5 17 53 
 
Further reducing the catalyst loading to 10% resulted in slightly lower enantioselectivity, with 
allyltriphenyltin adding in 68% ee and 66% yield (entry 3), and allyl phenyl dimethylsilane 
adding in 79% ee and 52% yield (entry 7). Reducing the catalyst loading to 5% resulted in 
significant drops in enantioselectivity, with 31% ee and 57% yield from allyltriphenyltin (entry 
4), and 17% ee and 53% yield from allyl phenyl dimethylsilane (entry 8). These 
substoichiometric results indicate the turn-over rate of the BINOL catalyst is not impressively 
high, and at lower catalyst loading the uncatalyzed background reaction can become competitive, 
but useful enantioselectivities can still be obtained with 10% to 20% loading of the catalyst. 
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Compound 3.15 has not been prepared in enantiomerically pure form in literature. Therefore its 
absolute stereochemistry has to be determined through an independent synthetic route (Scheme 
3.4). Commercially available o-bromohydrocinnamic acid 3.16 was converted to its methyl ester, 
and partially reduced to obtain the corresponding aldehyde 3.17. The key stereocenter in 3.18 
was then introduced using a well-known Brown allylation reaction with predictable 
stereochemical outcome.65 A palladium-mediated cyclization66 followed by hydrogenation of the 
alkene group provided 3.19 (observed [α]D + 99.1). Another hydrogenation on the alkene 3.15, 
which was prepared with the present methodology (73% ee before hydrogenation), afforded the 
same product with an observed [α]D + 73.0. Retention times with both products as well as 
racemic products also matched very well. 
 
 
Scheme 3.4 Synthetic approach to determine absolute stereochemistry. 
 
We attempted to expand the scope of the present methodology, but the results were not 
successful. Scheme 3.5 demonstrates two of such examples. Replacing allyl phenyl 
dimethylsilane with methallyl phenyl dimethylsilane on 3.3, with stoichiometric amount of the 
optimal catalyst 3.11 under optimal conditions, afforded 3.20 in 33% ee. When an methoxy 
group was installed on the substrate, also with stoichiometric amount of the optimal catalyst 3.11 
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under optimal conditions, the reaction afforded 3.22 only in 9% ee. We noticed that the 
background reactions for both processes were quite fast in the absence of catalyst. We postulate 
that the enhanced nucleophilicity of the methallyl phenyl dimethylsilane in comparison to the 
allyl phenyl dimethylsilane creates the potential for the competitive reaction with intermediates 
related to 3.4 (Scheme 3.2). The electron donation  from  the  methoxy  group  stabilizes  the  
intermediate cation and weakens its interaction with the chiral counterion. 
 
 
Scheme 3.5 Unsuccessful attempts to expand the reaction scope. 
 
3.3 SUMMARY 
We have discovered that DDQ-mediated carbon-hydrogen bond cleavage reactions, in the 
presence of a chiral Brønsted acid, can be used to generate chiral aromatic electrophiles that react 
with intermolecular nucleophiles to prepare enantiomerically enriched products. Mechanistic 
studies implicate the formation of a mixed acetal intermediate upon cation formation that ionizes 
in the presence of chiral phosphoric acids to generate chiral ion pairs with reactive oxocarbenium 
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cations, despite the absence of conventional hydrogen bonding sites. While the scope of this 
process is still very limited, several interesting observations have been noted. The uncatalyzed 
background reaction to form racemic addition products is a significant competitive process, but 
can be suppressed by choosing non-polar solvent at low temperature. For higher 
enantioselectivity the best solvent is non-polar aromatic solvent (with PhCF3 being the best), and 
the best nucleophile are allyl phenyl dimethylsilane and allyltriphenyltin. These facts indicate 
possible aromatic interactions between the chiral ion pairs, nucleophiles and solvent which are 
beneficial for the enantioselective outcome. We postulate the best enantioselectivity requires a 
delicate balance of electronic effects and aromatic interactions in the chiral ion pair 
intermediates. Despite these limitations we were able to conduct reactions with good 
enantiocontrol at reasonable catalyst loadings. These processes are, to the best of our knowledge, 
the first examples of enantioselective reactions with chiral electrophiles that arise from oxidative 
carbon-hydrogen bond cleavage. 
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APPENDIX A 
TOTAL SYNTHESIS OF NEOPELTOLIDE AND ANALOGS 
Experimental 
General Experimental  
Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were recorded on 
Bruker Avance 300 spectrometer at 300 MHz and 75 MHz，respectively. The chemical shifts 
are given in parts per million (ppm) on the delta (δ) scale. Tetramethylsilane (TMS) or the 
solvent peak was used as a reference value, for 1H NMR: TMS (in CDCl3) = 0.00 ppm, CD3OD 
=3.31, for 13C NMR: TMS (in CDCl3) = 0.00, CD3OD = 49.00. Data are reported as follows: (s = 
singlet; d = doublet; t = triplet; q = quartet; dd = doublet of doublets; dt = doublet of triplets; br = 
broad). High resolution and low resolution mass spectra were recorded on a VG 7070 
spectrometer. Infrared (IR) spectra were collected on a Mattson Cygnus 100 spectrometer. 
Optical rotations were measured on a Perkin-Elmer 241 polarimeter. Samples for IR were 
prepared as a thin film on a NaCl plate by dissolving the compound in CH2Cl2 and then 
evaporating the CH2Cl2. Analytical TLC was performed on E. Merck pre-coated (25 mm) silica 
gel 60F-254 plates. Visualization was done under UV (254 nm). Flash chromatography was done 
using ICN SiliTech 32-63 60 Å silica gel. Methylene chloride was distilled under N2 from CaH2. 
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Reagent grade ethyl acetate, diethyl ether, pentane and hexanes (commercial mixture) were 
purchased from EM Science and used as is for chromatography. Benzene was dried with 4A 
molecular sieves. THF was distilled from sodium. Other reagents were obtained from 
commercial source without further purification. All reactions were performed in oven or flame-
dried glassware with magnetic stirring unless otherwise noted. 
 
General protocol for the preparation of macrocyclic alcohol from macrocyclic ketone with 
NaBH4 (general protocol A) 
To a one-dram vial charged with macrocyclic ketone (0.020 mmol) was added MeOH (0.5 mL). 
The reaction mixture was cooled to 0 °C and NaBH4 (0.040 mmol) was added. After 10 min, 
AcOH (0.40 mmol) was added and the reaction was concentrated under vacuum. The resulting 
residue was purified by flash column chromatography to afford the desired macrocyclic alcohol. 
 
General protocol for the Mitsunobu coupling (general protocol B) 
To a one-dram vial charged with macrocyclic alcohol (0.019 mmol), oxazolic acid (0.078 mmol) 
and PPh3 (0.086 mmol) was added benzene (0.5 mL). To the reaction mixture was added DIAD 
(0.086 mmol). After ten minutes the reaction was concentrated under vacuum. The resulting 
residue was purified by flash column chromatography to afford the desired product. 
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(1R,5S,7S,9S,11R,13S)-13-hydroxy-7-methoxy-9-methyl-5-propyl-4,15-
dioxabicyclo[9.3.1]pentadecan-3-one (1.5) 
General protocol A was followed, starting from the macrocyclic 
ketone 1.8 (6.5 mg, 0.020 mmol) and NaBH4 (1.6 mg, 0.042 mmol). 
Flash column chromatography (50% EtOAc in hexanes) yielded 6.2 
mg (95%) of the desired product. 1H NMR (300MHz, CDCl3) δ 5.12-5.21(m, 1H), 3.75-3.87(m, 
1H), 3.73(ddd, J = 2.0, 4.4, 10.9 Hz, 1H), 3.59(t, J = 9.4 Hz, 1H), 3.32(s, 3H), 3.18(t, J =9.3 Hz, 
1H), 2.63(dd, J = 4.4, 14.5 Hz, 1H), 2.44(dd, J = 10.7, 14.5 Hz, 1H), 1.99(ddd, J = 1.8, 1.8, 11.5 
Hz, 1H), 1.81-1.92(m, 2H), 1.43-1.78(m, 5H), 1.12-1.41(m, 6H), 1.0(d, J = 6.7 Hz, 3H), 0.92(t, J 
= 7.3 Hz, 3H); 13C NMR (75MHz, CDCl3) δ 170.8, 78.6, 75.6, 73.3, 72.3, 68.1, 56.2, 44.1, 42.2, 
42.2, 41.9, 40.7, 40.0, 36.9, 31.2, 25.5, 19.0, 13.9; IR (film) 3416, 2918, 2871, 1730, 1650, 1459, 
1087 cm-1; HRMS (ESI) calc. for C18H32O5Na ([M+Na]+): 351.2147, found 351.2159; [α]D25 = 
+17.1 (CHCl3, c = 0.2). 
 
(Z)-(1R,5S,7S,9S,11R,13R)-7-methoxy-9-methyl-3-oxo-5-propyl-4,15-dioxabicyclo[9.3.1] 
pentadecan-13-yl 5-(2-((Z)-3-((methoxycarbonyl)amino)prop-1-en-1-yl)-oxazol-4-yl)pent-2-
enoate (1.2) 
General protocol B was followed, starting from the 
macrocyclic alcohol 1.5 (6.2 mg, 0.019 mmol), the 
oxazolic acid 1.6 (22.0 mg, 0.078 mmol), PPh3 (11.4 
mg, 0.086 mmol) and DIAD (16.8 µL, 0.086 mmol). 
Flash column chromatography (30% EtOAc in hexanes) 
yielded 10.5 mg (93%) of neopeltolide. 1H NMR (300MHz, CD3OD) δ 7.66(s,1H), 6.32-6.41(m, 
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1H), 6.28(dt, J = 2.1, 13.8 Hz, 1H), 6.03(pentet, J = 6.0 Hz, 1H), 5.88(d, J = 11.6 Hz, 1H), 
5.20(t, J = 2.8 Hz, 1H), 5.12-5.22(m, 1H), 4.30(dd, J = 1.4, 4.2 Hz, 2H), 4.06(t, J = 9.3 Hz, 1H), 
3.70(s, 1H), 3.65(s, 3H), 3.56(t, J = 9.0 Hz, 1H), 3.28(s, 3H), 3.01(dd, J = 7.6, 15.1 Hz, 2H), 
2.71(s, 1H), 2.70(dt, J = 4.4, 14.7 Hz, 1H), 2.23(dd, J = 11.0, 14.7 Hz, 1H), 1.73-1.90(m, 2H), 
1.65-1.73(m, 2H), 1.44-1.60(m, 5H), 1.26-1.44(m, 6H), 1.07-1.18(m, 1H), 0.97(d, J = 6.3 Hz, 
3H), 0.92(d, J = 13.6 Hz, 3H); 13C NMR (75MHz, CD3OD) δ 173.1, 166.9, 161.9, 159.5, 150.0, 
142.3, 139.3, 136.0, 121.7, 116.0, 77.2, 77.1, 74.0, 71.4, 69.2, 56.4, 52.6, 45.3, 43.5, 43.3, 41.1, 
38.0, 37.6, 37.4, 36.2, 32.6, 29.0, 26.4, 26.0, 20.0, 14.2; IR (film) 3357, 2954, 2922, 2854, 1719, 
1646, 1537, 1458, 1376, 1342, 1249, 1178, 1064, 994, 777cm-1; HRMS (ESI) calc. for 
C31H47N2O9Na ([M+Na]+): 613.3101, found 613.3076; [α]D25 = +17.5 (MeOH, c = 0.24). 
 
(1R,5S,7S,11S,13R,Z)-13-hydroxy-7-methoxy-9-methyl-5-propyl-4,15-dioxabicyclo[9.3.1] 
pentadec-9-en-3-one (1.48) 
General protocol A was followed, starting from the alkene ketone 1.30 
(14.9 mg, 0.046 mmol) and NaBH4 (3.6 mg, 0.095 mmol). Flash 
column chromatography (50% EtOAc in hexanes) yielded 12.6mg 
(84%) of the desired product. 1H NMR (300MHz, CDCl3) δ 5.31-5.37(m, 1H), 5.30(d, J =7.2 Hz, 
1H), 3.82-3.93(m, 3H), 3.49-3.56(m, 1H), 3.36(s, 3H), 2.63(dd, J = 3.8, 15.1 Hz, 1H), 2.51(dd, J 
= 11.1, 15.1 Hz, 1H), 2.33(d, J = 13.3 Hz, 1H), 1.95-2.05(m, 3H), 1.86(d, J = 0.6 Hz, 3H), 1.81-
1.89(m, 1H), 1.64-1.74(m, 1H), 1.47-1.59(m, 2H), 1.44(s, 1H), 1.18-1.40(m, 3H), 0.92(t, J = 7.2 
Hz, 3H); 13C NMR (75MHz, CDCl3) δ 170.3, 146.9, 125.1, 81.8, 74.1, 72.4, 72.0, 68.1, 57.9, 
43.3, 42.1 ,41.8, 40.5, 40.3, 37.4, 25.2, 18.7, 13.9; IR (film) 3422, 2959, 2923, 2854, 1732, 1654, 
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1454, 1373, 1315, 1264, 1195, 1080, 1035, 981, 939, 842, 755 cm-1; HRMS (ESI) calc. for 
C18H30O5Na ([M+Na]+): 349.1991, found 349.1992; [α]D25 = -47.0 (CHCl3, c = 0.38). 
 
(Z)-(1R,5S,7S,11S,13S,Z)-7-methoxy-9-methyl-3-oxo-5-propyl-4,15-dioxabicyclo[9.3.1] 
pentadec-9-en-13-yl 5-(2-((Z)-3-((methoxycarbonyl)amino)prop-1-en-1-yl)-oxazol-4-yl)pent-
2-enoate (1.49) 
General protocol B was followed, starting from the 
alkene alcohol 1.48 (6.8 mg, 0.021 mmol), the oxazolic 
acid (23.0 mg, 0.083 mmol), PPh3 (23.5 mg, 0.090 
mmol) and DIAD (17.8 µL, 0.090mmol). Flash column 
chromatography (30% EtOAc in hexanes) yielded 8.6 
mg (70%) of the alkene analog. 1H NMR (300MHz, CD3OD) δ 7.67(s, 1H), 6.34-6.43(m, 1H), 
6.28(dt, J = 2.0, 12.0 Hz, 1H), 6.05(pentet, J = 6.0 Hz, 1H), 5.90(dt, J = 1.5, 11.5 Hz, 1H), 5.25-
5.33(m, 1H), 5.27(t, J = 2.8 Hz, 1H), 5.22(d, J = 6.7 Hz, 1H), 4.31(d, J = 4.7 Hz, 2H), 4.19-
4.28(m, 2H), 3.66(s, 3H), 3.58-3.65(m, 1H), 3.34(s, 3H), 3.03(ddd, J = 1.4, 7.7, 7.7 Hz, 2H), 
2.73(t, J = 7.0 Hz, 2H), 2.69(dd, J = 3.4, 10.2 Hz, 1H), 2.27-2.38(m, 2H), 1.95(dd, J = 10.4, 13.6 
Hz, 1H), 1.84(s, 3H), 1.62-1.88(m, 5H), 1.49-1.58(m, 3H), 1.23-1.30(m, 3H), 0.95(t, J = 7.3 Hz, 
3H); 13C NMR (75MHz, CD3OD) δ 172.7, 166.9, 162.0, 159.7, 150.1, 148.0, 142.3, 139.3, 136.0, 
127.0, 121.8, 116.0, 83.4, 75.2, 71.3, 71.1, 69.1, 58.2, 52.7, 44.2, 43.3, 42.5, 41.1, 38.5, 36.3, 
35.9, 29.1, 26.5, 25.8, 19.9, 14.3; IR (film) 3351, 2957, 2923, 1719, 1521, 1458, 1268, 1170, 
1097, 1072, 892, 818, 776 cm-1; HRMS (ESI) calc. for C31H44N2O9Na ([M+Na]+): 611.2945, 
found 611.2997; [α]D25 = -44.1 (MeOH, c = 0.56). 
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(1S,5S,7S,9R,11R)-7-methoxy-9-methyl-5-propyl-15-oxabicyclo[9.3.1]pentadecane-3,13-
dione (1.50) 
To a 10 mL flask containing the alkene ketone 1.30 (6.1 mg, 0.019 
mmol) was added Crabtree’s catalyst (3.2 mg, 0.004 mmol). The flask 
was quickly evacuated and backfilled with H2, and this process was 
repeated for three times. Then CH2Cl2 (0.2 mL) was charged and the 
reaction mixture was well stirred at room temperature for 30 min. The reaction mixture was then 
filtered through Celite, concentrated and purified with flash chromatography (5% Et2O in 
CH2Cl2) to afford 3.3 mg (54%) of the diastereomeric ketone. 1H NMR (300MHz, CDCl3) δ 
5.14-5.22(m, 1H), 3.93-4.02(m, 1H), 3.69(ddd, J = 2.6, 6.5, 20.6 Hz, 1H), 3.32(s, 3H), 3.23-
3.31(m, 1H), 2.72(dd, J = 4.5, 14.4 Hz, 1H), 2.46(dd, J = 8.5, 14.4 Hz, 1H), 2.42(dd, J = 4.1, 7.0 
Hz, 1H), 2.31(d, J = 7.8 Hz, 2H), 1.92(dt, J = 2.2, 14.8 Hz, 1H), 1.74-1.83(m, 1H), 1.43-1.73(m, 
4H), 1.16-1.39(m, 6H), 0.94(d, J = 6.8 Hz, 3H), 0.92(t, J = 7.3 Hz, 3H); 13C NMR (75MHz, 
CDCl3) δ 206.4, 179.8, 80.4, 75.0, 73.8, 72.6, 56.3, 48.2, 46.8, 41.7, 41.6, 40.1, 39.0, 37.7, 28.6, 
20.9, 18.7, 13.9; IR (film) 2956, 2923, 2853, 1723, 1459, 1370, 1330, 1252, 1185, 1105, 1081, 
844, 799 cm-1; HRMS (ESI) calc. for C18H30O5Na ([M+Na]+): 349.1991, found 349.1974; [α]D25 
= -7.9 (CHCl3, c = 0.17). 
 
(1R,5S,7S,9R,11R,13S)-13-hydroxy-7-methoxy-9-methyl-5-propyl-15-oxabicyclo[9.3.1]-
pentadecan-3-one 
General protocol A was followed, starting from the diastereomeric 
ketone 1.50 (3.3 mg, 0.010 mmol) and NaBH4 (1.1 mg, 0.029 mmol). 
Flash column chromatography (35% EtOAc in hexanes) yielded 3.2 
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mg (96%) of the desired product. 1H NMR (300MHz, CDCl3) δ 5.11-5.20(m, 1H), 3.80-3.86(m, 
1H), 3.69(tdd, J = 1.9, 4.6, 11.0 Hz, 1H), 3.78(tt, J = 2.4, 8.7 Hz, 1H), 3.31(s, 3H), 3.27(dt, J = 
2.0, 9.1 Hz, 1H), 2.64(dd, J = 4.6, 14.3 Hz, 1H), 2.41(dd, J = 9.0, 14.3 Hz, 1H), 1.90-1.99(m, 
2H), 1.83-1.88(m, 2H), 1.60-1.80(m, 3H), 1.43-1.60(m, 3H), 1.13-1.40(m, 4H), 0.89-0.93(m, 
6H); 13C NMR (75MHz, CDCl3) δ 170.5, 80.5, 74.6, 72.4, 71.5, 68.4, 56.4, 41.8, 41.7, 41.5, 40.3, 
39.6, 39.4, 37.7, 28.7, 21.1, 18.7, 13.9; IR (film) 3363, 3296, 2916, 2852, 1718, 1490, 1457, 
1364, 1274, 1256, 1220, 1160, 1108, 1074, 1036, 931 cm-1; HRMS (ESI) calc. for C18H32O5Na 
([M+Na]+): 351.2147, found 351.2166; [α]D25 = -9.6 (CHCl3, c = 0.32). 
 
(Z)-(1R,5S,7S,9R,11R,13R)-7-methoxy-9-methyl-3-oxo-5-propyl-4,15-dioxabicyclo[9.3.1]- 
pentadecan-13-yl 5-(2-((Z)-3-((methoxycarbonyl)amino)prop-1-en-1-yl)- oxazol-4-yl)pent-2-
enoate (1.51) 
General protocol B was followed, starting from the 
diastereomeric alcohol (3.1 mg, 0.0095 mmol), the 
oxazolic acid 1.6 (10.5 mg, 0.038 mmol), PPh3 (10.7 
mg, 0.041 mmol) and DIAD (8.1 µL, 0.041 mmol). 
Flash column chromatography (30% EtOAc in hexanes) 
yielded 3.8 mg (67%) of the diastereomeric analog. 1H NMR (300MHz, CD3OD) δ 7.65(s, 1H), 
6.36(dt, J = 7.4, 11.6 Hz, 1H), 6.26(dt, J = 2.0, 11.8 Hz, 1H), 6.02(pentet, J = 6.1 Hz, 1H), 
5.86(dt, J = 1.6, 11.5 Hz, 1H), 5.22(t, J = 2.8 Hz, 1H), 5.11-5.20(m, 1H), 4.29(dd, J = 1.5, 5.8 
Hz, 2H), 3.95-4.05(m, 1H), 3.76(t, J =6.0 Hz, 1H), 3.64(s, 3H), 3.29(s,3H), 2.99(dd, J = 7.1, 7.1 
Hz, 2H), 2.69(t, J = 7.7 Hz, 2H), 2.65(dd, J = 4.4, 9.4 Hz, 1H), 2.24(dd, J = 9.2, 14.4 Hz, 1H), 
1.90(d, J = 8.9 Hz, 1H), 1.75-1.84(m, 3H), 1.39-1.68(m, 4H), 1.23-1.39(m, 6H), 1.22(t, J = 7.2 
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Hz, 2H), 1.09-1.19(m, 1H), 0.91(t, J = 7.3 Hz, 3H), 0.89(d, J = 6.7 Hz, 3H); 13C NMR (75MHz, 
CD3OD) δ 172.6, 166.9, 161.9, 159.6, 150.0, 142.2, 139.2 135.9, 121.7, 115.9, 82.1, 75.8, 70.8, 
70.6, 69.4, 68.9, 56.5, 52.6, 42.6, 41.0, 40.9, 40.5, 38.8, 37.0, 35.8, 30.0, 29.0, 26.4, 21.5, 19.8, 
14.2; IR (film) 2923, 2854, 1716, 1519, 1458, 1375, 1249, 1179, 1103, 817 cm-1; HRMS (ESI) 
calc. for C31H46N2O9Na ([M+Na]+): 613.3101, found 613.3075; [α]D25 = +0.2 (MeOH, c = 0.20). 
 
(1R,5S,7R,9R,10S,11S)-9,10-dihydroxy-7-methoxy-9-methyl-5-propyl-4,15-dioxabicyclo-
[9.3.1]pentadecane-3,13-dione (1.52) 
To a one-dram vial charged with osmium tetroxide (6.1 mg, 0.024 
mmol) and pyridine (61 µL, 0.76 mmol) was added THF (0.2 mL). The 
reaction mixture was cooled to 0 °C and the alkene ketone 1.30 (5.3 
mg, 0.016 mmol) in THF (0.2 mL) was added drop wise. After 10 min, 
4-Methylmorpholine N-oxide monohydrate (4.3 mg, 0.032 mmol) was added and the reaction 
was allowed to room temperature over 30 min. The reaction was quenched by 1 mL saturated 
Na2S2O3 at 0 °C and extracted with three 2 mL portions of EtOAc. The organic layer was 
concentrated under vacuum and purified by flash column chromatography (5% MeOH in 
CH2Cl2) to afford 4.4 mg (75%) of the diol. 1H NMR (300MHz, CDCl3) δ 5.03-5.14(m, 1H), 
4.04(tt, J = 3.4, 11.2 Hz, 1H), 3.66(tt, J = 3.0, 11.2 Hz, 1H), 3.59(s, 1H), 3.54-3.58(m, 1H), 
3.39(s, 3H), 3.28(t, J = 7.4 Hz, 1H), 2.84(d, J = 7.2 Hz, 1H), 2.71(dt, J = 1.8, 15.0, 1H), 2.65(dd, 
J = 3.8, 14.5 Hz, 1H), 2.50(dd, J = 11.1, 14.3 Hz, 2H), 2.40(dd, J = 12.2, 15.1 Hz, 1H), 2.27(dd, 
J = 11.5, 13.5 Hz, 1H), 2.15(ddd, J = 1.3, 3.5, 14.4 Hz, 1H), 1.92(dd, J = 2.9, 15.2 Hz, 1H), 
1.63(dd, J = 10.5, 14.8 Hz, 2H), 1.42-1.62(m, 2H), 1.15-1.39(m, 5H), 0.92(t, J = 7.3 Hz, 3H); 13C 
NMR (75MHz, CDCl3) δ 205.5, 169.5, 77.8, 77.7, 73.3, 73.0, 72.9, 56.2, 47.1, 45.0, 42.7, 41.5, 
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38.2, 37.5, 24.8, 18.4, 13.9; IR (film) 3441, 2923, 1721, 1555, 1460, 1377, 1267, 1183, 1100, 
1069, 964, 934, 817 cm-1; HRMS (ESI) calc. for C18H30O7Na ([M+Na]+): 381.1889, found 
381.1902; [α]D25 = -28.5 (MeOH, c = 0.13). 
 
(1R,5S,7R,9R,10S,11S,13R)-9,10,13-trihydroxy-7-methoxy-9-methyl-5-propyl-4,15-
dioxabicyclo[9.3.1]pentadecan-3-one 
General protocol A was followed, starting from the diol 1.52 (3.6 mg, 
0.010 mmol) and NaBH4 (1.1 mg, 0.029 mmol). Flash column 
chromatography (5% MeOH in CH2Cl2) yielded 3.3 mg (92%) of the 
desired triol. 1H NMR (300MHz, CD3OD) δ 5.09-5.18(m, 1H), 3.70-
3.83(m, 2H), 3.49-3.55(m, 1H), 3.46(ddd, J = 1.7, 7.1, 11.1, 1H), 3.32(s, 3H), 3.28(s, 1H), 
2.76(dd, J = 4.6, 14.1 Hz, 1H), 2.30(dd, J = 8.8, 14.1 Hz, 1H), 2.12(dt, J = 2.2, 12.4 Hz, 1H), 
1.97(t, J = 14.8 Hz, 2H), 1.91-1.95(m, 1H), 1.68(dd, J = 10.8, 14.7 Hz, 2H), 1.50-1.65(m, 3H), 
1.20(dd, J = 11.1, 23.4 Hz, 2H), 1.28-1.40(m, 7H), 0.97(t, J =7.2 Hz, 3H); 13C NMR (75MHz, 
CD3OD) δ 171.2, 77.0, 76.6, 76.5, 74.1, 74.0, 72.0, 67.5, 55.0, 45.4, 41.2, 40.6, 39.9, 37.6, 37.4, 
25.6, 18.2, 12.8; IR (film) 3397, 2924, 1729, 1457, 1373, 1263, 1195, 1099, 1044, 937, 731 cm-1; 
HRMS (ESI) calc. for C18H32O7Na ([M+Na]+): 383.2046, found 383.2034; [α]D25 = -8.6 (MeOH, 
c = 0.32). 
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(Z)-(1R,5S,7R,9R,10S,11S,13S)-9,10-dihydroxy-7-methoxy-9-methyl-3-oxo-5-propyl-4,15-
dioxabicyclo[9.3.1]pentadecan-13-yl 5-(2-((Z)-3-((methoxycarbonyl)-amino)prop-1-en-1-
yl)oxazol-4-yl)pent-2-enoate (1.53) 
To a one-dram vial charged with triol (3.5 mg, 0.01 
mmol), oxazole acid 1.6 (4.1 mg, 0.015 mmol) and PPh3 
(4.2 mg, 0.016 mmol) was added benzene (0.2 mL). The 
reaction mixture was cooled to 15 °C and DIAD (3.2 
µL, 0.016 mmol) in benzene (0.1 mL) was added drop 
wise. One hour later an additional PPh3 (1.4 mg, 0.005 mmol) and DIAD (1.07µL, 0.005 mmol) 
in benzene (0.1 mL) was added sequentially. The reaction was quenched with 1 drop of water 
after 20 min, concentrated under vacuum and purified with flash chromatography (5% MeOH in 
CH2Cl2) to afford the desired product (3.0 mg, 50%).1H NMR (300MHz, CDCl3) δ 7.40(s, 1H), 
6.26-6.34(m, 2H), 6.09(pentet, J = 6.4 Hz, 1H), 5.90(dt, J = 1.7, 11.5 Hz, 1H), 5.57(br, 1H), 
5.32(t, J = 2.8 Hz, 1H), 5.06-5.14(m, 1H), 4.31(t, J = 6.1 Hz, 2H), 4.00(tdd, J = 1.9, 1.9, 9.3 Hz, 
1H), 3.69(s, 3H), 3.59-3.67(m, 2H), 3.40(s, 1H), 3.37(s, 3H), 3.35(s, 1H), 3.16(dd, J = 5.7, 8.4 
Hz, 1H), 3.04(ddt, J = 1.9, 7.4, 7.4 Hz, 2H), 2.90(d, J = 6.0 Hz, 1H), 2.72(t, J = 7.2 Hz, 2H), 
2.54(dd, J = 3.8, 14.4 Hz, 1H), 2.36(dd, J = 11.2, 14.4 Hz, 1H), 2.01-2.11(m, 3H), 1.83(d, J = 9.6 
Hz, 1H), 1.68(dt, J = 3.0, 11.5 Hz, 1H), 1.50-1.65(m, 5H), 1.35(t, J = 7.3 Hz, 2H), 1.27(s, 3H), 
0.91(t, J = 7.2 Hz, 3H); 13C NMR (75MHz, CD3OD) δ 171.5, 165.5, 148.6, 140.8, 137.8, 134.6, 
120.3, 114.5, 77.3, 76.8, 74.0, 73.9, 73.6, 69.5, 67.6, 54.9, 45.1, 41.1, 40.1, 37.4, 34.5, 32.5, 27.5, 
25.6, 24.9, 18.2, 12.8; IR (film) 3358, 2957, 2922, 2853, 2500, 1715, 1635, 1553, 1460, 1396, 
1262, 1169, 1095, 1052, 1019, 816, 795, 780 cm-1; HRMS (ESI) calc. for C31H46N2O11Na 
([M+Na]+): 645.2999, found 645.2996; [α]D25 = -2.1 (MeOH, c = 0.16). 
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(1R,5S,7S,9S,10R,11S,13R)-10,13-dihydroxy-7-methoxy-9-methyl-5-propyl-4,15-
dioxabicyclo[9.3.1]pentadecan-3-one (54) and (1R,5S,7S,9R,10S,11S,13R)-10,13-dihydroxy-
7-methoxy-9-methyl-5-propyl-4,15-dioxabicyclo[9.3.1]pentadecan-3-one (1.55) 
To a solution of 1.48 (11.5 mg, 0.035 
mmol) in THF (0.4 mL) at -78 °C, was 
added dropwise 1M BH3/THF solution (135 
µL, 0.135 mmol), and then the reaction was 
allowed to room temperature overnight. A 10% NaOH solution (60 µL) and a 30% aqueous H2O2 
solution (150 µL) were successively added dropwise at 0 °C. After three hours at room 
temperature, the resulting mixture was extracted with Et2O and the combined extracts were 
washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The 
residue was purified by flash chromatography (5% MeOH in DCM) to afford 4.2 mg (35%) of 
1.54 and 3.9 mg (32%) of 1.55. 
1.54: 1H NMR (300MHz, CDCl3) δ 4.80-4.88 (m, 1H), 3.69-3.88(m, 2H), 3.33-3.39(m, 1H), 
3.32(s, 3H), 3.12(apt, J = 9.3 Hz, 1H), 2.59(dd, J = 4.6, 13.6 Hz, 1H), 2.39(dd, J = 9.8, 13.6 Hz, 
1H), 2.22-2.27(m, 1H), 1.97-2.06(m, 2H), 1.73-1.83(m, 2H), 1.48-1.62(m, 4H), 1.19-1.37(m, 
6H), 0.97(d, J = 7.0 Hz, 3H), 0.92(t, J = 7.4 Hz, 3H); 13C NMR (75MHz, CDCl3) δ 170.8, 79.2, 
75.6, 72.1, 68.1, 62.8, 56.3, 42.2, 40.9, 38.6, 38.2, 37.8, 37.0, 34.7, 29.8, 19.0, 16.2, 13.9; IR 
(film) 3358, 2957, 2925, 2872, 1727, 1454, 1374, 1262, 1186, 1148, 1084, 1027, 799 cm-1; 
HRMS (ESI) calc. for C18H32O6Na ([M+Na]+): 367.2097, found 367.2084; [α]D25 = +0.7 (CHCl3, 
c = 0.58). 
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1.55: 1H NMR (300MHz, CDCl3) δ 5.19-5.27(m, 1H), 3.85-3.94(m, 2H), 3.35-3.44(m, 1H), 
3.33(s, 3H), 3.27-3.33(m, 2H), 2.66(dd, J = 3.8, 15.2 Hz, 1H), 2.50(dd, J = 11.2, 15.4 Hz, 1H), 
2.18(s, 1H), 2.14(dd, J = 3.5, 4.6 Hz, 1H), 2.00(ddd, J = 2.4, 2.4, 12.4 Hz, 1H), 1.81-1.93(m, 
2H), 1.77(dd, J = 3.4, 10.7 Hz, 1H), 1.45-1.68(m, 5H), 1.15-1.45(m, 4H), 1.08(d, J = 7.0 Hz, 
3H), 0.91(t, J = 7.3 Hz, 3H); 13C NMR (75MHz, CDCl3) δ 170.4, 80.0, 78.5, 72.9, 72.8, 67.9, 
56.6, 41.9, 40.3, 39.3, 38.8, 37.2, 35.8, 33.8, 24.0, 18.8, 13.9; IR (film) 3400, 2956, 2922, 1727, 
1457, 1366, 1263, 1153, 1089 cm-1; HRMS (ESI) calc. for C18H32O6Na ([M+Na]+): 367.2097, 
found 367.2089; [α]D25 = +2.7 (CHCl3, c = 0.26) 
 
(Z)-(1R,5S,7S,9S,10R,11S,13S)-10-hydroxy-7-methoxy-9-methyl-3-oxo-5-propyl-4,15-
dioxabicyclo[9.3.1]pentadecan-13-yl 5-(2-((Z)-3-((methoxycarbonyl)amino)-prop-1-en-1-
yl)oxazol-4-yl)pent-2-enoate (1.56) 
 To a one-dram vial charged with 1.54 (5.8 mg, 0.017 
mmol), the oxazole acid 6 (7.0 mg, 0.025 mmol) and 
PPh3 (8.8 mg, 0.034 mmol) was added benzene (0.4 
mL). The reaction mixture was cooled to 15 °C and 
DIAD (6.7 µL, 0.034 mmol) in benzene (0.1 mL) was 
added drop wise. Two hours later the reaction was quenched with 1 drop of water, concentrated 
under vacuum and purified with flash chromatography (30% THF in pentane) to afford the 
desired product (4.5 mg, 42%). 1H NMR (400MHz, MeOD) δ 7.70(s, 1H), 6.39(dt, J = 7.7, 12.0 
Hz, 1H), 6.31(d, J = 11.9 Hz, 1H), 6.06(dt, J = 6.1, 12.2 Hz, 1H), 5.90(d, J = 10.6 Hz, 1H), 
5.31(aps, 1H), 4.33(d, J = 5.6 Hz, 2H), 4.07(dd, J = 6.8, 9.4 Hz, 1H), 3.75(apt, J = 6.1 Hz, 1H), 
3.67(s, 3H), 3.49(apt, J = 10.1 Hz, 1H), 3.39-3.43(m, 1H), 3.33(s, 3H), 3.19(dd, J = 2.0, 8.5 Hz, 
OMeO
O
OPr
O
OH
O
N
O
HN
OMe
O
 79 
1H), 3.04(dt, J = 7.4, 7.4 Hz, 2H), 2.74(t, J = 7.4 Hz, 2H), 2.66(dd, J = 4.2, 13.7 Hz, 1H), 
2.30(dd, J = 10.1, 13.6 Hz, 1H), 2.05(apq, J = 12.7 Hz, 2H), 1.76-1.90(m, 3H), 1.51-1.67(m, 
4H), 1.22-1.38(m, 4H), 0.97(d, J = 7.2 Hz, 3H), 0.94(t, J = 7.3 Hz, 3H); 13C NMR (100MHz, 
MeOD) δ 173.1, 167.0, 162.0, 150.1, 142.4, 139.3, 136.1, 121.8, 116.1, 78.7, 77.9, 77.6, 71.1, 
69.0, 68.9, 56.6, 52.7, 43.3, 41.2, 40.0, 39.7, 38.3, 36.7, 36.0, 33.8, 29.1, 26.5, 20.2, 17.0, 14.3; 
IR (film) 3366, 2958, 2924, 2873, 1714, 1520, 1461, 1417, 1264, 1182, 1154, 1091, 820 cm-1; 
HRMS (ESI) calc. for C31H46N2O10Na ([M+Na]+): 629.3050, found 629.3055; [α]D25 = +13.3 
(CHCl3, c = 0.36).  
 
(Z)-(1R,5S,7S,9R,10S,11S,13S)-10-hydroxy-7-methoxy-9-methyl-3-oxo-5-propyl-4,15-
dioxabicyclo[9.3.1]pentadecan-13-yl 5-(2-((Z)-3-((methoxycarbonyl)amino)-prop-1-en-1-
yl)oxazol-4-yl)pent-2-enoate (1.57) 
To a one-dram vial charged with 1.55 (2.6 mg, 0.0075 
mmol), the oxazole acid 1.6 (3.6 mg, 0.013 mmol) and 
PPh3 (4.4 mg, 0.017 mmol) was added benzene (0.2 
mL). The reaction mixture was cooled to 15 °C and 
DIAD (3.4 µL, 0.017 mmol) in benzene (0.1 mL) was 
added drop wise. Two hours later the reaction was quenched with 1 drop of water, concentrated 
under vacuum and purified with flash chromatography (30% THF in pentane) to afford the 
desired product (2.1 mg, 45%). 1H NMR (400MHz, CDCl3) δ 7.39(s, 1H), 6.34(dt, J = 7.3, 11.5 
Hz, 1H), 6.29(dt, J = 1.5, 11.6 Hz, 1H), 6.10(dt, J = 6.3, 11.9 Hz, 1H), 4.89(dt, J = 1.6, 11.4 Hz, 
1H), 5.52(brs, 1H), 5.20-5.28(m, 2H), 4.32(t, J = 5.8 Hz, 2H), 4.22(apt, J = 14.9 Hz, 1H), 3.69(s, 
3H), 3.65(dd, J = 1.7, 12.1 Hz, 1H), 3.79-3.42(m, 1H), 3.32(s, 3H), 3.21(d, J = 9.7 Hz, 1H), 
OMeO
O
OPr
O
OH
O
N
O
HN
OMe
O
 80 
3.04(dtd, J = 1.6, 7.5, 7.5 Hz, 2H), 2.72(t, J = 7.1 Hz, 2H), 2.61(dd, J = 3.8, 15.4 Hz, 1H), 
2.42(dd, J = 11.4, 15.4 Hz, 1H), 2.10-2.17(m, 1H), 2.00(ddd, J = 3.0, 12.1, 15.7 Hz, 1H), 1.80-
1.88(m, 2H), 1.60-1.69(m, 2H), 1.41-1.56(m, 4H), 1.25-1.38(m, 4H), 1.07(d, J = 7.1 Hz, 3H), 
0.92(t, J = 7.3 Hz, 3H); 13C NMR (100MHz, CDCl3) δ 170.4, 165.3, 149.6, 136.4, 133.9, 133.1, 
120.5, 116.7, 78.3, 72.9, 70.4, 67.5, 56.6, 53.4, 42.0, 39.3, 37.3, 35.7, 34.9, 33.7, 33.2, 31.9, 27.7, 
25.6, 23.9, 22.7, 18.8, 13.9; IR (film) 3406, 2956, 2923, 2853, 1713, 1643, 1533, 1377, 1261, 
1151, 1117, 798 cm-1; HRMS (ESI) calc. for C31H46N2O10Na ([M+Na]+): 629.3050, found 
629.3079; [α]D25 = +6.7 (CHCl3, c = 0.21) 
 
(1S,2S,4R,6R,8S,12R,14R)-14-hydroxy-6-methoxy-4-methyl-8-propyl-3,9,16-trioxatricyclo-
[10.3.1.02,4]hexadecan-10-one (1.58) 
To a one-dram vial charged with the alkene alcohol 1.48 (5.9 mg, 
0.018 mmol) and NaHCO3 (5.8 mg, 0.069 mmol) was added CH2Cl2 
(1 mL). The reaction mixture was cooled to 0 °C and recrystallized m-
CPBA (4.5 mg, 0.026 mmol) was added in one portion. The reaction 
was maintained at 0 °C for 4 hours, and then allowed to room temperature overnight. The 
reaction was quenched by the addition of 0.7 mL saturated Na2S2O3 solution and 0.7 mL 
saturated NaHCO3 solution at 0 °C, and extracted with three 1 mL portions of ethyl acetate. 
Flash chromatography with (50% EtOAc in hexanes) afforded 3.4 mg (55%) of the epoxy 
alcohol. 1H NMR (300MHz, CDCl3) δ 5.32-5.42(m, 1H), 3.8(br, 1H), 3.76(tdd, J = 1.5, 3.8, 10.9 
Hz, 1H), 3.65(dd, J = 5.4, 8.9 Hz, 1H), 3.06(ddd, J = 2.0, 8.0, 10.9 Hz, 1H), 2.71(d, J = 7.8 Hz, 
1H), 2.58(dd, J = 3.8, 15.1 Hz, 1H), 2.50(dd, J = 10.8, 15.2 Hz, 1H), 2.25(dt, J = 2.4, 12.4 Hz, 
1H), 2.12(dd, J = 11.2, 14.6 Hz, 1H), 1.86-2.00(m, 3H), 1.43-1.62(m, 5H), 1.34(s, 3H), 1.24-
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1.39(m, 6H), 0.91(t, J = 7.2 Hz, 3H); 13C NMR (75MHz, CDCl3) δ 170.2, 73.9, 73.4, 67.4, 64.6, 
61.8, 57.2, 44.4, 41.8, 41.6, 39.8, 39.3, 37.3, 23.3, 22.7, 18.7, 13.9; IR (film) 3435, 2924, 2854, 
1732, 1459, 1374, 1262, 1200, 1078, 942, 799cm-1; HRMS (ESI) calc. for C18H30O6Na 
([M+Na]+): 365.1940, found 365.1932; [α]D25 = -23.5 (CHCl3, c = 0.33). 
 
(Z)-(1S,2S,4R,6R,8S,12R,14S)-6-methoxy-4-methyl-10-oxo-8-propyl-3,9,16-
trioxatricyclo[10.3.1.02,4]hexadecan-14-yl 5-(2-((Z)-3-((methoxycarbonyl)amino)prop-1-en-
1-yl)oxazol-4-yl)pent-2-enoate (1.59) 
General protocol B was followed, starting from the 
epoxy alcohol 1.58 (3.1 mg, 0.009 mmol), the oxazolic 
acid 1.6 (11.2 mg, 0.040 mmol), PPh3 (11.4 mg, 0.044 
mmol) and DIAD (8.6 µL, 0.044 mmol). Flash column 
chromatography (30% EtOAc in CH2Cl2) yielded 3.6 
mg (66%) of the epoxy analog. 1H NMR (300MHz, CD3OD) δ 7.65(s, 1H), 6.36(dt, J = 4.1, 7.3 
Hz, 1H), 6.27(dt, J = 2.1, 11.9 Hz, 1H), 6.03(pentet, J = 6.0 Hz, 1H), 5.89(dt, J = 1.6, 11.6 Hz, 
1H), 5.27-5.39(m, 1H), 5.28(t, J = 3.0 Hz, 1H), 4.30(dd, J = 1.8, 6.1 Hz, 2H), 4.08-4.18(m, 1H), 
3.72(dd, J = 5.3, 10.0 Hz, 1H), 3.65(s, 3H), 3.34-3.42(m, 1H), 3.37(s, 3H), 3.00(ddd, J = 1.7, 7.4, 
7.4 Hz, 2H), 2.71(t, J = 7.1 Hz, 2H), 2.63-2.70(m, 2H), 2.33(dd, J = 11.6, 15.2 Hz, 1H), 2.04(dd, 
J = 10.4, 14.7 Hz, 2H), 1.74-1.96(m, 4H), 1.47-1.66(m, 4H), 1.26-1.40(m, 4H), 1.30(s, 3H), 
0.93(t, J = 7.3 Hz, 3H); 13C NMR (75MHz, CD3OD) δ 172.4, 166.7, 161.9, 150.2, 142.2, 139.1, 
136.0, 121.6, 116.0, 77.8, 74.9, 72.2, 68.2, 66.1, 63.0, 57.0, 44.8, 42.7, 42.0, 38.4, 35.4, 34.9, 
29.0, 26.4, 23.7, 19.7, 14.1; IR (film) 3352, 2960, 2924, 1724, 1644, 1521, 1440, 1380, 1266, 
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1253, 1173, 1126, 1077, 1006, 968, 778 cm-1; HRMS (ESI) calc. for C31H46N2O10Na ([M+Na]+): 
627.2894, found 627.2910; [α]D25 = -11.3 (MeOH, c = 0.34). 
 
(1R,5S,7S,9S,11R,13R)-13-azido-7-methoxy-9-methyl-5-propyl-4,15-dioxa-bicyclo[9.3.1]-
pentadecan-3-one (1.61) 
To a mixture of the macrocyclic alcohol 1.5 (11.3 mg, 0.031 mmol), 
triethylamine (48 µL, 0.34 mmol) and dichloromethane (0.5 mL) at 0 
°C was added MsCl (8.0 µL, 0.10 mmol). The reaction was kept at 0 
°C for 30 minutes, allowed to room temperature and stirred for 4 hours. Then the reaction 
mixture was cooled to 0 °C, treated with 1N HCl, and extracted with dichloromethane for three 
times. The organic extracts were dried with MgSO4, filtered and concentrated under vacuum to 
afford 1.60. 1H NMR (300MHz, CDCl3) δ 5.12-5.20(m, 1H), 4.82(ddd, J = 5.0, 11.3, 16.3 Hz, 
1H), 3.80(dddd, J = 2.2, 4.3, 11.2, 11.2 Hz, 1H), 3.52(apt, J = 8.9 Hz, 1H), 3.31(s, 3H), 3.23(apt, 
J = 10.0 Hz, 1H), 3.03(s, 3H), 2.65(dd, J = 4.4, 14.5 Hz, 1H), 2.44(dd, J = 10.7, 14.5 Hz, 1H), 
2.12-2.19(m, 1H), 2.03-2.08(m, 1H), 1.84(dd, J = 10.5, 13.4 Hz, 1H), 1.61-1.73(m, 2H), 1.45-
1.59(m, 5H), 1.10-1.41(m, 7H), 0.99(d, J = 6.7 Hz, 3H), 0.91(t, J = 7.2 Hz, 3H). This residual 
crude product was re-dissolved in DMF (1 mL) and treated with sodium azide (16.9 mg, 0.26 
mmol) at 80 °C overnight. The reaction mixture was dispersed between water and diethyl ether, 
and the organic layer was concentrated under vacuum. Flash chromatography (30% ethyl acetate 
in pentane) afforded the desired azide (4.9mg, 42% over two steps). 1H NMR (300MHz, CDCl3) 
δ 5.19 (ddd, J = 4.5, 10.0, 10.0 Hz, 1H), 4.02-4.09(m, 2H), 3.54(apt, J = 9.5 Hz, 2H), 3.30(s, 
3H), 2.61(dd, J = 4.3, 14.5 Hz, 1H), 2.35(dd, J = 10.8, 14.6 Hz, 1H), 1.84(dd, J = 10.9, 14.7 Hz, 
1H), 1.63-1.76(m, 2H), 1.46-1.61(m, 6H), 1.31-1.43(m, 5H), 1.11-1.25(m, 3H), 0.99(d, J = 6.4 
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Hz, 3H), 0.92(t, J = 7.3 Hz, 3H); 13C NMR (75MHz, CDCl3) δ 170.6, 75.6, 75.3, 73.0, 69.4, 
56.2, 44.0, 42.2, 40.1, 37.0, 35.9, 34.8, 31.3, 25.6, 19.0, 13.9; IR (film) 2956, 2922, 2871, 2100, 
1731, 1460, 1438, 1382, 1272, 1244, 1197, 1165, 1086, 1032, 992, 797 cm-1; HRMS (ESI) calc. 
for C18H33N3O4Na ([M+Na]+): 376.2212, found 376.2239; [α]D25 = +39.1 (CHCl3, c = 0.45) 
 
(1R,5S,7S,9S,11R,13R)-13-amino-7-methoxy-9-methyl-5-propyl-4,15-dioxa-bicyclo[9.3.1]-
pentadecan-3-one (1.62) 
A mixture of 1.61 (4.9 mg, 0.013 mmol) and 10% Pd/C (4.9 mg) in 
ethanol (0.5 mL) was stirred under hydrogen atmosphere for 5 
hours. The mixture was then filtered through Celite and purified on a 
flash column (10% MeOH in dichloromethane with 1% ammonium hydroxide) to give 3.9 mg 
(83%) of the desired product. 1H NMR (300MHz, CDCl3) δ 5.14-5.23(m, 1H), 4.09-4.21(m, 1H), 
3.63(m, 2H), 3.44(app s, 1H), 3.31(s, 3H), 2.57(dd, J = 3.8, 14.7 Hz, 1H), 2.35(dd, J = 10.8, 14.0 
Hz, 1H), 2.17(s, 1H), 1.86(dd, J = 10.6, 14.6 Hz, 1H), 1.30-1.40(m, 5H), 1.42-1.75(m, 8H), 
1.14(t, J = 11.6 Hz, 2H), 0.98(d, J = 6.1 Hz, 3H), 0.91(t, J = 7.4 Hz, 3H); 13C NMR (75MHz, 
CDCl3) δ 171.2, 75.6, 74.7, 72.8, 69.0, 56.2, 44.3, 42.6, 42.3, 40.2, 39.5, 38.3, 37.0, 31.4, 25.7, 
19.9, 13.9; IR (film) 3372, 2956, 2923, 2869, 1728, 1460, 1439, 1382, 1341, 1275, 1196, 1157, 
1088, 1029, 795 cm-1; HRMS (ESI) calc. for C18H33NO4Na ([M+Na]+): 350.2307, found 
350.2320; [α]D25 = +21.8 (CHCl3, c = 0.38). 
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Methyl (Z)-3-(4-((Z)-5-((1R,5S,7S,9S,11R,13R)-7-methoxy-9-methyl-3-oxo-5-propyl-4,15-
dioxa-bicyclo[9.3.1]pentadecan-13-ylamino)-5-oxopent-3-enyl)oxazol-2-yl)allylcarbamate 
(1.63) 
The macrolactone amine 1.62 (3.8 mg, 0.012 mmol), the 
oxazole acid 1.6 (7.6 mg, 0.027 mmol), 
diisopropylethylamine (9 µL, 0.052 mmol) and DCM 
(0.8 mL) were mixed and cooled to 0 °C. PyBOP (19.0 
mg, 0.036 mmol) was added, and it was allowed to room 
temperature overnight. The reaction mixture was then concentrated and purified through a flash 
column (60% ethyl acetate in pentane) to afford 5.3 mg (77%) of the desired amide. 1H NMR 
(300MHz, MeOD) δ 7.67(s, 1H), 6.30(dt, J = 2.1, 11.9 Hz, 1H), 6.10(dt, J = 7.1, 11.5 Hz, 1H), 
6.06(d, J = 11.9 Hz, 1H), 5.99(dt, J = 1.4, 11.5 Hz, 1H), 5.16-5.25(m, 1H), 4.33(dd, J = 1.7, 5.8 
Hz, 2H), 4.16-4.22(m, 1H), 4.08(dddd, J = 1.3, 1.3, 10.9, 10.9 Hz, 1H), 3.71(app t, J = 8.8 Hz, 
1H), 3.68(s, 3H), 3.56(app t, J = 9.7 Hz, 1H), 3.31(s, 3H), 3.01(dt, J = 7.4, 7.4 Hz, 2H), 2.71(t, J 
= 7.4 Hz, 2H), 2.67-2.74(m, 1H), 2.32(dd, J = 10.9, 14.8 Hz, 1H), 1.91(dd, J = 10.9, 14.8 Hz, 
1H), 1.69-1.79(m, 2H), 1.45-1.61(m, 7H), 1.10-1.43(m, 6H), 1.02(d, J = 6.5 Hz, 3H), 0.96(t, J = 
7.3 Hz, 3H); 13C NMR (75MHz, MeOD) δ 173.2, 168.9, 161.9, 145.0, 142.6, 139.2, 136.1, 
124.3, 116.0, 77.2, 77.1, 73.9, 56.5, 52.7, 45.5, 44.9, 43.6, 43.5, 41.2, 41.1, 38.1, 173.2, 168.9, 
161.9, 145.0, 142.6, 139.2, 136.1, 124.3, 116.0, 77.2, 77.1, 73.9, 56.5, 52.7, 45.5, 44.9, 43.6, 
43.5, 41.2, 41.1, 38.1, 37.4, 36.2, 32.7, 28.7, 26.7, 26.1, 20.1, 14.2; IR (film) 3413, 2922, 2851, 
1725, 1711, 1660, 1631, 1550, 1533, 1462, 1377, 1260, 1086, 1018, 798 cm-1; HRMS (ESI) calc. 
for C31H47N3O8Na ([M+Na]+): 612.3261, found 612.3264; [α]D25 = +10.7 (MeOH, c = 0.53). 
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Methyl 3-(3-bromophenyl)propanoate (1.69) 
To a solution of 3-(3-bromophenyl)propanoic acid (1.603 g, 7.0 mmol) in 
methanol (20 mL) was added dropwise SOCl2 (1.03 mL, 14.2 mmol) at 0 
°C. The reaction was allowed to room temperature and stirred overnight. 
Concentration at reduced temperature and flash chromatography (20% ethyl acetate in hexanes) 
afforded 1.727 g (quantitative yield) of the desired ester. 1H NMR (300MHz, CDCl3) δ 7.35(s, 
1H), 7.34(d, J = 7.4 Hz, 1H), 7.12-7.19(m, 2H), 3.68(s, 3H), 2.92(t, J = 7.6 Hz, 2H), 2.62 (t, J = 
7.9 Hz, 2H). 
 
 
Methyl 3-(3-(3-(methoxycarbonyl)prop-1-ynyl)phenyl)propanoate (1.71) 
To a flame-dried 50 mL round bottom flask was charged methyl 3-(3-
bromophenyl)propanoate 1.69 (122 mg, 0.50 mmol), PdCl2(PPh3)2 (35 mg, 
0.050 mmol), PPh3 (26 mg, 0.10 mmol), CuI (9.5 mg, 0.050 mmol) , 
distilled diisopropylamine (0.64 mL, 4.5 mmol) and distilled THF (2 mL). 
The reaction was degassed with argon for 15 minutes, and then methyl 
prop-2-ynylcarbamate 1.70 (124 mg, 1.1 mmol) was added drop wise with a syringe. The 
reaction mixture was heated to 55 °C overnight with argon protection. Flash chromatography 
with 40% ethyl acetate in hexanes gave 121 mg (88%) of the desired product. 1H NMR 
(300MHz, CDCl3) δ 7.14-7.26(m, 4H), 5.12(brs, 1H), 4.16(d, J = 4.9 Hz, 2H), 3.71(s, 3H), 
3.67(s, 3H), 2.91(t, J = 7.8 Hz, 2H), 2.61(t, J = 7.7 Hz, 2H). 
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(Z)-methyl 3-(3-(3-(methoxycarbonyl)prop-1-enyl)phenyl)propanoate (1.72) 
To a 25 mL round bottom flask was charged nickel acetate tetra hydrate 
(21.7 mg, 0.087 mmol) and 95% ethanol (1 mL), and hydrogen atmosphere 
was applied. Then 0.11 mL NaBH4 solution (1N, 0.11 mmol) in 95% 
ethanol (with 0.1N NaOH) was added to the flask within 10 seconds. After 
three minutes ethylenediamine (11.7 µL, 0.175 mmol) was added, followed by another three 
minutes of stirring. Methyl 3-(3-(3-(methoxycarbonyl)prop-1-ynyl)phenyl)propanoate 1.71 (55 
mg, 0.20 mmol) was added. After 1.5 hours the reaction mixture was partitioned between diethyl 
ether and water. The organic phase was dried with sodium sulfate, filtered and concentrated 
under vacuum. Flash chromatography with 50% ethyl acetate in hexanes gave 44.1 mg (80%) of 
the desired product. 1H NMR (300MHz, CDCl3) δ 7.27(t, J= 7.0 Hz, 1H), 7.04-7.11(m, 3H), 
6.54(d, J = 11.6 Hz, 1H), 5.67(dt, J = 6.6, 11.5 Hz, 1H), 4.86(brs, 1H), 4.06(t, J = 5.4 Hz, 2H), 
3.68(s, 3H), 3.67(s, 3H), 2.95(t, J = 7.8 Hz, 2H), 2.64(t, J = 7.5 Hz, 2H). 
 
 
(Z)-methyl 3-(3-(3-oxopropyl)phenyl)allylcarbamate (1.73) 
To a 25 mL round bottom flask was charged (Z)-methyl 3-(3-(3-
(methoxycarbonyl)prop-1-enyl)phenyl)propanoate 1.72 (44.1 mg, 0.159 
mmol) and dichloromethane (3 mL). The reaction was cooled to -78 °C, and 
1M DIBAL-H (0.21 mL, 0.21 mmol) solution in hexanes was added drop 
wise under nitrogen. After 1 hour of stirring at -78 °C, The reaction was quenched with saturated 
ammonium chloride aqueous solution. Flash chromatography with 40% ethyl acetate in hexanes 
gave 25.2 mg (64%) of the desired product. 1H NMR (300MHz, CDCl3) δ 9.82(s, 1H), 7.26(t, J 
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= 4.0 Hz, 1H), 7.02-7.11(m, 3H), 6.54(d, J = 11.6 Hz, 1H), 5.67(dt, J = 6.6, 11.6 Hz, 1H), 
4.81(brs, 1H), 4.07(t, J = 5.3 Hz, 2H), 3.68(s, 3H), 2.96(t, J = 7.4 Hz, 2H), 2.79(t, J = 7.6 Hz, 
2H). 
 
 
(Z)-methyl 5-(3-((Z)-3-(methoxycarbonyl)prop-1-enyl)phenyl)pent-2-enoate 
To a 25 mL round bottom flask was charged methyl 
bis(trifluoroethyl)phosphonoacetate (27 µL, 0.13 mmol), 18-crown-6 (102 
mg, 0.39 mmol) and THF (1 mL). The mixture was cooled to -78 °C, and 
KHMDS (19 mg, 0.095 mmol) in 2 mL THF was added drop wise under 
nitrogen. After 30 minutes of stirring the (Z)-methyl 3-(3-(3-oxopropyl)phenyl)allylcarbamate 
1.73 (16.7 mg, 0.068 mmol) in 2 mL THF was added drop wise, followed by 4 hours of stirring 
at -78 °C. The reaction was quenched with saturated NH4Cl aqueous solution and extracted with 
ethyl acetate. Flash chromatography with 30% ethyl acetate in hexanes gave 16.8 mg (82%) of 
the desired product. 1H NMR (300MHz, CDCl3) δ 7.27(t, J = 7.6 Hz, 1H), 7.12(d, J = 7.7 Hz, 
1H), 7.07(s, 1H), 7.06(d, J = 8.1 Hz, 1H), 6.54(d, J = 11.6 Hz, 1H), 6.26(dt, J = 7.5, 11.5 Hz, 
1H), 5.80(dt, J = 1.6, 11.5 Hz, 1H), 5.67(dt, J = 6.7, 11.8 Hz, 1H), 4.84(brs, 1H), 4.08(t, J = 5.2 
Hz, 2H), 3.70(s, 3H), 3.68(s, 3H), 2.99(td, J = 1.3, 7.6 Hz, 2H), 2.76(t, J = 8.0 Hz, 2H); ); 13C 
NMR (75MHz, CDCl3) δ 166.7, 149.2, 141.2, 136.4, 131.5, 128.9, 128.4, 127.4, 126.5, 120.0, 
52.2, 51.1, 39.3, 35.0, 30.4; IR (film) 3399, 1719, 1643, 1570, 1453, 1251, 1147, 1071, 1023, 
819 cm-1; HRMS (ESI) calc. for C17H21NO4Na ([M+Na]+): 326.1368, found 326.1360. 
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(Z)-5-(3-((Z)-3-((methoxycarbonyl)amino)prop-1-en-1-yl)phenyl)pent-2-enoic acid (1.74) 
The (Z)-methyl 5-(3-((Z)-3-(methoxycarbonyl)prop-1-enyl)- phenyl)-pent-2-
enoate (14.1 mg, 0.046 mmol) was dissolved in THF (0.22 mL) at room 
temperature. After 1N LiOH aqueous solution (0.45 mL, 0.45 mmol) was 
added, the reaction mixture was stirred at room temperature for 4 hours. The 
reaction mixture was acidified with 2N HCl drop wise at 0 °C to pH 3, and extracted with three 2 
mL portions of ethyl acetate. The organic phase was dried with Na2SO4, filtered and 
concentrated under vacuum. Flash chromatography with 5% methanol in dichloromethane gave 
12.7 mg (95%) of the desired product. 1H NMR (300MHz, CDCl3) δ 7.26(t, J = 7.8 Hz, 1H), 
7.03-7.10(m, 3H), 6.55(d, J = 11.6 Hz, 1H), 6.34(dt, J = 7.5, 11.3 Hz, 1H), 5.81(d, J = 11.5 Hz, 
1H), 5.64(dt, J = 6.5, 11.8 Hz, 1H), 4.84(brs, 1H), 4.09(app s, 2H), 3.69(s, 3H), 3.00(dt, J = 7.5, 
7.5 Hz, 2H), 2.77(t, J = 7.6 Hz, 2H); 13C NMR (75MHz, CDCl3) δ 169.9, 157.2, 150.5, 141.0, 
136.4, 131.6, 128.8, 128.3, 128.1, 127.6, 126.6, 120.2, 52.4, 39.6, 34.9, 30.6; IR (film) 3336, 
2924, 1700, 1641, 1531, 1435, 1260, 1194, 1152, 803 cm-1; HRMS (ESI) calc. for C16H19NO4Na 
([M+Na]+): 312.1212, found 312.1215. 
 
(Z)-(1R,5S,7S,9S,11R,13R)-7-methoxy-9-methyl-3-oxo-5-propyl-4,15-dioxabicyclo[9.3.1]-
pentadecan-13-yl 5-(3-((Z)-3-((methoxycarbonyl)amino)prop-1-en-1-yl)-phenyl)pent-2-
enoate (1.64) 
General protocol B was followed, starting from the 
macrocyclic alcohol 1.5 (2.2 mg, 0.0067 mmol), the phenyl 
acid 1.74 (7.1 mg, 0.024 mmol), PPh3 (7.0 mg, 0.027 
mmol) and DIAD (5.4 µL, 0.027 mmol). Flash column 
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chromatography (30% THF in hexanes) yielded 3.5 mg (87%) of the desired product. 1H NMR 
(400MHz, CD3OD) δ 7.27(t, J = 7.8 Hz, 1H), 7.13(d, J = 5.8 Hz, 1H), 7.13(s, 1H), 7.09(d, J = 
7.8 Hz, 1H), 6.52(d, J = 11.6 Hz, 1H), 6.36(dt, J = 7.6, 11.6 Hz, 1H), 5.85(dt, J = 1.5, 11.6 Hz, 
1H), 5.65(dt, J = 6.5, 11.6 Hz, 1H), 5.14-5.20(m, 2H), 4.02-4.07(m, 1H), 3.99(apd, J = 5.3, 2H), 
3.66(apt, J = 9.7 Hz, 1H), 3.64(s, 3H), 3.54(apt, J = 9.5 Hz, 1H), 3.27(s, 3H), 3.00(dt, J = 7.8, 7.8 
Hz, 2H), 2.79(t, J = 7.4 Hz, 2H), 2.67(dd, J = 4.3, 14.8 Hz, 1H), 2.28(dd, J = 11, 14.8 Hz, 1H), 
1.75-1.89(m, 3H), 1.61-1.73(m, 2H), 1.44-1.60(m, 4H), 1.25-1.42(m, 5H), 1.11(ddd, J= 2.0, 
11.0, 13.0 Hz, 1H), 0.96(d, J = 6.7 Hz, 3H), 0.93(t, J = 7.3 Hz, 3H); 13C NMR (100MHz, 
CD3OD) δ 173.1, 166.9, 150.6, 142.6, 138.0, 131.8, 130.0, 129.4, 128.4, 127.6, 121.4, 77.1, 77.0, 
73.9, 71.3, 69.1, 56.4, 52.4, 45.3, 43.5, 43.2, 41.1, 40.4, 38.0, 37.4, 36.2, 36.0, 32.6, 31.9, 26.0, 
22.3, 20.0, 14.1; IR (film) 3338, 2956, 2923, 2854, 1717, 1643, 1527, 1460, 1375, 1250, 1180, 
1156, 1111, 1084, 1033, 800 cm-1; HRMS (ESI) calc. for C34H49NO8Na ([M+Na]+): 622.3356, 
found 622.3322; [α]D25 = +14.2 (MeOH, c = 0.33). 
 
 
(E)-ethyl 3-(6-bromopyridin-2-yl)acrylate (1.76) 
To a suspension of 60% sodium hydride (135 mg, 3.38 mmol) in THF (10 
mL) (EtO)2P(O)CH2CO2Et (0.62 mL, 3.1 mmol) was added drop wise at 0 
°C under nitrogen. Thirty minutes later, 6-bromopicolinaldehyde 1.75 (465 
mg, 2.5 mmol) in 2 mL THF was added dropwise, and the reaction mixture was allowed to room 
temperature afterwards. After 1 hour, the reaction mixture was partitioned between diethyl ether 
and water. The organic phase was dried, filtered and concentrated under vacuum. Flash 
chromatography with 20% diethyl ether in hexanes gave 615 mg (96%) of the desired product. 
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1H NMR (300MHz, CDCl3) δ 7.57(t, J = 7.3 Hz, 1H), 7.53(d, J = 15.5 Hz, 1H), 7.44(d, J = 7.7 
Hz, 1H), 7.46(d, J = 7.5 Hz, 1H), 6.95(d, J = 15.6 Hz, 1H), 4.22(q, J = 7.1 Hz, 2H), 1.33(t, J = 
7.1 Hz, 3H). 
 
Ethyl 3-(6-bromopyridin-2-yl)propanoate (1.77) 
In a 25 mL round bottom flask (E)-ethyl 3-(6-bromopyridin-2-yl)acrylate 
1.76 (595 mg, 2.32 mmol) and CuCl (241 mg, 2.43 mmol) was dissolved in 
80% methanol (13.5 mL) at 0 °C under nitrogen. NaBH4 (92.0 mg, 2.32 
mmol) was added, 1 hour later another NaBH4 (92.0 mg, 2.32 mmol), and an additional hour 
later a third NaBH4 (46.0 mg, 1.16 mmol) was added. After 30 minutes the reaction mixture 
was partitioned between diethyl ether and water, and the organic phase was dried, filtered and 
concentrated under vacuum. Flash chromatography with 20% diethyl ether in dichloromethane 
gave 448 mg (75%) of the desired product. 1H NMR (300MHz, CDCl3) δ 7.45(t, J = 7.6 Hz, 
1H), 7.31(d, J = 7.8 Hz, 1H), 7.16(d, J = 7.4 Hz, 1H), 4.13(q, J = 7.2 Hz, 2H), 3.08(t, J = 7.4 
Hz, 2H), 2.78(t, J = 7.4 Hz, 2H), 1.24(t, J = 7.2 Hz, 3H). 
 
Ethyl 3-(6-(3-(methoxycarbonyl)prop-1-ynyl)pyridin-2-yl)propanoate (1.78) 
To a flame-dried 50 mL round bottom flask was charged ethyl 3-(6-
bromopyridin-2-yl)propanoate 1.77 (194 mg, 0.75 mmol), PdCl2(PPh3)2 (52 
mg, 0.074 mmol), PPh3 (39 mg, 0.15 mmol), CuI (14.4 mg, 0.076 mmol) , 
distilled diisopropylamine (0.96 mL, 6.8 mmol) and distilled THF (3 mL). 
The reaction was degassed with argon for 15 minutes, and then methyl 
prop-2-ynylcarbamate 1.70 (186 mg, 1.65 mmol) was added drop wise with a syringe. The 
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reaction mixture was heated at 50 °C for 1.5 hours with argon protection. Flash 
chromatography with 40% ethyl acetate in hexanes gave 206 mg (91%) of the desired product. 
1H NMR (300MHz, CDCl3) δ 7.56(t, J = 7.8 Hz, 1H), 7.26(d, J = 7.8 Hz, 1H), 7.16(d, J = 7.8 
Hz, 1H), 5.28(brs, 1H), 4.24(d, J = 5.7 Hz, 2H), 4.11(q, J = 7.2 Hz, 2H), 3.71(s, 3H), 3.09(t, J = 
7.5 Hz, 2H), 2.78(t, J = 7.5 Hz, 2H), 1.23(t, J = 7.2 Hz, 3H). 
 
 
(Z)-ethyl 3-(6-(3-(methoxycarbonyl)prop-1-enyl)pyridin-2-yl)propanoate 
To a 25 mL round bottom flask was charged nickel acetate tetra hydrate 
(30.6 mg, 0.123 mmol) and 95% ethanol (1 mL), and hydrogen atmosphere 
was applied. Then 0.15 mL NaBH4 solution (1N, 0.15 mmol) in 95% 
ethanol (with 0.1N NaOH) was added to the flask within 10 seconds. After 
three minutes ethylenediamine (16.5 µL, 0.25 mmol) was added, followed by another three 
minutes of stirring. Ethyl 3-(6-(3-(methoxycarbonyl)prop-1-ynyl)pyridin-2-yl)propanoate 1.78 
(90 mg, 0.31 mmol) was added. After 1 hour the reaction mixture was partitioned between 
diethyl ether and water. The organic phase was dried with sodium sulfate, filtered and 
concentrated. Flash chromatography with 40% ethyl acetate in hexanes gave 58.8 mg (65%) of 
the desired product. 1H NMR (300MHz, CDCl3) δ 7.57(t, J = 7.7 Hz, 1H), 7.05(d, J = 6.9 Hz, 
1H), 7.02(d, J = 6.6 Hz, 1H), 6.46(d, J = 11.7 Hz, 1H), 5.97(dt, J = 6.9, 11.5 Hz, 1H), 5.97(brs, 
1H), 4.30(t, J = 6.1 Hz, 2H), 4.15(q, J = 7.1 Hz, 2H), 3.68(s, 3H), 3.13(t, J = 7.4 Hz, 2H), 
2.82(t, J = 7.3 Hz, 2H), 1.22(t, J = 7.1 Hz, 3H); 13C NMR (75MHz, CDCl3) δ 173.0, 159.3, 
157.1, 154.9, 136.6, 133.0, 129.9, 122.1, 120.9, 60.3, 51.8, 39.2, 32.9, 32.7, 14.0. 
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(Z)-methyl 3-(6-(3-oxopropyl)pyridin-2-yl)allylcarbamate (1.79) 
To a 25 mL round bottom flask was charged (Z)-ethyl 3-(6-(3-
(methoxycarbonyl)prop-1-enyl)pyridin-2-yl)propanoate (79.9 mg, 0.273 
mmol) and dichloromethane (3.5 mL). The reaction was cooled to -78 °C, 
and 1M DIBAL-H (0.33 mL, 0.33 mmol) solution in hexanes was added 
drop wise under nitrogen. After 2 hour of stirring at -78 °C, The reaction was quenched with 
saturated ammonium chloride aqueous solution. Flash chromatography with 40% ethyl acetate in 
hexanes gave 28.4 mg (42%) of the desired product, together with 14 mg (18%) of recycled 
starting material and 25 mg (37%) of over-reduced alcohol. 1H NMR (300MHz, CDCl3) δ 9.88(t, 
J = 1.2 Hz, 1H), 7.57(t, J = 7.7 Hz, 1H), 7.05(d, J = 7.5 Hz, 1H), 7.03(d, J = 7.7 Hz, 1H), 6.45(d, 
J = 11.7 Hz, 1H), 5.95(dt, J = 6.6, 11.7 Hz, 1H), 5.76(brs, 1H), 4.31(td, J = 1.6, 6.5 Hz, 2H), 
3.68(s, 3H), 3.15(t, J = 6.8 Hz, 2H), 2.98(t, J = 7.2 Hz, 2H). 
 
 
(Z)-methyl 5-(6-((Z)-3-(methoxycarbonyl)prop-1-enyl)pyridin-2-yl)pent-2-enoate (1.80) 
To a 25 mL round bottom flask was charged methyl 
bis(trifluoroethyl)phosphonoacetate (44 µL, 0.21 mmol), 18-crown-6 (165 
mg, 0.624 mmol) and THF (2 mL). The mixture was cooled to -78 °C, and 
KHMDS (30 mg, 0.15 mmol) in 3 mL THF was added drop wise under 
nitrogen. After 30 minutes of stirring (Z)-methyl 3-(6-(3-oxopropyl)pyridin-2-yl)allylcarbamate 
1.79 (27.0 mg, 0.109 mmol) in 3 mL THF was added drop wise, followed by 4 hours of stirring 
at -78 °C. The reaction was quenched with saturated NH4Cl aqueous solution and extracted with 
ethyl acetate. Flash chromatography with 10% THF in dichloromethane gave 23.6 mg (71%) of 
N
O
NH
O OMe
N
NH
O OMe
MeO2C
 93 
the desired product. 1H NMR (300MHz, CDCl3) δ 7.57(t, J = 7.7 Hz, 1H), 7.04(d, J = 7.1 Hz, 
1H), 7.02(d, J = 6.7 Hz, 1H), 6.48(d, J = 11.7 Hz, 1H), 6.30(dt, J = 7.5, 11.5 Hz, 1H), 6.06(brs, 
1H), 6.01(dt, J = 6.1, 11.4 Hz, 1H), 5.81(dt, J = 1.6, 11.5 Hz, 1H), 4.29(t, J = 6.3 Hz, 2H), 
3.70(s, 3H), 3.67(s, 3H), 3.12(dtd, J = 1.0, 7.4, 7.4 Hz, 2H), 2.95(t, J = 7.8 Hz, 2H); 13C NMR 
(100MHz, CDCl3) δ 166.7, 160.2, 157.3, 155.0, 149.2, 136.8, 132.9, 130.4, 122.1, 120.9, 120.0, 
52.0, 51.1, 39.1, 37.4, 28.7; IR (film) 3399, 1719, 1643, 1570, 1530, 1453, 1521, 1147, 1023, 
819 cm-1; HRMS (ESI) calc. for C16H20N2O4Na ([M+Na]+): 327.1321, found 327.1302. 
 
 
(Z)-5-(6-((Z)-3-(methoxycarbonyl)prop-1-enyl)pyridin-2-yl)pent-2-enoic acid 
(Z)-methyl 5-(6-((Z)-3-(methoxycarbonyl)prop-1-enyl)pyridin- 2-yl)pent-2-
enoate 1.80 (18.2 mg, 0.060 mmol) was dissolved in THF (0.35 mL) at 
room temperature. After 1N LiOH aqueous solution (0.90 mL, 0.90 mmol) 
was added, the reaction mixture was stirred at room temperature for 5 hours. 
The reaction mixture was adjusted to pH 8 at 0 °C, and extracted with 2 mL of ethyl acetate. The 
aqueous layer was continued to be acidified to pH 2, with ethyl acetate extraction at every 2 pH 
intervals. The combined organic phase was dried with MgSO4, concentrated, re-dissolved in 10% 
methanol in dichloromethane, filtered through a thin plug of silica gel and concentrated under 
vacuum. The salts was obtained in 14.8 mg (85%) and used directly in the next Mitsunobu 
reaction without further purification. 
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(Z)-(1R,5S,7S,9S,11R,13R)-7-methoxy-9-methyl-3-oxo-5-propyl-4,15-dioxabicyclo[9.3.1]-
pentadecan-13-yl 5-(6-((Z)-3-((methoxycarbonyl)amino)prop-1-en-1-yl)-pyridin-2-yl)pent-
2-enoate (1.65) 
General protocol B was followed, starting from the 
macrocyclic alcohol 1.5 (2.6 mg, 0.008 mmol), the pyridal 
acid (9.8 mg, 0.034 mmol), PPh3 (16.8 mg, 0.064 mmol) and 
DIAD (12.5 µL, 0.064 mmol). Flash column 
chromatography (first with 30% THF in pentane, then a 
second column with 50% EtOAc in pentane) yielded 3.2 mg 
(67%) of the desired analog. 1H NMR (300MHz, CDCl3) δ 7.59(t, J = 7.7 Hz, 1H), 7.00-7.09(m, 
3H), 6.49(d, J = 11.7 Hz, 1H), 5.94-6.04(m, 1H), 5.94(dt, J = 1.4, 15.6 Hz, 1H), 5.10-5.21(m, 
2H), 5.04(brs, 1H), 4.31(t, J = 6.5 Hz, 2H), 4.06(tdd, J = 2.2, 4.2, 11.3 Hz, 1H), 3.69(s, 3H), 
3.51-3.60(m, 2H), 3.32(s, 3H), 2.99(t, J = 8.0 Hz, 2H), 2.72(dd, J = 6.8, 14.9 Hz, 2H), 2.58(dd, J 
= 4.4, 9.3 Hz, 1H), 2.36(dd, J = 7.0, 10.8 Hz, 1H), 1.85-1.96(m, 1H), 1.62-1.79(m, 3H), 1.45-
1.58(4H), 1.11-1.43(m, 10H), 0.98(d, J = 6.4 Hz, 3H), 0.92(t, J = 7.3 Hz, 3H); 13C NMR 
(100MHz, CDCl3) δ 170.9, 165.8, 159.7, 157.2, 155.2, 148.5, 136.9, 133.1, 130.3, 122.3, 121.9, 
120.9, 75.6, 75.4, 73.4, 69.8, 67.8, 56.2, 52.0, 44.0, 42.4, 42.3, 40.0, 36.9, 36.5, 36.2, 35.3, 31.7, 
31.0, 25.6, 19.0, 13.9; IR (film) 2955, 2923, 1722, 1651, 1570, 1455, 1375, 1264, 1182, 1085, 
1031, 966, 820 cm-1; HRMS (ESI) calc. for C33H48N2O8Na ([M+Na]+): 623.3308, found 
623.3356; [α]D25 = +22.4 (CHCl3, c = 0.32). 
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(E)-methyl 3-(5-bromofuran-2-yl)acrylate (1.82) 
To a suspension of 60% sodium hydride (63.0 mg, 1.58 mmol) in THF (5 mL) 
(EtO)2P(O)CH2CO2Me (0.41 mL, 2.53 mmol) was added drop wise at 0 °C under 
nitrogen. One hour later, 5-bromofuran-2-carbaldehyde 1.81 (204 mg, 1.17 mmol) 
in 5 mL THF was added drop wise, and the reaction mixture was allowed to room 
temperature over 0.5 hour. The reaction mixture was partitioned between diethyl ether and water. 
The organic phase was dried, filtered and concentrated under vacuum. Flash chromatography 
with 20% diethyl ether in hexanes gave 261 mg (97%) of the desired product. 1H NMR 
(300MHz, CDCl3) δ 7.32(d, J = 15.7 Hz, 1H), 6.54(d, J = 2.9 Hz, 1H), 6.40(d, J = 3.0 Hz, 1H), 
6.29(d, J = 15.7 Hz, 1H), 3.78(s, 3H). 13C NMR (75MHz, CDCl3) δ 166.9, 152.5, 129.7, 125.3, 
116.6, 115.7, 114.0, 51.5. 
 
(E)-methyl 3-(5-(3-(methoxycarbonyl)prop-1-ynyl)furan-2-yl)acrylate (1.83) 
To a flame-dried 25 mL round bottom flask was charged 1.82 (310 mg, 1.34 
mmol), PdCl2(PPh3)2 (93.1 mg, 0.133 mmol), PPh3 (69.8 mg, 0.266 mmol), CuI 
(25.8 mg, 0.136 mmol), distilled triethylamine (1.70 mL, 12.2 mmol) and 
distilled THF (5 mL). The reaction was degassed with argon for 15 minutes, and 
then methyl prop-2-ynylcarbamate 1.70 (310 mg, 2.75 mmol) was added drop 
wise with a syringe. The reaction mixture was heated at 50 °C for 1.5 hours 
under argon protection. Flash chromatography with 40% ethyl acetate in hexanes gave 289 mg 
(82%) of the desired product. 1H NMR (300MHz, CDCl3) δ 7.34(d, J = 15.7 Hz, 1H), 6.59(d, J = 
3.5 Hz, 1H), 6.57(d, J = 3.5 Hz, 1H), 6.33(d, J = 15.7 Hz, 1H), 5.79(brs, 1H), 4.25(d, J = 5.6 Hz, 
2H), 3.78(s, 3H), 3.71(s, 3H). 
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(E)-methyl 3-(5-((Z)-3-(methoxycarbonyl)prop-1-enyl)furan-2-yl)acrylate (1.84) 
To a 25 mL round bottom flask was charged nickel acetate tetra hydrate (46.6 
mg, 0.187 mmol) and 95% ethanol (1 mL), and hydrogen atmosphere was 
applied. Then 0.25 mL NaBH4 solution (1N, 0.25 mmol) in 95% ethanol (with 
0.1N NaOH) was added to the flask within 10 seconds. After three minutes 
ethylenediamine (26 µL, 0.37 mmol) was added, followed by another three minutes of stirring. 
To the resulting black colloidal 1.83 (123 mg, 0.467 mmol) was added via a syringe followed by 
washing with 95% EtOH. After 1.5 hour the reaction mixture was filtered through a pad of silica 
gel and concentrated under vacuum. Flash chromatography with 30% THF in hexanes gave 80.3 
mg (65%) of the desired product. 1H NMR (300MHz, CDCl3) δ 7.40(d, J = 15.7 Hz, 1H), 6.62(d, 
J = 3.5 Hz, 1H), 6.35(d, J = 3.5 Hz, 1H), 6.27(d, J = 15.6, 1H), 6.22(d, J = 10.4 Hz, 1H), 5.68(dt, 
J = 6.4, 11.8 Hz, 1H), 5.11(brs, 1H), 4.29(t, J = 5.4 Hz, 2H), 3.79(s, 3H), 3.70(s, 3H). 
 
Methyl (Z)-3-(5-((E)-3-oxoprop-1-enyl)furan-2-yl)allylcarbamate (1.85) 
A solution of 1.84 (60.0 mg, 0.226 mmol) in dichloromethane (3 mL) was 
cooled to -78 °C under nitrogen. Then DIBAL-H (1.34 mL, 1M in hexanes) 
was added drop wise, followed by one hour of stirring at the same 
temperature. The reaction was quenched with saturated ammonium chloride 
solution, extracted with ethyl acetate for three times, and concentrated under vacuum. Flash 
chromatography with 70% ethyl acetate in hexanes gave 50.8 mg (95%) of the alcohol. The 
alcohol was dissolved in dichloromethane (3.3 mL) and acetonitrile (1.2 mL) and cooled to 0 °C. 
Pyridine (28 µL, 0.35 mmol) was added, followed by Dess-Martin reagent (144 mg, 0.34 mmol). 
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After two hours of stirring at 0 °C , the reaction mixture was concentrated and purified with 40% 
ethyl acetate in hexanes to afford 34.7 mg (71%) of the desired aldehyde. 1H NMR (300MHz, 
CDCl3) δ 9.63(d, J = 7.9 Hz, 1H), 7.20(d, J = 15.6 Hz, 1H), 6.79(d, J =3.5 Hz, 1H), 6.55(dd, J = 
7.9, 15.6 Hz, 1H), 6.43(d, J = 3.5 Hz, 1H), 6.26(d, J = 11.8 Hz, 1H), 5.75(dt, J = 6.3, 11.8 Hz, 
1H), 5.07(brs, 1H), 4.30(t, J = 5.8 Hz, 2H), 3.71(s, 3H). 
 
(2Z,4E)-methyl 5-(5-((Z)-3-(methoxycarbonyl)prop-1-enyl)furan-2-yl)penta-2,4- dienoate 
To a 25 mL round bottom flask was charged methyl 
bis(trifluoroethyl)phosphonoacetate (86 µL, 0.41 mmol), 18-crown-6 (330 
mg, 1.23 mmol) and THF (4 mL). The mixture was cooled to -78 °C, and 
KHMDS (60.8 mg, 0.29 mmol) in 2 mL THF was added drop wise under 
nitrogen. After 30 minutes of stirring methyl (Z)-3-(5-((E)-3-oxoprop-1-enyl)furan-2-
yl)allylcarbamate (1.85) (34.6 mg, 0.15 mmol) in 4 mL THF was added drop wise, followed by 3 
hours of stirring at -78 °C. The reaction was quenched with saturated NH4Cl aqueous solution, 
extracted with ethyl acetate and concentrated under vacuum. Flash chromatography first with 
30% ethyl acetate in pentane, and then 20% ethyl acetate in toluene gave 30 mg (70%) of the 
desired product. 1H NMR (300MHz, CDCl3) δ 7.93(dd, J = 11.9, 15.5 Hz, 1H), 6.66(dd, J = 
11.6, 11.6 Hz, 1H), 6.56(d, J = 15.5 Hz, 1H), 6.49(d, J = 3.5 Hz, 1H), 6.32(d, J = 3.5 Hz, 1H), 
6.22(d, J = 11.6 Hz, 1H), 5.69(d, J = 11.2 Hz, 1H), 5.60-5.70(m, 1H), 5.12(brs, 1H), 4.29(td, J = 
1.5, 6.2 Hz, 2H), 3.75(s, 3H), 3.69(s, 3H); 13C NMR (100MHz, CDCl3) δ 166.9, 157.1, 153.3, 
152.3, 143.8, 128.5, 127.1, 123.8, 118.1, 117.2, 113.6, 113.0, 52.1, 51.2, 40.0; IR (film) 3340, 
2950, 1708, 1608, 1528, 1438, 1253, 1197, 1169, 1020, 785 cm-1; HRMS (ESI) calc. for 
C15H17NO5Na ([M+Na]+): 314.1004, found 314.1028. 
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(2Z,4E)-5-(5-((Z)-3-((methoxycarbonyl)amino)prop-1-en-1-yl)furan-2-yl)penta-2,4-dienoic 
acid (1.86) 
(2Z,4E)-methyl 5-(5-((Z)-3-(methoxycarbonyl)prop-1-enyl)furan-2-yl)penta-
2,4-dienoate (23.3 mg, 0.080 mmol) was dissolved in THF (0.45 mL) at room 
temperature. After 1N LiOH aqueous solution (0.9 mL, 0.9 mmol) was 
added, the reaction mixture was stirred at room temperature for 3 hours. The 
reaction mixture was carefully acidified with 3N HCl drop wise at 0 °C to pH 3, and extracted 
with three 5 mL portions of ethyl acetate. The organic phase was dried with Na2SO4, filtered and 
concentrated under vacuum. Flash chromatography (EtOAc : DCM : MeOH 1 : 1: 0.2) gave 24.9 
mg (90%) of the desired product. 1H NMR (400MHz, CDCl3) δ 8.01(dd, J = 12.0, 15.4 Hz, 1H), 
6.78(t, J = 11.5 Hz, 1H), 6.60(d, J = 15.5 Hz, 1H), 6.50(d, J = 3.5 Hz, 1H), 6.33(d, J = 3.3 Hz, 
1H), 6.23(d, J = 11.9 Hz, 1H), 5.73(d, J = 11.2 Hz, 1H), 5.66(dt, J = 6.4, 11.9 Hz, 1H), 5.12(brs, 
1H), 4.32(app s, 1H), 3.70(s, 3H). 13C NMR (400MHz, CDCl3) δ 170.7, 157.3, 153.5, 152.3, 
145.1, 128.6, 127.1, 124.2, 117.9, 117.1, 113.8, 112.9, 52.2, 40.3; IR (film) 3452, 2941, 1701, 
1524, 1253, 1189, 1173, 788 cm-1; HRMS (ESI) calc. for C14H15NO5Na ([M+Na]+): 300.0848, 
found 300.0859. 
(1R,5S,7S,9S,11R,13S)-7-methoxy-9-methyl-3-oxo-5-propyl-4,15-dioxa-bicyclo[9.3.1]-
pentadecan-13-yl methanesulfonate (1.66) 
General protocol B was followed, starting from the 
macrocyclic alcohol 1.5 (2.2 mg, 0.0067 mmol), 1.86 
(5.6 mg, 0.013 mmol), PPh3 (3.9 mg, 0.015 mmol) and 
DIAD (3.0 µL, 0.015 mmol). Flash column 
chromatography (50% EtOAc pentane) afforded 2.0 mg 
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(50%) of the desired analog.
.
1H NMR (400MHz, CDCl3) δ 8.01(dd, J = 12.0, 16.0 Hz, 1H), 
6.74(t, J = 11.7 Hz, 1H), 6.60(d, J = 15.6 Hz, 1H), 6.51(d, J = 3.4 Hz, 1H), 6.33(d, J = 3.5 Hz, 
1H), 6.24-6.28(m, 1H), 5.76(d, J = 11.1 Hz, 1H), 5.60-5.69(m, 1H), 5.23-5.26(m, 1H), 5.12-
5.19(m, 1H), 5.07(brs, 1H), 4.28(t, J = 6.6 Hz, 2H), 4.10(apt, J = 11.4 Hz, 1H), 3.70(s, 3H), 
3.57-3.62(m, 2H), 3.32(s, 3H), 2.60(dd, J = 4.4, 14.5 Hz, 1H), 2.36(dd, J = 10.8, 14.1 Hz, 1H), 
1.82-1.94(m, 2H), 1.70-1.75(m, 2H), 1.45-1.62(m, 4H), 1.23-1.39(m, 6H), 1.12-1.19(m, 1H), 
0.98(d, J = 6.5 Hz, 3H), 0.92(t, J = 7.3 Hz, 3H); 13C NMR (100MHz, MeOD) δ 173.1, 167.1, 
154.8, 145.2, 130.1, 128.7, 125.1, 118.7, 114.9, 114.3, 77.1, 77.0, 73.9, 71.3, 69.1, 56.4, 52.5, 
45.2, 43.5, 41.1, 40.4, 37.9, 37.4, 36.0, 32.6, 26.0, 20.0, 14.1; IR (film) 2947, 2854, 1713, 1528, 
1376, 1249, 1190, 1064, 994 cm-1; HRMS (pending); [α]D25 = +5.1 (MeOH, c = 0.20). 
 
 
(E)-methyl 3-(2-methyloxazol-4-yl)acrylate (1.88) 
To a suspension of 60% sodium hydride (63 mg, 1.358 mmol) in THF (5 mL) 
(EtO)2P(O)CH2CO2Me (0.41 mL, 2.53 mmol) was added drop wise at 0 °C under 
nitrogen. Thirty minutes later, 2-methyloxazole-4-carbaldehyde 1.87 (107 mg, 0.96 
mmol) in 2 mL THF was added dropwise, and the reaction mixture was kept at 0 °C 
for 1.5 hour. The reaction mixture was partitioned between diethyl ether and water. The organic 
phase was dried, filtered and concentrated under vacuum. Flash chromatography with 5% diethyl 
ether in hexanes gave 151 mg (93%) of the desired product. 1H NMR (300MHz, CDCl3) δ 
7.69(s, 1H), 7.47(d, J = 15.6, 1H), 6.58(dt, J = 2.6, 15.8 Hz, 1H), 3.78(s, 3H), 2.49(s, 1H). 
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methyl 3-(2-methyloxazol-4-yl)propanoate 
A mixture of (E)-methyl 3-(2-methyloxazol-4-yl)acrylate 1.88 (71 mg, 0.42 mmol) 
and 10% Pd/C (71 mg) in methanol (10 mL) was stirred under hydrogen atmosphere 
for 2 hours. The mixture was then filtered through Celite and purified on a flash 
column with 40% ethyl acetate in hexanes to give 59 mg (82%) of the desired 
product. 1H NMR (300MHz, CDCl3) δ 7.30(t, J = 1.1 Hz, 1H), 3.68(s, 3H), 2.81(t, J = 7.5 Hz, 
2H), 2.65(td, J = 1.1, 7.1 Hz, 2H), 2.42(s, 3H). 
 
3-(2-methyloxazol-4-yl)propanal (1.89) 
To a 25 mL round bottom flask was charged methyl 3-(2-methyloxazol-4-
yl)propanoate (48 mg, 0.28 mmol) and dichloromethane (3 mL). The reaction was 
cooled to -78 °C, and 1M DIBAL-H (0.42 mL, 0.42 mmol) solution in hexanes was 
added drop wise under nitrogen. After 1.5 hour of stirring at -78 °C, The reaction was 
quenched with saturated ammonium chloride aqueous solution. Flash chromatography with 40% 
ethyl acetate in hexanes gave 27 mg (69%) of the desired product. 1H NMR (300MHz, CDCl3) δ 
9.82(s, 1H), 7.29(t, J = 5.2 Hz, 1H), 2.81(app s, 4H), 2.42(s, 1H). 
 
(Z)-methyl 5-(2-methyloxazol-4-yl)pent-2-enoate (1.90) 
To a 25 mL round bottom flask was charged methyl 
bis(trifluoroethyl)phosphonoacetate (114 µL, 0.54 mmol), 18-crown-6 (430 
mg, 1.63 mmol) and THF (5 mL). The mixture was cooled to -78 °C and 
KHMDS (80 mg, 0.40 mmol) in 5 mL THF was added drop wise under 
nitrogen. After 30 minutes of stirring 3-(2-methyloxazol-4-yl)propanal 1.89 (26.2 mg, 0.19 
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mmol) in 5 mL THF was added drop wise, followed by 5 hours of stirring at -78 °C. The reaction 
was quenched with saturated NH4Cl aqueous solution and extracted with ethyl acetate. Flash 
chromatography with 30% ethyl acetate in pentane gave 23.2 mg (71%) of the desired product. 
1H NMR (300MHz, CDCl3) δ 7.29(s, 1H), 6.26(dt, J = 7.3, 11.5 Hz, 1H), 5.82(dt, J = 1.7, 11.5 
Hz, 1H), 3.71(s, 3H), 2.98(dtd, J = 1.6, 7.2, 7.2 Hz, 2H), 2.64(dd, J = 6.9, 7.6 Hz, 2H), 2.42(s, 
3H); 13C NMR (300MHz, CDCl3) δ 166.7, 161.3, 149.1, 139.7, 133.9, 120.1, 51.1, 27.5, 25.6, 
13.9; IR (film) 2921, 1722, 1646, 1581, 1439, 1201, 1177, 1096, 820 cm-1; HRMS (ESI) calc. for 
C10H13NO3Na ([M+Na]+): 218.0793, found 218.0786;. 
 
(Z)-5-(2-methyloxazol-4-yl)pent-2-enoic acid (1.91) 
(Z)-methyl 5-(2-methyloxazol-4-yl)pent-2-enoate 1.90 was dissolved in THF 
(0.6 mL) at room temperature. After 1N LiOH aqueous solution (1.1 mL, 1.1 
mmol) was added, the reaction mixture was stirred at room temperature for 3 
hours. The reaction mixture was acidified with 3N HCl drop wise at 0 °C to pH 
3, and extracted with three 5 mL portions of ethyl acetate. The organic phase was dried with 
Na2SO4, filtered and concentrated under vacuum. Flash chromatography with 10% methanol in 
dichloromethane gave 13.7 mg (80%) of the desired product. 1H NMR (300MHz, CDCl3) δ 
7.31(s, 1H), 6.25(dt, J = 7.3, 11.1 Hz, 1H), 5.85(d, J = 11.0 Hz, 1H), 2.97(dt, J = 7.1, 7.1 Hz, 
2H), 2.68(t, J = 7.0 Hz, 2H), 2.45(s, 3H); 13C NMR (75MHz, CDCl3) δ 170.0, 161.8, 148.6, 
139.1, 134.1, 121.2, 27.5, 24.9, 13.7; IR (film) 3139, 2922, 2537, 1700, 1643, 1577, 1437, 1203, 
1096, 1017, 935, 822 cm-1; HRMS (EI) calc. for C9H11NO3 (M+): 181.073893, found 
181.073688. 
 
N
O
CO2H
 102 
(Z)-(1R,5S,7S,9S,11R,13R)-7-methoxy-9-methyl-3-oxo-5-propyl-4,15-
dioxabicyclo[9.3.1]pentadecan-13-yl 5-(2-methyloxazol-4-yl)pent-2-enoate (1.67) 
General protocol B was followed, starting from the macrocyclic 
alcohol 5 (2.2 mg, 0.0067 mmol), 1.91 (4.9 mg, 0.027 mmol), 
PPh3 (9.4 mg, 0.036 mmol) and DIAD (7.1 µL, 0.036 mmol). 
Flash column chromatography (20% EtOAc in DCM, then 
switched to 40% EtOAc in hexanes) yielded 2.5 mg (76%) of the desired analog.
.
1H NMR 
(400MHz, MeOD) δ 7.54(t, J = 1 Hz, 1H), 6.34(dt, J = 7.4, 11.5 Hz, 1H), 5.88(dt, J = 1.7, 11.5 
Hz, 1H), 5.14-5.20(m, 2H), 4.07(dddd, J = 2.2, 2.2, 11.5, 11.5 Hz, 1H), 3.67(app t, J = 9.7, 1H), 
3.57(app t, J = 10.8 Hz, 1H), 3.28(s, 3H), 2.97(dtd, J = 1.6, 7.1, 7.1 Hz, 2H), 2.70(dd, J = 4.3, 
14.8 Hz, 1H), 2.64(t, J = 7.3, 2H), 2.30(dd, J = 11.0, 14.8 Hz, 1H), 1.87(dd, J = 10.9, 14.0 Hz, 
1H), 1.80-1.86(m, 1H), 1.66-1.76(m, 2H), 1.46-1.62(m, 4H), 1.26-1.44(m, 6H), 1.29(s, 3H), 
1.12(ddd, J = 1.8, 11.0, 12.8 Hz, 1H), 0.97(t, J = 5.8 Hz, 3H), 0.94(t, J = 7.3 Hz, 3H); 13C NMR 
(100MHz, MeOD) δ 173.0, 167.7, 164.4, 150.8, 141.6, 136.9, 122.5, 78.0, 77.9, 74.8, 72.2, 70.0, 
57.3, 46.1, 44.3, 44.1, 41.9, 38.8, 38.3, 37.1, 33.4, 29.8, 27.1, 26.8, 20.9, 15.0, 14.4; IR (film) 
2956, 2922, 2836, 1718, 1642, 1580, 1458, 1382, 1334, 1261, 1175, 1087, 1030, 797 cm-1 ; 
HRMS (ESI) calc. for C27H41NO7Na ([M+Na]+): 514.2781, found 514.2766; [α]D25 = +27.8 
(MeOH, c = 0.21). 
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APPENDIX B 
SYNTHESIS OF SULFUR-CONTAINING HETEROCYCLES THROUGH 
OXIDATIVELY GENERATED THIOCARBENIUM IONS 
General protocols 
Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were recorded at 
300/400/500/600 MHz and 75/100/125/150 MHz, respectively. The chemical shifts are given in 
parts per million (ppm) on the delta (δ) scale. Tetramethylsilane (TMS) or the solvent peak was 
used as a reference value, for 1H NMR: TMS (in CDCl3) = 0.00 ppm, CD3OD =3.31, for 13C 
NMR: TMS (in CDCl3) = 0.00, CD3OD = 49.00. Data are reported as follows: (s = singlet; d = 
doublet; t = triplet; q = quartet; dd = doublet of doublets; dt = doublet of triplets; br = broad). 
Samples for IR were prepared as a thin film on a NaCl plate by dissolving the compound in 
CH2Cl2 and then evaporating the CH2Cl2. Analytical TLC was performed on pre-coated (25 mm) 
silica gel 60F-254 plates. Visualization was done under UV (254 nm). Flash column 
chromatography was done using 32-63 60 Å silica gel. Methylene chloride was distilled under 
N2 from CaH2. Reagent grade ethyl acetate, diethyl ether, pentane and hexanes (commercial 
mixture) were used as purchased for chromatography. Benzene was dried with 4Å molecular 
sieves. THF was distilled from sodium. Other reagents were obtained from commercial sources 
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without further purification. All reactions were performed in oven or flame-dried glassware with 
magnetic stirring under nitrogen unless otherwise noted. 
 
General protocol for allyl or benzyl sulfide synthesis (general protocol C) 
The corresponding thiol or thioacetate was added dropwise into the solution of potassium 
hydroxide (2.5 equiv) in methanol (~0.25 M) at 0 °C, and the reaction mixture was stirred 
vigorously for 20 minutes. The corresponding allyl or benzyl bromide (~1.2 equiv) was added 
dropwise, and the reaction was heated at 50 °C for 2 hours. White precipitates were formed 
during the process. The reaction mixture was cooled, concentrated under vacuum and dissolved 
in diethyl ether. The ether solution was washed with brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. Flash column chromatography with 3% ethyl acetate in 
hexanes afforded the desired allyl sulfide. 
 
General protocol for enol acetate synthesis (general protocol D) 
The corresponding alkyne, [(p-cymene)RuCl2]2 (4 mol%), (2-furyl)3P (8 mol%), Na2CO3 (15 
mol%), acetic acid (2 equiv) and toluene were mixed and stirred at 80 °C overnight. Flash 
column chromatography with 10% ethyl acetate in hexanes afforded the desired enol acetate. 
 
General protocol E1 for thioacetate synthesis (the Mitsunobu reaction) (general protocol E1) 
To a solution of PPh3 (2.3 equiv) in THF (~0.1 M solution) at 0 °C, DIAD (2.3 equiv) was added 
drop wise over 10 minutes, and the resulting white suspension was stirred for 20 minutes. 
Thioacetic acid (2.5 equiv) and the corresponding alcohol was added successively. The white 
precipitates disappeared after 0.5 hours, and the solution was stirred overnight at RT. The 
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reaction mixture was concentrated and purified by flash column chromatography with 10% 
diethyl ether in hexanes to afford the desired thioacetate. 
 
General protocol E2 for thioacetate synthesis (general protocol E2) 
To a mixture of the corresponding mesylate or bromide and Cs2CO3 (2.4 equiv) in DMF (~0.25 
M) at 0 °C, Thioacetic acid (2.7 equiv) was added dropwise. The reaction mixture was stirred 
either at RT overnight (for primary mesylates) or at 40 °C overnight (for secondary mesylates). 
The reaction was then diluted with diethyl ether, washed with brine for three times and 
concentrated. Flash column chromatography with appropriate solvents afforded the desired 
thioacetate. 
 
General protocol F1 for vinyl sulfide synthesis (general protocol F1) 
In a round bottom flask the corresponding thioacetate, KOH (2.5 equiv), CuI (0.1 equiv) and 
vinyl iodide (1.5 equiv) were mixed in dioxane (~0.4 M). The reaction mixture was heated 
overnight at 100 °C, resulting a dark brown heterogeneous mixture. Then it was cooled to room 
temperature, concentrated under vacuum and subjected to Flash column chromatography with 
appropriate solvents to afford the desired vinyl sulfide. 
 
General protocol F2 for vinyl sulfide synthesis (general protocol F2) 
To a flame-dried round bottom flask were added (E)-1-iodohex-1-ene (1.2 equiv), 
Pd(dppf)Cl2·CH2Cl2 complex (0.05 equiv), distilled Et3N (2.7 equiv) and THF (~0.2 M). The 
mixture was stirred for 15 minutes at RT and then 15 minutes at 45°C. The corresponding thiol 
was added drop wise into the mixture, and the reaction was stirred overnight at 45°C. 
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Concentration and Flash column chromatography with appropriate solvents afforded the desired 
vinyl sulfide. 
 
 General protocol for the cyclization of allyl or benzyl sulfide substrates (general protocol G1) 
The enol acetate, 2,6-dichloropyridine (4 equiv), LiClO4 or Mg(ClO4)2 (0.2 equiv) and 4 Å 
molecular sieves (3 mass equiv) were dissolved in anhydrous DCM or DCE to give a ~0.09 M 
solution. The mixture was stirred for 15 minutes, then DDQ (2.0 equiv) was added in one 
portion. The reaction was monitored by TLC at room temperature unless specified, and quenched 
by Et3N when the starting material was gone. After concentration under vacuum, the residue was 
purified with Flash column chromatography to give the desired product. 
 
General protocol for the cyclization of vinyl sulfide and allylsilanes (general protocol G2) 
The enol acetate, 2,6-dichloropyridine (2 equiv) and 4 Å molecular sieves (3 mass equiv) were 
dissolved in anhydrous MeNO2 or DCM to give a ~0.09 M solution. The mixture was stirred at 0 
°C for 15 minutes, then DDQ (1.05 equiv) was added in one portion. The starting material 
disappeared in 5 minutes as monitored by TLC. After concentration under vacuum, the residue 
was purified by Flash column chromatography with appropriate solvents to give the desired 
product. 
 
General protocol for the synthesis of vinyl iodide (general protocol H) 
To a suspension of ZrCp2Cl2 (1.1 equiv) in distilled THF (~0.35 M) protected with argon, 1M 
DIBAL-H solution (1.1 equiv) was added drop wise at 0 °C. White precipitates were formed in a 
few minutes, and the mixture was stirred for 30 minutes. Then the alkyne was added drop wise, 
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followed by THF rinsing. The reaction mixture was allowed to RT and stirred for 1 hr, during 
which the reaction mixture became clear and green. The reaction was cooled to -78 °C, I2 (1.1 
equiv) in THF was added dropwise, and it was then allowed to -10 °C. The reaction was 
quenched with 1:1 saturated aqueous solution of NaHCO3 and Na2S2O3, extracted with diethyl 
ether twice and concentrated under vacuum. Flash column chromatography with appropriate 
solvents afforded the corresponding vinyl iodide. 
 
General protocol for Kumada coupling (general protocol I) 
To a suspension of Pd(PPh3)4 (0.1 equiv) in distilled THF (~3 M solution) protected with argon, 
1M trimethylsilyl methylmagnesium chloride (1.5 equiv) was added drop wise at RT. Fifteen 
minutes later, the corresponding vinyl iodide was added drop wise, followed by another 15 
minutes of stirring. The reaction mixture was then quenched with saturated NH4Cl solution at 0 
°C, extracted twice with ether and concentrated under vacuum. Flash column chromatography 
with appropriate solvents afforded the corresponding ally silane. 
 
 (E)-but-3-yn-1-yl(hex-2-en-1-yl)sulfane 
General protocol C for allyl sulfide synthesis was followed, starting from S-
but-3-yn-1-yl ethanethioate (2.1) (486 mg, 3.6 mmol), potassium hydroxide 
(430 mg, 7.7 mmol) and (E)-1-bromohex-2-ene (550 mg, 3.1 mmol). Flash column 
chromatography with 3% ethyl acetate in hexanes afforded 542 mg (95%) of the desired product. 
1H NMR (300 MHz, CDCl3) δ 5.54 (dt, J =15.2, 6.5 Hz, 1H), 5.40 (dtt, J = 15.2, 7.1, 1.0), 3.14 
(dd, J = 7.0 Hz, 2H), 2.64 (td, J = 7.4, 0.9 Hz, 2H), 2.45 (tdd, J = 7.4, 2.6, 0.7 Hz, 2H), 2.06-
1.99 (m, 3H), 1.46-1.34 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 133.7, 
S
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125.6, 82.5, 69.1, 34.1, 33.7, 29.0, 22.3, 19.5, 13.5; IR (film) 3309, 2958, 2930, 2872, 1461, 
1427, 1379, 1230, 967 cm-1; HRMS (EI) m/z calcd. for C10H16S [M] 168.0973, found 168.0978.  
 
(E)-4-(hex-2-en-1-ylthio)but-1-en-2-yl acetate (2.2) 
General protocol D for enol acetate synthesis was followed, starting from 
the above alkyne (169 mg, 1.0 mmol), [(p-cymene)RuCl2]2 (24.5 mg, 0.04 
mmol), (2-furyl)3P (18.5 mg, 0.08 mmol), Na2CO3 (15.1 mg, 0.15 mmol) 
and acetic acid (0.11 mL, 2.0 mmol). Flash column chromatography with 10% ethyl acetate in 
hexanes afforded 129 mg (57%) of the desired enol acetate 2.2.  
(E)-4-(hex-2-en-1-ylthio)but-1-en-2-yl acetate (2.2): 1H NMR (300 MHz, CDCl3) δ 5.58-5.46 
(dt, J = 15.1, 6.4 Hz, 1H), 5.39 (dtt, J = 15.1, 6.9, 1.2 Hz, 1H), 4.88-4.65 (m, 2H), 3.11 (dd, J = 
6.9, 0.8 Hz, 2H), 2.58 (ddd, J = 8.3, 6.7, 1.8 Hz, 2H), 2.48 (m, 2H), 2.15 (s, 3H), 2.02 (dt, J = 
6.6, 6.6 Hz, 2H), 1.48-1.32 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
168.8, 154.3, 133.6, 125.7, 102.3, 34.2, 33.7, 33.5, 27.1, 22.4, 20.9, 13.5; IR (film) 2959, 2927, 
2872, 1759, 1666, 1434, 1370, 1197, 1020, 966, 914, 876 cm-1; HRMS (ESI) m/z calcd. for 
C12H20O2SNa [M+Na]+ 251.1082, found 251.1077. 
 
(E)-2-(pent-1-en-1-yl)dihydro-2H-thiopyran-4(3H)-one (2.3) AND (E)-6-(pent-1-en-1-yl)-
2H-thiopyran-4(3H)-one (2.4) 
General protocol G1 for the cyclization of allyl sulfide substrates was followed, starting from 
compound 1 (80 mg, 0.35 mmol), DDQ (200 mg, 0.88 mmol), 2,6-dichloropyridine (261 mg, 
1.76 mmol), LiClO4 (7.5 mg, 0.07 mmol), 4Å M.S. (240 mg) and 1,2-dichloroethane (5 mL). 
The reaction was quenched with triethylamine 100 minutes after the addition of DDQ. Flash 
S
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column chromatography with 10% ethyl acetate in hexanes afforded 32.3 mg (50%) of the 
desired cyclization product 2.3 and 2.6 mg (4%) of the over-oxidized product 2.4.  
(E)-2-(pent-1-en-1-yl)dihydro-2H-thiopyran-4(3H)-one (2.3): 1H NMR 
(400 MHz, CDCl3) δ 5.70-5.57 (dtd, J = 15.4, 6.7, 1.1 Hz, 1H), 5.46 (ddt, J 
= 15.4, 6.8, 1.3 Hz, 1H), 3.84-3.68 (m, 1H), 3.02-2.86 (m, 2H), 2.77 (ddd, J = 14.1, 3.9, 0.8 Hz, 
1H), 2.72-2.59 (m, 3H), 2.01 (dt, J = 7.0, 7.0 Hz, 2H), 1.48-1.33 (m, 2H), 0.89 (t, J = 7.4 Hz, 
3H); 13C NMR (100 MHz, CDCl3) δ 208.1, 133.2, 128.5, 49.3, 45.1, 43.1, 34.2, 27.6, 22.1, 13.4; 
IR (film) 2957, 2927, 2871, 1713, 1421, 1317, 1262, 970 cm-1; HRMS (EI) m/z calcd. for 
C10H16OS [M] 184.0922, found 184.0937. 
(E)-6-(pent-1-en-1-yl)-2H-thiopyran-4(3H)-one (2.4): 1H NMR (300 MHz, 
CDCl3) δ 6.45 (dt, J = 15.5, 7.0 Hz, 1H), 6.19 (d, J = 15.7 Hz, 1H), 6.08 (s, 
1H), 3.18 (t, J = 6.8 Hz, 2H), 2.71 (t, J = 6.4 Hz, 2H), 2.19 (dtd, J = 7.2, 7.2, 1.3 Hz, 2H), 1.55-
1.41 (m, 2H), 0.88 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 195.2, 156.9, 136.9, 
130.2, 113.8, 37.6, 34.04, 26.5, 21.8, 13.6; IR (film) 3122, 2947, 1689, 1441, 1282, 1212, 1147, 
931 cm-1; HRMS (EI) m/z calcd. for C10H14OS [M] 182.0765, found 182.0782. 
 
S-Hept-1-yn-4-yl ethanethioate 
Hept-1-yn-4-yl methanesulfonate (855 mg, 4.5 mmol) was reacted with HSAc 
(0.87 mL, 9.75 mmol) and Cs2CO3 (3.52 g, 8.86 mmol) according to the general 
protocol E2. Flash column chromatography with 3% diethyl ether in hexanes afforded the 
desired thioacetate (453 mg, 60% yield). 1H NMR (300 MHz, CDCl3) δ 3.64 (ddd, J = 11.3, 8.4, 
6.0 Hz, 1H), 2.65-2.44 (m, 2H), 2.34 (s, 3H), 2.02 (t, J = 2.7 Hz, 1H), 1.82-1.55 (m, 2H), 1.51-
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1.31 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 195.5, 79.3, 70.3, 42.3, 
36.1, 34.9, 30.7, 24.8, 13.7. 
 
(E)-hept-1-yn-4-yl(hex-2-en-1-yl)sulfane 
S-hept-1-yn-4-yl ethanethioate (372 mg, 2.18 mmol) was reacted with 
(E)-1-bromohex-2-ene (469 mg, 2.61 mmol), KOH (245 mg, 4.36 
mmol) in methanol (10 mL) according to the general protocol C to afford the desired allyl sulfide 
(444 mg, 97% yield). 1H NMR (300 MHz, CDCl3) δ 5.54 (dt, J = 15.2, 6.5 Hz, 1H), 5.43 (dt, J = 
14.1, 6.8 Hz, 1H), 3.16 (dd, J = 6.7, 2.5 Hz, 2H), 2.75 (ddd, J = 12.6, 7.1, 5.5 Hz, 1H), 2.55 
(ddd, J = 16.9, 5.2, 2.6 Hz, 1H), 2.43 (ddd, J = 17.0, 7.1, 2.6 Hz, 1H), 2.11-1.89 (m, 3H), 1.80-
1.63 (m, 1H), 1.62-1.34 (m, 6H), 0.91 (t, J = 7.2 Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 133.4, 126.2, 81.7, 69.8, 69.7, 42.3, 35.8, 34.2, 33.3, 25.2, 19.8, 13.8, 13.6; IR 
(film) 3309, 2958, 2930, 2872, 1461, 1427, 1379, 1230, 967 cm-1; HRMS (EI) m/z calcd. for 
C13H22S [M] 210.1442, found 210.1431. 
 
(E)-4-(hex-2-en-1-ylthio)hept-1-en-2-yl acetate (2.6) 
General protocol D for enol acetate synthesis was followed, starting 
from (E)-hept-1-yn-4-yl(hex-2-en-1-yl)sulfane (252.5 mg, 1.2 mmol), 
[(p-cymene)RuCl2]2 (30.8 mg, 0.05 mmol), (2-furyl)3P (22.0 mg, 0.10 
mmol), Na2CO3 (18.1 mg, 0.18 mmol) and acetic acid (0.13 mL, 2.4 mmol). Flash column 
chromatography with 10% ethyl acetate in hexanes afforded 86 mg (27%) of the desired enol 
acetate 2.6. 1H NMR (300 MHz, CDCl3) δ 5.52 (dt, J = 14.9, 6.2 Hz, 1H), 5.47-5.35 (m, 1H), 
4.86-4.76 (m, 2H), 3.11 (d, J = 6.7 Hz, 2H), 2.75-2.67 (m, 1H), 2.53 (dd, J = 15.3, 6.9 Hz, 1H), 
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2.45 (dd, J = 15.3, 6.9 Hz, 1H), 2.14 (s, 3H), 2.01 (dt, J = 6.6, 6.6 Hz, 2H), 1.52-1.32 (m, 6H), 
0.90 (t, J = 7.3 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 169.0, 153.7, 133.3, 126.4, 103.7, 40.8, 
39.5, 36.2, 34.3, 33.1, 22.5, 21.1, 19.7, 13.9, 13.7; IR (film) 2958, 2930, 2872, 1758, 1665, 1461, 
1432, 1369, 1199, 1020, 966, 874 cm-1; HRMS (ESI) m/z calcd. for C15H26O2SNa [M+Na]+ 
293.1551, found 293.1522. 
 
(2S,6S)-2-((E)-pent-1-en-1-yl)-6-propyldihydro-2H-thiopyran-4(3H)-one (2.7) and (E)-6-
(pent-1-en-1-yl)-2-propyl-2H-thiopyran-4(3H)-one (2.8) 
 General protocol G1 for the cyclization of allyl sulfide substrates was 
followed, starting from the substrate 2.6 (77.3 mg, 0.29 mmol), DDQ 
(130 mg, 0.57 mmol), 2,6-dichloropyridine (213 mg, 1.46 mmol), 
LiClO4 (6.1 mg, 0.06 mmol), 4Å M.S. (200 mg) and DCE (4 mL). The 
reaction was quenched with triethylamine 100 minutes after the 
addition of DDQ. Flash column chromatography with 10% ethyl 
acetate in hexanes afforded 32.0 mg (50%) of the desired cyclization product 2.7 with a cis:trans 
ratio of 11:1. 2.7: 1H NMR (400 MHz, CDCl3) δ 5.69 (dtd, J = 15.2, 6.8, 0.8 Hz, 1H), 5.40 (ddt, 
J = 15.2, 7.6, 1.4 Hz, 1H), 3.65 (ddd, J = 12.4, 7.6, 4.2 Hz, 1H), 3.10 (dtd, J = 12.2, 6.7, 2.9 Hz, 
1H), 2.75-2.63 (m, 2H), 2.52 (dd, J = 19.7, 6.4 Hz, 1H), 2.37 (dd, J = 19.3, 6.9 Hz, 1H), 2.01 
(dtd, J = 7.9, 7.9, 1.1 Hz, 2H), 1.64-1.53 (m, 2H), 1.52-1.44 (m, 2H), 1.44-1.36 (m, 2H), 0.92 (t, 
J =7.6 Hz, 2H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 208.8, 133.5, 128.1, 
50.0, 49.8, 45.3, 43.6, 37.9, 34.2, 22.1, 19.8, 13.8, 13.5; IR (film) 2958, 2930, 2872, 1712, 1461, 
1249, 967 cm-1; HRMS (EI) m/z calcd. for C13H22SO [M] 226.1391, found 226.1388. 
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2.8: 1H NMR (300 MHz, CDCl3) δ 6.44 (dt, J = 15.4, 7.1 Hz, 1H), 6.15 (d, J = 15.4 Hz, 1H), 
6.07 (s, 1H), 3.16 (dtd, J = 12.2, 6.6, 2.9 Hz, 1H), 2.76-2.65 (m, 2H), 2.19 (dtd, J = 7.6, 7.6, 1.1 
Hz, 2H), 1.68-1.44 (m, 4H), 1.44-1.36 (m, 2H), 0.91 (t, J =7.5 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H); 
13C NMR (75 MHz, CDCl3) δ 195.4, 156.9, 136.7, 130.1, 113.8, 49.8, 43.6, 37.6, 33.8, 21.8, 
19.8, 13.6; IR (film) 2957, 2849, 1686, 1431, 1281, 1231, 1082, 867 cm-1; HRMS (EI) m/z calcd. 
for C13H20OS [M] 224.1235, found 224.1247. 
 
Benzyl(hept-1-yn-4-yl)sulfane 
Hept-1-yne-4-thiol (413 mg, 2.41 mmol, prepared by LAH reduction of the 
corresponding thioacetate) was reacted with benzyl bromide (0.37 mL, 3.14 
mmol), KOH (336 mg, 2.5 mmol) in methanol (10 mL) according the general protocol C, except 
the reaction was carried out at RT overnight. Flash column chromatography with 10% 
dichloromethane in hexanes afforded the desired benzyl sulfide (453 mg, 95% yield). 1H NMR 
(400 MHz, CDCl3) δ 7.33-7.18 (m, 5H), 3.75 (s, 2H), 2.64 (tt, J = 7.6, 5.4 Hz, 1H), 2.45 (dddd, J 
= 17.0, 9.7, 6.2, 2.6 Hz, 2H), 2.01 (t, J = 2.6 Hz, 1H), 1.66 (ddt, J = 13.7, 9.7, 5.8 Hz, 1H), 1.58-
1.20 (m, 3H), 0.83 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 138.2, 128.7, 128.3, 
126.8, 81.6, 69.9, 42.9, 35.6, 35.4, 25.1, 19.7, 13.6; IR (film) 3299, 3028, 2958, 2929, 2871, 
1494, 1454, 1238, 915 cm-1; HRMS (EI) m/z calcd. for C14H18S [M] 218.1129, found 218.1128. 
 
4-(Benzylthio)hept-1-en-2-yl acetate (2.10) 
General protocol D for enol acetate synthesis was followed, starting from the 
above benzyl sulfide (391 mg, 1.79 mmol), [(p-cymene)RuCl2]2 (43.8 mg, 
0.07 mmol), (2-furyl)3P (32.4 mg, 0.14 mmol), Na2CO3 (27.2 mg, 0.26 mmol) 
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and acetic acid (0.20 mL, 3.6 mmol). Flash column chromatography with 5% diethyl ether in 
hexanes afforded 164 mg (33%) of the desired enol acetate 2.10. 1H NMR (400 MHz, CDCl3) δ 
7.37-7.18 (m, 5H), 4.85-4.67 (m, 2H), 3.72 (d, J = 4.3 Hz, 2H), 2.65-2.55 (m, 1H), 2.53 (dd, J = 
6.3, 0.6 Hz, 1H), 2.43 (dd, J = 14.1, 7.4 Hz, 1H), 2.06 (s, 3H), 1.61-1.50 (m, 1H), 1.50-1.38 (m, 
2H), 1.38-1.27 (m, 1H), 0.88-0.68 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 168.9, 153.4, 138.4, 
128.9, 128.3, 126.9, 103.7, 41.1, 39.4, 35.9, 35.1, 21.0, 19.6, 13.7; IR (film) 2958, 2930, 2871, 
1757, 1665, 1454, 1370, 1200, 1021, 876 cm-1; HRMS (ESI) m/z calcd. for C16H22O2SNa 
[M+Na]+ 301.1238, found 301.1248. 
 
(2S,6S)-2-phenyl-6-propyldihydro-2H-thiopyran-4(3H)-one (2.11) 
General protocol G1 was followed, starting from compound 2.10 (59.1 mg, 
0.21 mmol), DDQ (119 mg, 0.53 mmol), 2,6-dichloropyridine (156 mg, 1.06 
mmol), MgClO4 (8.8 mg, 0.04 mmol), 4Å M.S. (180 mg) and dichloromethane 
(4 mL). The reaction mixture was stirred overnight at RT. The reaction afforded 30.4 mg (61% 
yield) of the desired cyclization product 2.11 with a cis:trans ratio of 25:1. 1H NMR (400 MHz, 
CDCl3) δ 7.39-7.25 (m, 5H), 4.16 (dd, J = 11.9, 3.6 Hz, 1H), 3.26-3.15 (m, 1H), 2.95-2.84 (m, 
2H), 2.76 (dd, J = 13.5, 2.0 Hz, 1H), 2.49 (apt, J = 12.4, 1H), 1.62 (dd, J = 15.1, 7.3 Hz, 2H), 
1.54-1.41 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 208.5, 139.7, 128.8, 
127.9, 127.1, 77.3, 77.0, 76.6, 50.8, 50.1, 47.6, 44.4, 37.8, 19.8, 13.8.; IR (film) 2958, 2930, 
2872, 1710, 1454, 1247 cm-1; HRMS (EI) m/z calcd. for C14H18SO [M] 234.1078, found 
234.1076. 
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(E)-but-3-yn-1-yl(hex-1-en-1-yl)sulfane 
General protocol F2 was followed, starting from 3-butyn-1-thiol 2.12 (534 
mg, 2.40 mmol), (E)-1-iodohex-1-ene (420 mg, 1.91 mmol), 
Pd(dppf)Cl2·DCM complex (82mg, 0.095 mmol) and distilled Et3N (0.72 
mL, 5.1 mmol). Flash column chromatography with 3% diethyl ether in hexanes afforded 238 
mg (74%) of the desired vinyl sulfide. 1H NMR (400 MHz, CDCl3) δ 5.90 (dt, J = 15.0, 1.2 Hz, 
1H), 5.77-5.64 (dt, J = 15.0, 7.8 Hz, 1H), 2.77 (t, J = 7.6 Hz, 2H), 2.50 (td, J = 7.5, 2.6 Hz, 2H), 
2.08 (m, 2H), 2.04 (t, J = 2.6 Hz, 1H), 1.40-1.21 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 133.3, 121.3, 82.4, 69.4, 32.8, 31.7, 31.3, 22.1, 19.6, 13.9; IR (film) 3305, 
2958, 2927, 2871, 2858, 1459, 1436, 946 cm-1; HRMS (EI) m/z calcd. for C10H16S [M] 168.0973, 
found 168.0967. 
 
(E)-4-(hex-1-en-1-ylthio)but-1-en-2-yl acetate (2.13) 
General protocol D for enol acetate synthesis was followed, starting from 
the above vinyl sulfide (232 mg, 1.38 mmol), [(p-cymene)RuCl2]2 (32.7 mg, 
0.06 mmol), (2-furyl)3P (24.7 mg, 0.12 mmol), Na2CO3 (20.2 mg, 0.20 
mmol) and acetic acid (0.15 mL, 2.7 mmol). Flash column chromatography with 5% diethyl 
ether in hexanes afforded 135 mg (43%) of the desired enol acetate 2.13. 1H NMR (400 MHz, 
CDCl3) δ 5.88 (dt, J = 15.0, 1.3 Hz, 1H), 5.67 (dt, J = 14.9, 7.0 Hz, 1H), 4.86-4.68 (m, 2H), 2.75 
(t, J = 7.2 Hz, 2H), 2.52 (t, J = 7.6 Hz, 2H), 2.14 (s, 3H), 2.12-2.03 (m, 2H), 1.42-1.23 (m, 4H), 
0.89 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 168.7, 154.0, 132.2, 121.5, 102.4, 33.5, 
32.6, 31.2, 29.4, 21.9, 20.8, 13.7; IR (film) 2958, 2927, 2857, 1759, 1666, 1434, 1370, 1197, 
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1020, 947, 876 cm-1; HRMS (ESI) m/z calcd. For C12H20O2SNa [M+Na]+ 251.1082, found 
251.1079. 
 
(E)-2-(pent-1-en-1-yl)dihydro-2H-thiopyran-4(3H)-one (2.3) 
General protocol G2 was followed, starting from the enol acetate 2.13 (45.4 
mg, 0.20 mmol), DDQ (47.7 mg, 0.21 mmol), 2,6-dichloropyridine (59.2 mg, 
0.40 mmol) and 4Å M.S. (140 mg) in DCM (2 mL). Flash column 
chromatography with 10% diethyl ether in hexanes afforded 21.4 mg (58%) of the desired 
cyclization product 2.3. 
 
(E)-hept-1-yn-4-yl(hex-1-en-1-yl)sulfane 
General protocol F2 was followed, starting from hept-1-yne-4-thiol 2.14 
(406 mg, 2.37 mmol), (E)-1-iodohex-1-ene (430 mg, 1.95 mmol), 
Pd(dppf)Cl2·CH2Cl2 complex (82mg, 0.10 mmol) and distilled Et3N (0.74 mmol, 5.3 mmol). 
Flash column chromatography with 1% diethyl ether in hexanes afforded 212.2 mg (52%) of the 
desired vinyl sulfide. 1H NMR (300 MHz, CDCl3) δ 5.93 (dt, J = 15.0, 0.9 Hz, 1H), 5.80 (dt, J = 
14.9, 6.7 Hz, 1H), 2.88 (tt, J = 7.7, 5.3 Hz, 1H), 2.58 (ddd, J = 17.0, 5.2, 2.7 Hz, 1H), 2.43 (ddd, 
J = 17.0, 7.5, 2.6 Hz, 1H), 2.08 (dt, J = 6.8, 6.8 Hz, 2H), 2.03 (t, J = 2.6 Hz, 1H), 1.84-1.67 (m, 
1H), 1.64-1.38 (m, 4H), 1.38-1.25 (m, 4H), 0.91 (t, J = 7.2 Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 135.5, 120.4, 81.6, 69.9, 45.2, 35.4, 32.8, 31.2, 25.1, 22.0, 19.9, 13.8, 
13.7. 
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(E)-4-(hex-1-en-1-ylthio)hept-1-en-2-yl acetate (2.15) 
General protocol D for enol acetate synthesis was followed, starting 
from the above vinyl sulfide (204.2 mg, 0.97 mmol), [(p-
cymene)RuCl2]2 (24.5 mg, 0.04 mmol), (2-furyl)3P (18.5 mg, 0.08 
mmol), Na2CO3 (15.1 mg, 0.15 mmol) and acetic acid (0.11 mL, 2.0 mmol). Flash column 
chromatography with 3% diethyl ether in hexanes afforded 89.1 mg (34%) of the desired enol 
acetate 2.15. 1H NMR (400 MHz, CDCl3) δ 5.89 (dt, J = 14.9, 1.0 Hz, 1H), 5.78 (dt, J = 14.9, 6.8 
Hz, 1H), 4.88-4.74 (m, 2H), 2.87-2.80 (m, 1H), 2.55 (ddd, J = 15.0, 6.6, 0.7 Hz, 1H), 2.45 (ddd, 
J = 15.0, 6.6, 0.7 Hz, 1H), 2.14 (s, 3H), 2.08 (dt, J = 6.6, 6.6 Hz, 2H), 1.68-1.58 (m, 1H), 1.58-
1.45 (m, 3H), 1.43-1.23 (m, 5H), 0.91 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 168.9, 153.4, 135.3, 120.2, 103.8, 43.7, 39.4, 36.0, 32.8, 31.2, 22.0, 21.0, 
20.0, 13.8, 13.7; IR (film) 2958, 2928, 2872, 1759, 1666, 1461, 1436, 1370, 1200, 1020, 952 cm-
1; HRMS (ESI) m/z calcd. for C15H26O2SNa [M+Na]+ 293.1551, found 293.1561. 
 
(2S,6S)-2-((E)-pent-1-en-1-yl)-6-propyldihydro-2H-thiopyran-4(3H)-one (2.7) 
General protocol G2 was followed, starting from the above enol acetate 
2.15 (36.2 mg, 0.13 mmol), DDQ (29.5 mg, 0.13 mmol), 2,6-
dichloropyridine (38.4 mg, 0.26 mmol) and 4Å M.S. (140 mg) in DCM 
(1.5 mL). The reaction afforded 21.4 mg (71% yield) of the desired cyclization product 2.7 with 
a cis: trans ratio of 25:1.  
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S-(3-(methoxy(methyl)amino)-3-oxopropyl) ethanethioate (2.17) 
To a vigorously stirred solution of Me(OMe)NH HCl (2.77 g, 28.4 mmol) and 3-
bromopropanoyl chloride 2.16 (4.43 g, 25.8 mmol) in dichloromethane (50 mL) at 0 
°C, Et3N (7.89 mL, 56.7 mmol) was added over three hours, and then the reaction 
mixture was stirred at RT for 24 hours. The reaction mixture was concentrated under vacuum, 
dissolved in 150 mL diethyl ether, and washed twice with 200 mL brine. The organic phase was 
dried with Na2SO4, filtered and concentrated under vacuum. Flash column chromatography with 
15% acetone in hexanes afforded 2.63 g (52%) the desired product. 1H NMR (400 MHz, 
(CD3)2CO) δ 3.71 (s, 3H), 3.64 (t, J = 6.8 Hz, 2H), 3.21 (s, 3H), 3.05 (t, J = 6.8, 2H). 
The above bromide (2.05 g, 10.4 mmol) was reacted with HSAc (2.05 mL, 28.7 mmol) and 
Cs2CO3 (8.31 g, 25.5 mmol) according to the general protocol E2. Flash column chromatography 
with 15% acetone in hexanes afforded the desired thioacetate 2.17 (0.95 g, 48% yield). 1H NMR 
(500 MHz, CDCl3) δ 3.67 (s, 3H), 3.19 (s, 3H), 3.14 (t, J = 7.0 Hz, 2H), 2.77 (t, J = 6.5 Hz, 2H), 
2.33 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 194.2, 171.0, 60.3, 31.1, 29.4, 23.0. 
 
 (E)-N-methoxy-N-methyl-3-(pent-1-en-1-ylthio)propanamide (2.18) 
The above thioacetate 2.17 (191 mg, 1 mmol) was treated with K2CO3 (204 mg, 
1.5 mmol) in methanol (3 mL) at RT for 40 minutes. The reaction mixture was 
diluted with 15 mL diethyl ether, washed successively with 14 mL of 1N HCl 
and 15 mL brine and concentrated under vacuum. . Flash column chromatography with 15% 
acetone in pentane afforded 117 mg (78%) of the desired thiol. 1H NMR (400 MHz, CDCl3) δ 
3.71 (s, 3H), 3.20 (s, 3H), 2.85-2.78 (m, 4H), 1.71 (t, J = 8.0 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 171.5, 60.7, 35.4, 31.4, 18.9. 
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General protocol F2 was followed, starting from the above thiol (625 mg, 4.19 mmol), (E)-1-
iodohex-1-ene (1.32 g, 6.29 mmol), Pd(dppf)Cl2·CH2Cl2 complex (342mg, 0.42 mmol) and 
distilled Et3N (1.46 mL, 10.5 mmol). Flash column chromatography with 15% acetone in 
hexanes afforded 403 mg (42%) of the desired vinyl sulfide 2.18. 1H NMR (300 MHz, CDCl3) δ 
5.91 (dt, J = 15.0, 1.2 Hz, 1H), 5.69 (dt, J = 15.0, 7.0 Hz, 1H), 3.70 (s, 3H), 3.19 (s, 3H), 2.95 (t, 
J = 7.5 Hz, 2H), 2.75 (t, J = 7.5 Hz, 2H), 2.08 (dt, J = 7.2, 7.2 Hz, 2H), 1.39-1.27 (m, 4H), 0.91 
(t, J = 7.3 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 172.3, 131.2, 121.8, 61.1, 32.7, 32.1, 31.3, 
27.3, 21.9, 13.7. 
 
Triethyl((1-((E)-hex-1-en-1-ylthio)non-3-en-3-yl)oxy)silane (2.19) 
To a stirred solution of the Weinreb amide 2.18 (112 mg, 0.48 mmol) in THF 
(3 mL) at -78 °C, 1M vinyl magnesium bromide solution (1.45 mL, 1.45 
mmol) in THF was added drop wise. The reaction mixture was allowed to RT 
over 1 hr, quenched with 0.2 mL saturated NH4Cl solution and concentrated under vacuum. 
Flash column chromatography with 10% acetone in hexanes afforded 56.2 mg (59%) of the 
desired product. 1H NMR (400 MHz, CDCl3) δ 6.36 (dd, J = 18.0, 10.4 Hz, 1H), 6.24 (d, J = 
17.6 Hz, 1H), 5.91-5.86 (m, 2H), 5.68 (dt, J =14.8, 7.2 Hz, 1H), 2.92-2.78 (m, 4H), 2.08 (dt, J = 
7.2, 7.2 Hz, 2H), 1.77-1.69 (m, 1H), 1.65-1.48 (m, 1H), 1.54-1.48 (m, 1H), 1.33-1.28 (m, 1H), 
0.88 (t, J = 7.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 198.7, 136.3, 132.6, 128.6, 121.7, 39.4, 
34.1, 32.8, 26.6, 22.1, 14.0. 
To a suspension of CuBr Me2S (206 mg, 1.0 mmol) in THF (1 mL) was added 1.6M butyl 
lithium solution (1.25 mL, 2.0 mmol) in hexanes at -40 °C. The mixture was stirred for 0.5 h and 
then cooled to -78 °C. To this solution were added TES-Cl (190 mg, 1.26 mmol), HMPA (0.22 
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mL, 1.26 mmol), and the enone (25 mg, 0.126 mmol) in THF (1 mL) in this order. The mixture 
was stirred at this temperature for 40 minutes and then quenched with 1 mL saturated NH4Cl 
solution. The mixture was extracted with ethyl acetate. The extracts were washed with water, 
dried over Na2SO4, and concentrated under vacuum. Flash column chromatography with 10% 
acetone in hexanes afforded 37.7 mg (81%) of the desired product mixture 2.19 with a Z:E ratio 
of 1.21:1. 1H NMR (400 MHz, CDCl3) δ 5.95-5.84 (m, 1H), 5.66 (dtd, J = 15.0, 7.0, 0.8 Hz, 1H), 
4.65 (t, J = 7.6 Hz, 0.5 H), 4.47 (t, J = 7.0 Hz, 0.4 H), 3.61 (t, J = 6.7 Hz, 1H), 3.48 (q, J = 7.0 
Hz, 1H), 2.81-2.69 (m, 2H), 2.37 (dd, J = 8.9, 6.6 Hz, 1H), 2.29 (dd, J = 13.6, 5.8 Hz, 1H), 2.08 
(qdd, J = 8.4, 2.8, 1.3 Hz, 2H), 2.03-1.96 (m, 1H), 1.95-1.82 (m, 2H), 1.79-1.67 (m, 1H), 1.64-
1.56 (m, 2H), 1.54-1.47 (m, 2H), 1.02-0.91 (m, 10H), 0.91-0.84 (m, 13H); 13C NMR (100 MHz, 
CDCl3) δ 149.2, 148.2, 131.6, 131.1, 122.3, 122.3, 109.5, 108.1, 65.8, 62.6, 37.3, 35.0, 34.6, 
34.5, 32.9, 31.94, 31.7, 31.6, 31.5, 31.4, 30.6, 30.3, 29.4, 29.3, 26.8, 25.2, 22.6, 22.5, 22.3, 22.1, 
20.6, 19.0, 15.2, 14.1, 14.0, 13.9, 6.7, 6.4, 5.50, 5.0, 4.4; IR (film) 2956, 2925, 2875, 1668, 1460, 
1377, 1238, 1179, 1122, 1005, 942 cm-1; HRMS (ESI) m/z calcd. for C21H43OSSi [M+H]+ 
371.2804, found 371.2817. 
 
(E)-2-(pent-1-en-1-yl)-3-pentyldihydro-2H-thiopyran-4(3H)-one (2.20) 
General protocol G2 was followed, starting from the above enol silyl ether 
2.19 (41.2 mg, 0.11 mmol), DDQ (25.0 mg, 0.11 mmol), 2,6-dichloropyridine 
(32.6 mg, 0.22 mmol) and 4Å M.S. (130 mg) in MeNO2. Flash column 
chromatography with 10% diethyl ether in hexanes afforded 21.7 mg (78%) of the inseparable 
cyclization product mixture 2.20 with a trans:cis ratio 1:0.63. 1H NMR (400 MHz, CDCl3) δ 
5.65-5.54 (m, 1H), 5.47-5.39 (m, 0.4H), 5.37-5.29 (m, 0.6H), 3.75 (dd, J =8.2, 4.7 Hz, 0.6H), 
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3.49 (t, J =7.2 Hz, 0.4H), 3.12 (ddd, J =13.8, 8.3, 5.5 Hz, 0.6 H), 3.00-2.82 (m, 2H), 2.75-2.66 
(m, 2H), 2.65-2.58 (m, 1H), 2.11-1.90 (m, 2H), 1.89-1.68 (m, 2H), 1.45-1.33 (m, 2H), 0.99-0.94 
(m, 3H); 13C NMR (125 MHz, CDCl3) δ 210.7, 210.4, 134.0, 133.8, 128.7, 125.7, 56.7, 50.4, 
49.2, 43.4, 42.5, 34.3, 31.8, 29.1, 26.4, 22.4, 22.2, 14.0, 13.5; IR (film) 2956, 2926, 1710, 1627, 
1464, 1281, 1128 cm-1; HRMS (EI) m/z calcd. for C15H26OS [M] 254.1704, found 254.1748. 
 
5-((tert-butyldimethylsilyl)oxy)pent-1-en-3-ol (R = H): To a stirred solution of 
the aldehyde 2.21 (2.8 g, 14.9 mmol) in THF (20 mL) at -78 °C, 1M vinyl 
magnesium bromide solution (22.3 mL, 22.3 mmol) in THF was added drop wise. 
The reaction mixture was allowed to RT over 1 hr, and was quenched with 1 mL saturated 
NH4Cl solution. Flash column chromatography with 10% ethyl acetate in hexanes afforded 56.2 
mg (59%) of the desired product. 1H NMR (400 MHz, CDCl3) δ 5.85 (ddd, J = 17.2, 10.5, 5.4 
Hz, 1H), 5.24 (dt, J = 17.2, 1.6 Hz, 1H), 5.07 (dt, J = 10.5, 1.5 Hz, 1H), 4.32 (brs, 1H), 3.86 
(ddd, J = 10.5, 6.0, 4.6 Hz, 1H), 3.78 (ddd, J = 10.2, 7.5, 4.4 Hz, 1H), 3.39 (brs, 1H), 1.80-1.60 
(m, 2H), 0.88 (s, 9H), 0.05 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 140.5, 114.0, 72.2, 61.7, 38.2, 
25.7, -5.6. 
5-((tert-butyldimethylsilyl)oxy)hex-1-en-3-ol (R = methyl): Prepared similarly as the above 
intermediate, starting from 3-((tert-butyldimethylsilyl)oxy)butanal. The yield was 54%. 1H NMR 
(400 MHz, CDCl3) δ 5.98-5.74 (m, 1H), 5.26 (d, J = 17.2 Hz, 1H), 5.08 (d, J = 10.5 Hz, 1H), 
4.44 (brs, 0.4 H), 4.33-4.23 (m, 0.6 H), 4.21-4.17 (m, 1H), 4.13-4.05 (m, 1H), 3.44 (s, 1H), 3.31 
(s, 1H), 1.71-1.55 (m, 2H), 1.23 (d, J = 6.3 Hz, 1.2H), 1.19 (d, J = 6.1 Hz, 1.8 H), 0.90 (d, J = 3.1 
Hz, 9H), 0.11 (d, J = 4.9 Hz, 3.6H), 0.09 (d, J = 2.4 Hz, 2.4H); 13C NMR (100 MHz, CDCl3) δ 
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141.1, 140.6, 113.9, 113.7, 72.1, 69.5, 69.4, 67.1, 45.8, 44.3, 25.7, 24.5, 23.0, 17.9, 17.8, -3.8, -
4.4, -4.8, -5.0. 
 
5-((tert-butyldimethylsilyl)oxy)pent-1-en-3-yl diethylcarbamate (2.22) (R = 
H): To a stirred solution of the above alcohol (0.55 g, 2.54 mmol) and N,N-
diethylcarbamoyl chloride (0.80 mL, 6.4 mmol) in THF (5 mL) was added 60% 
NaH (256 mg, 6.4 mmol) carefully at 0 °C. The reaction was stirred overnight at room 
temperature, treated with H2O (10 mL) and diethyl ether (2 X 10 mL), separated and 
concentrated under vacuum. Flash column chromatography with 10% ether in hexanes afforded 
670 mg (84%) of the desired product 2.22. 1H NMR (500 MHz, CDCl3) δ 5.81 (ddd, J = 16.7, 
10.5, 6.0 Hz, 1H), 5.31-5.15 (m, 2H), 5.11 (d, J = 10.6 Hz, 1H), 3.66 (t, J = 6.6 Hz, 2H), 3.25 
(brs, 4H), 1.90-1.79 (m, 2H), 1.10 (t, J = 7.1 Hz, 6H), 0.85 (s, 9H), 0.02 (s, 6H); 13C NMR (100 
MHz, CDCl3) δ 155.0, 137.4, 115.3, 72.2, 59.2, 37.5, 25.8, 18.1, -5.5; IR (film) 3090, 2861, 
1703, 1474, 1423, 1380, 1272, 1172, 1098, 986, 838, 776 cm-1; HRMS (ESI) m/z calcd. for 
C16H34NO3Si [M+H]+ 316.2308, found 316.2312. 
5-((tert-Butyldimethylsilyl)oxy)hex-1-en-3-yl diethylcarbamate (R = Methyl): Prepared 
similarly as above, and the yield was 76%. 1H NMR (400 MHz, CDCl3) δ 5.80 (ddd, J = 17.2, 
10.4, 6.0 Hz, 1H), 5.18 (d, J = 17.5 Hz, 1H), 5.08 (d, J = 10.6 Hz, 1H), 3.99-3.78 (m, 1H), 3.23 
(brs, 4H), 1.70-1.65 (m, 2H), 1.10 (t, J = 6.9 Hz, 6H), 0.86 (s, 9H), 0.01 (s, 6H); 13C NMR (100 
MHz, CDCl3) δ 155.0, 138.0, 115.0, 72.4, 64.9, 44.8, 25.8, 25.6, 24.3, 17.9, -3.6, -4.4, -5.0. 
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(Z)-5-((tert-butyldimethylsilyl)oxy)pent-2-en-3-yl diethylcarbamate (2.23) 
(R = H): To a stirred solution of freshly prepared LDA (2.75 mmol) in THF (6 
mL) was added successively HMPA (0.69 mL, 4.0 mmol) and the substrate 
2.22 (687 mg, 2.18 mmol) in THF (3 mL) at -78 °C. The reaction was stirred for 15 minutes, 
after which MeI (0.21 mL, 3.4 mmol) was added. The reaction was allowed to -30 °C and treated 
with water (20 mL) and diethyl ether (20 mL). The organic layer was separated, dried and 
concentrated under vacuum. Flash column chromatography with 10% ether in hexanes afforded 
434 mg (63%) of the desired product 2.23. 1H NMR (400 MHz, CDCl3) δ 5.06 (q, J = 6.8 Hz, 
1H), 3.69 (t, J = 6.9 Hz, 2H), 3.31 (q, J = 7.1 Hz, 4H), 2.41 (t, J = 6.9 Hz, 2H), 1.50 (d, J = 6.8 
Hz, 3H), 1.16-1.12 (m, 6H), 0.86 (s, 9H), 0.02 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 153.4, 
146.3, 112.3, 60.7, 37.6, 31.5, 25.8, 22.6, 18.2, 14.0, 10.5, -5.4; IR (film) 3070, 2862, 1703, 
1648, 1474, 1423, 1380, 1273, 1172, 1098, 986, 937, 838, 777 cm-1; HRMS (ESI) m/z calcd. for 
C16H34NO3Si [M+H]+ 316.2308, found 316.2310. 
(Z)-5-((tert-butyldimethylsilyl)oxy)hex-2-en-3-yl diethylcarbamate (R = Methyl): Prepared 
similarly as above with a yield of 58%. 1H NMR (500 MHz, CDCl3) δ 5.07 (q, J = 6.8 Hz, 1H), 
3.96-3.89 (m, 1H), 3.33 (q, J = 6.7 Hz, 4H), 2.35 (dd, J = 14.3, 7.1 Hz, 1H), 2.27 (dd, J = 14.2, 
5.7 Hz, 1H), 1.51 (d, J = 6.7 Hz, 3H), 1.16 (t, J = 6.5 Hz, 6H), 0.87 (s, 9H), 0.04 (s, 3H), 0.03 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 146.7, 113.0, 77.3, 77.2, 77.0, 76.7, 66.1, 44.7, 25.8, 23.7, 
18.1, 10.6, -4.7, -4.9. 
 
(Z)-5-hydroxypent-2-en-3-yl diethylcarbamate (R = H): The above product 
(410 mg, 1.30 mmol) was treated with a mixture of 1M TBAF (3.9 mL, 3.9 
mmol) and HOAc (0.15 mL, 2.6 mmol) at RT for two hours. Flash column 
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chromatography with 50% ethyl acetate in hexanes afforded 184 mg (70%) of the desired 
alcohol. 1H NMR (500 MHz, CDCl3) δ 5.25 (q, J = 7.0 Hz, 1H), 3.61 (aps, 2H), 3.39-3.32 (m, 
4H), 2.38 (t, J = 5.1 Hz, 2H), 1.53 (d, J = 7.0 Hz, 3H), 1.20 (t, J = 7.2 Hz, 3H), 1.17 (t, J = 7.2 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 155.1, 137.5, 115.4, 72.3, 59.3, 37.6, 25.9, -5.5; IR 
(film) 3454, 2873, 1697, 1475, 1424, 1379, 1276, 1219, 1167, 1098, 1054, 973 cm-1; HRMS 
(ESI) m/z calcd. for C10H19NO3Na [M+Na]+ 224.1263, found 224.1271. 
(Z)-5-hydroxyhex-2-en-3-yl diethylcarbamate (R = Methyl): Prepared similarly as above with 
a yield of 70%. 1H NMR (300 MHz, CDCl3) δ 5.14 (qd, J = 6.8, 1.2 Hz, 1H), 3.82-3.71 (m, 1H), 
3.28 (q, J = 6.9 Hz, 4H), 2.32-2.19 (m, 1H), 2.08 (dd, J = 14.2, 10.0 Hz, 1H), 1.45 (dd, J = 6.8, 
1.6 Hz, 3H), 1.15-1.07 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 154.4, 146.0, 114.7, 63.5, 44.9, 
42.0, 41.6, 22.0, 14.0, 13.1, 10.5. 
 
(Z)-5-((E)-hex-1-en-1-ylthio)pent-2-en-3-yl diethylcarbamate (2.24) (R 
= H):: General protocol E1 was followed, starting from the above alcohol 
(184 mg, 0.91 mmol), thioacetic acid (0.16 mL, 2.27 mmol), PPh3 (544 
mg, 2.07 mmol) and DIAD (0.42 mL, 2.12 mmol). Flash column chromatography with 20% 
diethyl ether in hexanes afforded 174 mg (73%) of the desired thioacetate. Then general protocol 
F1 was followed, starting from the thioacetate (213 mg, 0.82 mmol), (E)-iodo-1-hexene (260 mg, 
1.24 mmol), CuI (31 mg, 0.16 mmol) and KOH (115 mg, 2.06 mmol). Flash column 
chromatography with 5% ethyl acetate in hexanes afforded 128.6 mg (52%) of the desired 
product 2.24. 1H NMR (400 MHz, CDCl3) δ 5.89 (dt, J = 15.0, 1.2 Hz, 1H), 5.55 (dt, J = 15.0, 
7.0 Hz, 1H), 5.11 (q, J = 6.8 Hz, 1H), 3.34 (q, J = 7.0 Hz, 4H), 2.74 (dd, J = 8.3, 6.8 Hz, 2H), 
2.53 (t, J = 7.3 Hz, 2H), 206 (dt, J = 6.9, 6.9 Hz, 2H), 1.54 (dd, J = 6.8, 0.9 Hz, 4H), 1.38-1.23 
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(m, 4H), 1.12-1.14 (m, 6H), 0.89 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 153.3, 147.3, 
131.6, 122.0, 112.0, 34.2, 32.7, 31.3, 30.0, 22.0, 21.9, 13.8, 10.5; IR (film) 2960, 1714, 1473, 
1423, 1379, 1265, 1160, 1055, 1002, 946 cm-1; HRMS (EI) m/z calcd. for C16H29NO2S [M] 
299.1919, found 299.1891. 
(Z)-5-((E)-hex-1-en-1-ylthio)hex-2-en-3-yl diethylcarbamate (2.26) (R = methyl): Prepared 
similarly as above with a yield of 37% over two steps. 1H NMR (300 MHz, CDCl3) δ 5.93 (dt, J 
= 15.0, 1.2 Hz, 1H), 5.75 (dt, J = 15.0, 6.8 Hz, 1H), 5.10 (q, J = 6.8 Hz, 1H), 3.34 (q, J = 7.1 Hz, 
4H), 3.08-2.91 (m, 1H), 2.60 (ddt, J = 14.7, 5.9, 1.0 Hz, 1H), 2.33 (dd, J = 14.7, 8.4 Hz, 1H), 
2.13-2.00 (dt, J = 7.0, 7.0 Hz, 2H), 1.54 (dt, J = 6.7, 0.9 Hz, 3H), 1.42-1.25 (m, 7H), 1.20 (m, 
6H), 0.89 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 153.3, 146.6, 134.4, 134.4, 120.8, 
113.1, 41.9, 41.6, 38.8, 32.8, 31.3, 22.0, 20.6, 15.1, 13.8, 10.6, 10.6; IR (film) 2961, 2927, 2871, 
1714, 1457, 1378, 1267, 1159, 991 cm-1; HRMS (EI) m/z calcd. for C17H31NO2S [M] 313.2076, 
found 313.2108. 
 
(2R,3S)-3-methyl-2-((E)-pent-1-en-1-yl)dihydro-2H-thiopyran-4(3H)-one (2.25) (R = H): 
 General protocol G2 was followed, starting from the (Z)-vinyl carbamate 
2.24 (52.4 mg, 0.17 mmol), DDQ (41.8 mg, 0.18 mmol), 2,6-dichloropyridine 
(50.3 mg, 0.34 mmol) and 4Å M.S. (150 mg) in MeNO2 (1.5 mL). The 
reaction afforded 27.8 mg (80%) of the cyclization product 2.25 with a trans:cis ratio of 25:1. 1H 
NMR (400 MHz, CDCl3) δ 5.65 (dt, J = 15.6, 6.8 Hz, 1H), 5.36 (ddt, J = 15.2, 8.7, 1.4 Hz, 1H), 
3.37 (dd, J = 9.2, 9.2 Hz, 1H), 2.98 (ddd, J = 15.4, 9.3, 5.4 Hz, 1H), 2.90 (ddd, J = 13.6, 5.2, 5.2 
Hz, 1H), ), 2.71 (dd, J = 9.4, 4.6 Hz, 2H), 2.67 (dd, J = 9.4, 6.5 Hz, 1H), 2.02 (dt, J = 7.2, 7.2 Hz, 
2H), 1.48-1.30 (m, 2H), 1.09 (d, J = 6.7 Hz, 3H), 0.90 (t, J = 7.4 Hz, 4H); 13C NMR (100 MHz, 
S n-Pr
O
 125 
CDCl3) δ 210.3, 134.6, 128.0, 52.9, 51.9, 43.2, 34.2, 28.8, 22.1, 13.5, 13.1; IR (film) 3583, 2871, 
1712, 1651, 1453, 1328, 1277, 1225, 1156, 968 cm-1; HRMS (ESI) m/z calcd. for C11H17OS [M-
H]+ 197.1000 , found 197.1003. 
 
(2R,3S,6S)-3,6-dimethyl-2-((E)-pent-1-en-1-yl)dihydro-2H-thiopyran-4(3H)-one (2.27) 
General protocol G2 was followed, starting from the (Z)-vinyl carbamate 
2.26 (40.8 mg, 0.13 mmol), DDQ (31.0 mg, 0.14 mmol), 2,6-
dichloropyridine (38.6 mg, 0.26 mmol) and 4Å M.S. (80 mg) in MeNO2(1.2 mL).. The reaction 
afforded 22.6 mg (82%) of the cyclization product 2.27 with a ortho-trans:cis ratio of 25:1 and a 
meta-cis:trans ratio of 25:1. 1H NMR (400 MHz, CDCl3) δ 5.68 (dt, J = 15.6, 6.8 Hz, 1H), 5.29 
(dd, J = 15.5, 9.2 Hz, 1H), 3.33 (dd, J = 10.2, 10.2 Hz, 1H), 3.22 (dqd, J = 13.3, 6.7, 2.9 Hz, 
1H), 2.69 (dd, J = 12.5, 2.8 Hz, 1H), 2.56 (dq, J = 10.9, 6.6 Hz, 1H), 2.48 (dd, J = 12.4, 12.4 
Hz, 1H), 2.02 (dt, J = 6.8, 6.8 Hz, 2H), 1.47-1.36 (m, 2H), 1.30-1.26 (m, 4H), 1.03 (d, J = 6.6 
Hz, 3H), 0.90 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 210.1, 135.1, 127.6, 52.6, 52.4, 
51.3, 39.3, 34.2, 31.5, 22.6, 22.1, 21.2, 14.1, 13.5, 12.2; IR (film) 2959, 2870, 1711, 1646, 1451, 
1376, 1331, 1274, 1219, 1106, 965 cm-1; HRMS (ESI) m/z calcd. for C12H19OS [M-H]+ 
211.1157, found 211.1153. 
 
Ethynyl diethylcarbamate (2.28) 
Diisopropylamine (4.33 mL, 30.7 mmol) was dissolved in dry THF (20 mL) and 
the solution was cooled to −78 °C. N-BuLi (19.2 mL, 30.7 mmol; 1.6 M solution in hexane) was 
added dropwise and stirred for 30 min. 2,2,2-tribromoethyl N,N-diethylcarbamate (2.55 g, 6.67 
mmol) in THF (8 mL) was added dropwise over five minutes, and the mixture was stirred for 4 
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hrs. After addition of MeOH (0.81 mL), the reaction mixture was stirred for 2 hrs and then 
allowed to warm to 0 °C. The reaction mixture was treated with water and diethyl ether. The 
organic layer was dried (MgSO4), filtered, and concentrated under vacuum to afford the crude 
product. Flash column chromatography on silica gel (10:1 pentane/ether) furnished of the 1-
alkynyl carbamate 2.28 (537 mg, 57%). 1H NMR (300 MHz, CDCl3) δ 3.41-3.16 (m, 4H), 2.10 
(s, 1H), 1.19 (td, J = 7.2, 2.7 Hz, 6H), 0.88 (t, J = 6.7 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
151.3, 80.8, 44.1, 36.7, 22.8; IR (film) 3390, 2968, 2859, 1456, 1273, 1141, 1081 cm-1; HRMS 
(EI) m/z calcd. for C7H11NO2 [M] 141.0790, found 141.0831. 
 
(Z)-1-iodohex-1-en-1-yl diethylcarbamate (2.29) 
To a stirred suspension of CuI (838 mg, 4.4 mmol) in dry Et2O(5 mL), 4.4 
mL of freshly prepared solution of n-BuMgBr in ether (1M, 4.4 mmol) was 
added drop wise at -78 °C. The reaction mixture was warmed to -25 °C and stirred for 30 
minutes. The reaction mixture was cooled to -78 °C, and the alkynyl carbamate 2.28 (282 mg, 
2.0 mmol) in dry Et2O (1 mL) was added drop wise. After 90 minutes, I2 (1.27 g, 5.0 mmol) in 
dry Et2O (5 ml) was added at -78 °C. The reaction mixture was warmed to room temperature, 
stirred for 15 minutes and quenched with 1:1 saturated aqueous solution of NaHCO3 and 
Na2S2O3. The mixture was separated, extracted with diethyl ether, combined and concentrated 
under vacuum. Flash column chromatography with 5% E2O in hexanes afforded 340 mg (52%) 
of the desired product 2.29. 1H NMR (400 MHz, CDCl3) δ 5.49 (t, J = 7.2 Hz, 1H), 3.34-3.26 
(m, 4H), 2.07 (dt, J = 7.6, 7.6 Hz, 2H), 1.72-1.35 (m, 4H), 1.18 (t, J = 7.2 Hz, 6H), 0.89 (t, J = 
7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 152.6, 128.9, 101.9, 34.6, 31.6, 25.2, 22.6, 14.1; IR 
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(film) 2872, 1731, 1459, 1420, 1269, 1151, 1096, 1012 cm-1; HRMS (EI) m/z calcd. for 
C11H20NO2I [M] 325.0539 , found 325.0561. 
 
(E)-octa-1,3-dien-3-yl diethylcarbamate  
To a 25 mL flame-dried round bottom flask was added Pd(PPh3)4 (202 mg, 
0.175 mmol) , followed by argon exchange and protection. Distilled THF(0.6 
mL) and 1M vinyl magnesium bromide (3.0 mL, 3.0 mmol) was charged, and 
the resulting suspension was stirred for 15 minutes at °C. The substrate 2.29 (570 mg, 1.75 
mmol) in THF (1 mL) was then added drop wise, and the reaction mixture was stirred for 30 
minutes. The reaction was cooled to 0 °C, quenched with saturated aqueous NH4Cl solution (0.1 
mL), and concentrated under vacuum. Flash column chromatography with 10% Et2O in hexanes 
afforded 300 mg (71 %) of the desired diene. 1H NMR (300 MHz, CDCl3) δ 6.57 (dd, J = 17.1, 
11.0 Hz, 1H), 5.31 (dd, J = 8.4, 7.7 Hz, 1H), 5.23 (d, J = 17.0 Hz, 1H), 5.13 (dt, J = 11.0, 1.4 Hz, 
1H), 3.37 (q, J = 6.7 Hz, 4H), 2.21 (dt, J = 14.8, 7.4 Hz, 2H), 1.46-1.12 (m, 12H), 0.91 (t, J = 6.6 
Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 154.3, 145.2, 127.4, 122.3, 113.6, 31.6, 25.9, 22.1, 13.8. 
 
(E)-1-hydroxyoct-3-en-3-yl diethylcarbamate (2.30) 
To a solution of 1M BH3 in THF (1.29 mL, 1.29 mmol) at 0 °C, cyclohexene 
(0.28 mL, 2.58 mmol) was added dropwise. White precipitates were formed 
in several minutes. Thirty minutes later, the diene (194 mg, 0.86 mmol) was 
added drop wise. The reaction mixture became clear in 15 minutes and was stirred for 1.5 hours 
at 0 °C. A 10% solution of sodium hydroxide (2.8mL) and 33% hydrogen peroxide (1.1 mL were 
added carefully and successively, and the reaction mixture was stirred for 1 hr at room 
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temperature. Following the addition of Et2O, the organic layer was separated, re-extracted, 
combined and concentrated under vacuum. Flash column chromatography with 40% EtOAc in 
hexanes afforded 130 mg (62%) of the desired alcohol 2.30. 1H NMR (500 MHz, CDCl3) δ 5.28 
(t, J = 7.8 Hz, 1H), 3.73-3.54 (m, 4H), 3.32 (brs, J = 3.5 Hz, 4H), 2.47 (t, J = 5.7 Hz, 2H), 2.10 
(dt, J = 7.4, 7.4 Hz, 2H), 1.99-1.80 (m, 4H), 1.78-1.70 (m, 4H), 1.63-1.53 (m, 2H), 1.43-1.32 (m, 
4H), 1.33-1.24 (m, 6H), 1.18 (d, J = 19.9 Hz, 8H), 0.90 (t, J = 7.1 Hz, 3H).; 13C NMR (125 MHz, 
CDCl3) δ 156.0, 145.3, 122.0, 70.2, 58.8, 35.5, 33.4, 31.8, 26.3, 25.4, 24.1, 22.2, 13.8; IR (film) 
3456, 2960, 2931, 2873, 1697, 1475, 1424, 1276, 1167, 1053 cm-1; HRMS (ES) m/z calcd. for 
C13H25NO3 [M] 243.1834, found 243.1861. 
 
(E)-S-(3-((diethylcarbamoyl)oxy)oct-3-en-1-yl) ethanethioate 
General protocol E1 was followed, starting from the above alcohol (120 mg, 
0.49 mmol), thioacetic acid (0.17 mL, 2.5 mmol), PPh3 (603 mg, 2.3 mmol) 
and DIAD (0.45 mL, 2.3 mmol). Flash column chromatography with 5% 
ethyl acetate in hexanes afforded 110 mg (74%) of the desired thioacetate. 1H NMR (300 MHz, 
CDCl3) δ 5.21 (t, J = 7.8 Hz, 1H), 3.31 (q, J = 7.1 Hz, 4H), 2.98 (t, J = 7.6, 2H), 2.57 (t, J = 7.4 
Hz, 2H), 2.32 (s, 3H), 2.06 (dt, J = 7.2, 7.2 Hz, 2H), 1.90-1.49 (m, 4H), 1.16 (t, J = 6.5 Hz, 6H), 
0.88 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 195.6, 154.4, 146.4, 119.4, 41.8, 31.8, 
30.5, 29.4, 26.6, 26.2, 22.2, 14.0. 
 
(E)-1-((E)-hex-1-en-1-ylthio)oct-3-en-3-yl diethylcarbamate (2.31) 
General protocol F1 was followed, starting from the above thioacetate (105 
mg, 0.35 mmol), CuI (13.3 mg, 0.07 mmol) and KOH (493 mg, 0.88 
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mmol). Flash column chromatography with 5% ethyl acetate in hexanes afforded 70.5 mg (59%) 
of the desired product 2.31. 1H NMR (300 MHz, CDCl3) δ 5.90 (dt, J = 15.0, 1.3 Hz, 1H), 5.66 
(dt, J = 15.0, 6.9 Hz, 1H), 5.20 (t, J = 7.8 Hz, 1H), 3.30 (q, J = 7.0 Hz, 4H), 2.81-2.69 (m, 2H), 
2.60 (dd, J = 11.0, 4.4 Hz, 2H), 2.18-1.99 (m, 4H), 1.42-1.24 (m, 8H), 1.15 (t, J = 7.1 Hz, 6H), 
0.91-0.83 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 154.3, 146.7, 131.7, 122.0, 119.0, 32.8, 31.8, 
31.4, 30.0, 29.6, 26.2, 22.2, 22.0, 13.8; IR (film) 2958, 2928, 2872, 1712, 1468, 1421, 1379, 
1270, 1159, 1104 cm-1; HRMS (EI) m/z calcd. for C19H35NO2S [M] 341.2389, found 341.2413. 
 
(2R,3R)-3-butyl-2-((E)-pent-1-en-1-yl)dihydro-2H-thiopyran-4(3H)-one (2.32) 
General protocol G2 was followed, starting from the (E)-vinyl carbamate 19 
(49.3 mg, 0.14 mmol), DDQ (33.4 mg, 0.14 mmol), 2,6-dichloropyridine (41.4 
mg, 0.28 mmol) and 4Å M.S. (150 mg) in MeNO2 (1.5 mL). The reaction afforded 30.6 mg 
(88%) of the cyclization product 2.32 as a single diastereomer. 1H NMR (400 MHz, CDCl3) δ 
5.58 (dt, J = 15.2, 6.6 Hz, 1H), 5.32 (ddt, J = 15.2, 8.6, 0.8 Hz, 1H), 3.76 (dd, J = 8.6, 4.3 Hz, 
1H), 3.12 (ddd, J = 13.8, 8.1, 5.8 Hz, 1H), 2.96-2.82 (m, 2H), 2.77-2.64 (m, 2H), 2.10-1.93 (m, 
2H), 1.89-1.78 (m, 1H), 1.45-1.33 (m, 2H), 1.33-1.24 (m, 4H), 1.24-1.16 (m, 2H), 0.88 (t, J = 7.3 
Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 210.4, 133.9, 125.6, 56.5, 49.1, 43.4, 34.3, 31.5, 27.2, 
26.8, 22.6, 22.2, 14.0, 13.8, 13.4; IR (film) 2828, 1709, 1565, 1432, 1161, 1136, 966, 791 cm-1; 
HRMS (ESI) m/z calcd. for C14H25OS [M+H]+ 241.1626, found 241.1607. 
 
(E)-hex-1-en-1-yl(pent-4-yn-1-yl)sulfane (2.34) 
General protocol F2 was followed, starting from 4-pentyn-1-thiol 2.33 (5.72 
g, 25.7 mmol), (E)-1-iodohex-1-ene (4.49 g, 21.4 mmol), Pd(dppf)Cl2·CH2Cl2 
complex (874mg, 1.07 mmol) and Et3N (7.7 mL, 55.3 mmol, pre-soaked with 
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molecular sieves). Flash column chromatography with 2% diethyl ether in hexanes afforded 2.36 
g (61%) of the desired vinyl sulfide product 2.34. 1H NMR (400 MHz, CDCl3) δ 5.89 (dt, J = 
15.0, 1.3 Hz, 1H), 5.67 (dt, J = 15.0, 6.9 Hz, 1H), 2.75 (t, J = 7.3 Hz, 2H), 2.33 (td, J = 6.9, 2.6 
Hz, 2H), 2.08 (dtd, J = 7.1, 7.1, 1.2 Hz, 2H), 1.97 (t, J = 2.7 Hz, 1H), 1.87-1.80 (m, 2H), 1.39-
1.21 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 131.2, 122.0, 83.0, 68.8, 
32.6, 31.2, 28.0, 21.8, 17.0, 13.6; IR (film) 3304, 2956, 2926, 2857, 1454, 1433, 1254, 944 cm-1; 
HRMS (EI) m/z calcd. for C11H18S [M] 182.1129, found 182.1139. 
 
(E)-hex-1-en-1-yl((E)-5-iodopent-4-en-1-yl)sulfane 
General protocol H for the synthesis of vinyl iodide was followed, starting 
from the substrate 2.34 (638 mg, 3.5 mmol), ZrCp2Cl2(1.13 g, 3.85 mmol) 
and 1M DIBAL-H (3.85 mL, 3.85 mmol). Flash column chromatography with 2% 
dichloromethane in hexanes afforded 967 mg (78%) of the desired product. 1H NMR (400 MHz, 
CDCl3) δ 6.49 (dt, J = 14.4, 7.2 Hz, 1H), 6.06 (dt, J = 14.4, 1.4 Hz, 1H), 5.87 (dt, J = 15.0, 1.3 
Hz, 1H), 5.65 (dt, J = 15.0, 7.0 Hz, 1H), 2.62 (t, J = 7.3 Hz, 2H), 2.17 (dtd, J = 7.5, 7.5, 1.3 Hz, 
2H), 2.06 (dtd, J = 7.0, 7.0, 1.1 Hz, 2H), 1.75- 1.68 (m, 2H), 1.40-1.26 (m, 4H), 0.89 (t, J = 7.1 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 144.9, 131.1, 122.0, 75.5, 34.5, 32.6, 31.5, 31.2, 27.7, 
12.8, 13.7; IR (film) 2954, 2925, 2854, 1606, 1453, 1435, 1256, 1213, 942 cm-1. 
 
((E)-6-((E)-hex-1-en-1-ylthio)hex-2-en-1-yl)trimethylsilane (2.35) 
General protocol I for Kumada coupling reaction was followed, starting 
from the above vinyl iodide (468 mg, 1.5 mmol), Pd(PPh3)4 (173 mg, 0.15 
mmol) and 1M trimethylsilyl methylmagnesium chloride (2.25 mL, 2.25 mmol). Flash column 
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chromatography with 2% Dichloromethane in hexanes afforded 373 mg (91%) of the desired 
product 2.35. 1H NMR (400 MHz, CDCl3) δ 5.89 (dt, J = 15.0, 1.3 Hz, 1H), 5.62 (dt, J = 15.0, 
7.0 Hz, 1H), 5.41 (dtt, J = 15.0, 8.0, 1.2 Hz, 1H), 5.21 (dt, J = 15.1, 6.8 Hz, 1H), 2.62 (t, J = 7.5 
Hz, 2H), 2.11-2.04 (m, 4H), 1.69-1.62 (m, 2H), 1.42-1.26 (m, 4H), 0.89 (t, J = 7.6 Hz, 3H), -
0.02 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 130.7, 127.4, 127.2, 122.6, 32.8, 32.0, 31.7, 31.5, 
29.6, 22.6, 22.0, 13.8, -2.0; IR (film) 2954, 2926, 1454, 1437, 1247, 1155, 964, 940, 852 cm-1; 
HRMS (ESI) m/z calcd. for C15H30SSiNa [M+Na]+ 293.1735, found 293.1729. 
 
((Z)-6-((E)-hex-1-en-1-ylthio)hex-2-en-1-yl)trimethylsilane (2.36) 
To a solution of the substrate 2.34 (365 mg, 2.0 mmol) in THF (12 mL) 
cooled at -78 °C was added drop wise 1.6 M BuLi solution (1.38 mL, 2.2 
mmol). The reaction mixture was allowed to -20 °C, stirred for 15 minutes, 
and cooled back to -78 °C. Iodine (609 mg, 2.4 mmol) in THF (5 mL) was added dropwise, and 
the reaction mixture was slowly allowed to 0 °C. The reaction was quenched with 1:1 saturated 
aqueous solution of NaHCO3 and Na2S2O3, extracted with diethyl ether twice and concentrated 
under vacuum. Flash column chromatography with 10% dichloromethane in hexanes afforded 
529 mg (86%) of the desired product. 1H NMR (300 MHz, CDCl3) δ 5.90 (d, J =15.0 Hz, 1H), 
5.67 (dt, J = 15.0, 7.0 Hz, 1H), 2.72 (t, J = 7.0 Hz, 2H), 2.50 (t, J = 7.0 Hz, 2H), 2.80 (dt, J = 
7.0, 7.0 Hz, 2H), 1.86-1.79 (m, 2H), 1.40-1.26 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H). To a 25 mL 
round bottom flask was charged the above ethynyl iodide (374 mg, 1.21 mmol), K2N2(CO2)2 
(704 mg, 3.63 mmol), pyridine (0.6 mL, 7.4 mmol) and methanol (1.4 mL). Acetic acid (0.44 
mL, 7.7 mmol) diluted with methanol (1.7 mL) was added via a syringe pump over 8 hours at 
RT. The reaction mixture was carefully quenched with water, extracted twice with diethyl ether 
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and concentrated under vacuum. Flash column chromatography with 10% dichloromethane in 
hexanes afforded 124 mg (33%) of the desired (Z)-vinyl iodide. 1H NMR (300 MHz, CDCl3) δ 
6.26 (dt, J = 7.4, 0.8 Hz, 1H), 6.18 (dt, J = 7.0, 6.9 Hz, 1H), 5.90 (dt, J = 15.0, 1.3 Hz, 1H), 5.66 
(dt, J = 15.0, 6.9 Hz, 1H), 2.66 (t, J = 7.6 Hz, 2H), 2.26 (dt, J = 7.5, 7.5 Hz, 2H), 2.08 (dt, J = 
6.9, 6.9 Hz, 2H), 1.84-1.67 (m, 2H), 1.42-1.27 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H). General 
protocol I for Kumada coupling reaction was followed, starting from above (Z)-vinyl iodide 
(168.5 mg, 0.543 mmol), (PPh3)4 (63.3 mg, 0.055 mmol) and 1M trimethylsilyl 
methylmagnesium chloride (0.82 mL, 0.82 mmol). Flash column chromatography with 2% 
Dichloromethane in hexanes afforded 137 mg (93%) of the desired (Z)-allylsilane 2.36. 1H NMR 
(400 MHz, CDCl3) δ 5.90 (dt, J = 15.0, 1.3 Hz, 1H), 5.64 (dt, J = 15.0, 7.0 Hz, 1H), 5.44 (dtt, J = 
10.2, 8.6, 1.6 Hz, 1H), 5.30-5.18 (m, 1H), 2.64 (t, J = 7.2 Hz, 2H), 2.13-2.05 (m, 4H), 1.77-1.61 
(m, 2H), 1.48 (d, J = 12.6 Hz, 2H), 1.40-1.23 (m, 4H), 0.89 (t, J = 7.2 Hz, 3H), 0.01 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 130.9, 126.4, 126.1, 122.5, 32.8, 32.3, 31.4, 29.4, 26.0, 22.0, 18.4, 
13.9, -1.8; IR (film) 3006, 2928, 2856, 1645, 1456, 1419, 1392, 1248, 1150, 856 cm-1; HRMS 
(ESI) m/z calcd. for C15H31SSi [M+H]+ 271.1916, found 271.1929. 
 
((2E)-6-(hexa-1,3-dien-1-ylthio)hex-2-en-1-yl)trimethylsilane (2.38) 
General protocol G1 was followed, starting from the trans- allylsilane 2.35 
(55.9 mg, 0.21 mmol), DDQ (49.3 mg, 0.22 mmol), 2,6-dichloropyridine 
(0.43 mg, 0.75 mmol) and 4Å M.S. (150 mg) in DCM (2.5 mL). The reaction afforded 30.1 mg 
(54% yield) of the diene mixture 2.38 with a trans: cis ratio of about 1:1. 1H NMR (400 MHz, 
CDCl3) δ 6.41 (ddd, J = 14.9, 11.0, 1.1 Hz, 0.5H), 6.22-6.05 (m, 1.5 H), 6.05-5.97 (m, 0.5H), 
5.92 (dd, J = 16.9, 6.2 Hz, 0.5H), 5.59 (dt, J = 14.5, 6.6 Hz, 0.5H), 5.46-5.36 (m, 1H), 5.33-5.25 
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(m, 0.5H), 5.25-5.15 (m, 1H), 2.75-2.60 (m, 2H), 2.20-2.11 (m, 1H), 2.13-2.04 (m, 3H), 1.77-
1.61 (m, 2H), 1.41 (d, J = 8.0 Hz, 2H), 1.00 (td, J = 7.5, 1.8 Hz, 3H), -0.01 (s, 9H); 13C NMR 
(100 MHz, CDCl3) δ 133.7, 131.0, 128.5, 128.4, 127.8, 127.5, 127.4, 127.3, 127.2, 126.9, 125.1, 
123.5, 32.0, 31.9, 31.7, 29.6, 29.5, 25.6, 22.7, 21.0, 14.2, 13.6, -2.0; IR (film) 3378, 2952, 2360, 
1713, 1411, 1247, 1134, 1009, 844 cm-1; HRMS (ESI) m/z calcd. for C15H29SSi [M+H]+ 
269.1759, found 269.1775. 
 
(2R,3R)-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran (2.39) 
General protocol G2 was followed, starting from the trans- allylsilane 
2.35 (97.1 mg, 0.36 mmol), DDQ (85.5 mg, 0.38 mmol), 2,6-
dichloropyridine (111.6 mg, 0.75 mmol) and 4Å M.S. (290 mg) in MeNO2. The reaction 
afforded 46.8 mg (68% yield) of the desired cyclization product 2.39 with a trans: cis ratio of 
7.7:1. 
(2R,3R)-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran (2.39) (trans-product): 1H NMR 
(400 MHz, CDCl3) δ 5.65 (ddd, J = 13.7, 8.7, 6.2 Hz, 1H), 5.58 (dd, J = 12.8, 5.8 Hz, 1H)., 5.26 
(ddt, J = 15.3, 8.8, 1.4 Hz, 1H), 5.01-4.92 (m, 2H), 3.13 (dd, J = 9.4, 9.4 Hz, 1H), 2.71 (ddd, J = 
12.4, 12.4, 2.8 Hz, 1H), 2.54 (dddd, J = 13.4, 3.6, 3.6, 1.3 Hz, 1H), 2.17 (dddd, J = 10.2, 10.2, 
10.2, 3.2 Hz, 1H), 2.08-1.94 (m, 3H), 1.91-1.81 (m, 1H), 1.72-1.63 (m, 1H), 1.38 (dt, J = 14.6, 
4.1 Hz, 2H), 1.30-1.24 (m, 1H), 0.87 (t, J =7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 141.8, 
133.6, 129.7, 114.3, 48.2, 47.8, 34.3, 32.4, 29.6, 27.0, 22.2, 13.5; IR (film) 2957, 2926, 2847, 
1639, 1451, 1287, 1145, 990, 963 cm-1; HRMS (ESI) m/z calcd. for C12H21S [M+H]+ 197.1364, 
found 197.1368. 
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(2R,3S)-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran (cis-product): 1H NMR (400 
MHz, CDCl3) δ 6.01 (ddd, J = 17.2, 10.5, 7.8 Hz, 1H), 5.61 (dt, J = 15.2, 6.8 Hz, 1H), 5.52 (dd, 
J = 15.2, 8.0 Hz, 1H), 5.08-4.97 (m, 2H), 3.39 (dd, J = 7.8, 3.3 Hz, 1H), 2.72 (ddd, J = 13.4, 8.1, 
3.4 Hz, 1H), 2.64-2.53 (m, 2H), 2.06-1.90 (m, 3H), 1.79-1.70 (m, 1H), 1.70-1.62 (m, 2H), 1.48-
1.33 (m, 2H), 0.89 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 140.1, 132.9, 127.5, 
114.8, 46.1, 44.8, 34.4, 29.4, 26.7, 24.6, 22.4, 13.6; IR (film) 3008, 2853, 1726, 1659, 1451, 
1377, 1134, 1017, 891 cm-1; HRMS (ESI) m/z calcd. for C12H21S [M+H]+ 197.1364, found 
197.1374. 
 
(2R,3R)-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran (2.39) 
General protocol G2 was followed, starting from the cis-allylsilane 2.36 
(78.3 mg, 0.29 mmol) DDQ (68.9 mg, 0.30 mmol), 2,6-dichloropyridine 
(89.6 mg, 0.61 mmol) and 4Å M.S. (240 mg) in MeNO2. The reaction afforded 42.6 mg (75% 
yield) of the desired cyclization products 2.39 with a trans: cis ratio of 1.9:1. 
 
(E)-tert-butyl((1-iodonon-1-en-5-yl)oxy)dimethylsilane and (E)-tert-butyl((7-iodo-2-
methylhept-6-en-3-yl)oxy)dimethylsilane 
General protocol H for the synthesis of vinyl iodide was followed, starting from 
the corresponding alkyne 2.40 or 2.41. Flash column chromatography with 5% 
Dichloromethane in hexanes afforded the corresponding vinyl iodide. 
(E)-tert-butyl((1-iodonon-1-en-5-yl)oxy)dimethylsilane R: n-Bu: 73% yield. 1H NMR (300 
MHz, CDCl3) δ 6.52 (dt, J = 14.2, 7.1 Hz, 1H), 5.98 (dt, J = 14.3, 1.4 Hz, 1H), 3.81-3.53 (m, 
1H), 2.41-1.83 (m, 2H), 1.69-1.38 (m, 4H), 1.38-0.99 (m, 4H), 0.99-0.84 (m, 12H), 0.04 (s, 3H), 
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0.03 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 146.7, 74.3, 71.4, 36.7, 35.5, 31.9, 27.4, 25.9, 22.8, 
18.1, 14.1, -4.4, -4.5. 
(E)-tert-butyl((7-iodo-2-methylhept-6-en-3-yl)oxy)dimethylsilane R: i-pro: 76% yield. 1H NMR 
(300 MHz, CDCl3) δ 6.52 (dt, J = 14.4, 7.2 Hz, 1H), 5.99 (dt, J = 14.4, 1.5 Hz, 1H), 3.42 (dd, J 
= 11.1, 5.1 Hz, 1H), 1.91-2.20 (m, 2H), 1.65-1.75 (m, 1H), 1.43-1.51 (m, 2H), 0.89 (s, 9H), 0.85 
(d, J = 6.6 Hz, 3H), 0.84 (d, J = 6.6 Hz, 3H), 0.03 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 146.7, 
76.1, 74.3, 32.8, 32.2, 31.3, 25.9, 18.1, 18.0, 17.6, -4.3, -4.4. 
 
(E)-tert-butyldimethyl((10-(trimethylsilyl)dec-8-en-5-yl)oxy)silane (2.42) and (E)-tert-
butyldimethyl((2-methyl-8-(trimethylsilyl)oct-6-en-3-yl)oxy)silane (2.43) 
General protocol I for Kumada coupling reaction was followed, starting 
from the above vinyl iodide. Flash column chromatography with 5% 
Dichloromethane in hexanes afforded the corresponding allylsilane. 
(E)-tert-butyldimethyl((10-(trimethylsilyl)dec-8-en-5-yl)oxy)silane (2.42) R: n-Bu: 88% yield. 
1H NMR (400 MHz, CDCl3) δ 5.36 (dtt, J = 15.2, 7.6, 1.0 Hz, 1H), 5.23 (dt, J = 15.2, 6.8 Hz, 
1H), 3.64 (app t, J = 5.8 Hz, 1H), 2.09-1.92 (m, 2H), 1.50-1.36 (m, 6H), 1.28 (tt, J = 10.1, 3.8 
Hz, 4H), 0.92-0.80 (m, 12H), 0.04 (s, 3H), 0.04 (s, 3H), -0.02 (m, 9H); 13C NMR (100 MHz, 
CDCl3) δ 128.3, 125.9, 71.9, 37.5, 36.7, 28.7, 27.5, 25.9, 22.9, 22.6, 18.2, 14.1, -2.0, -4.4. 
(E)-tert-butyldimethyl((2-methyl-8-(trimethylsilyl)oct-6-en-3-yl)oxy)silane (2.43) R: i-pro: 80% 
yield. 1H NMR (400 MHz, CDCl3) δ 5.38 (dt, J = 15.2, 8.0 Hz, 1H), 5.23 (dt, J = 15.2, 6.8 Hz, 
1H), 3.45 (apq, J = 5.2 Hz, 1H), 1.91-2.05 (m, 2H), 1.67-1.75 (m, 1H), 1.42-1.46 (m, 1H), 1.39 
(d, J = 8.0 Hz, 2H), 0.89 (s, 9H), 0.86 (d, J = 6.8 Hz, 3H), 0.83 (d, J = 6.8 Hz, 3H), 0.04 (s, 3H), 
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0.03 (s, 3H), -0.01 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 128.9, 125.9, 76.3, 33.5, 32.5, 28.7, 
25.9, 22.6, 18.2, 18.1, 17.5, -2.0, -4.2, -4.5. 
 
(E)-10-(trimethylsilyl)dec-8-en-5-ol and (E)-2-methyl-8-(trimethylsilyl)oct-6-en-3-ol 
The above allylsilane was stirred with 9-CSA (0.1 equiv) in methanol 
(~0.4 M) at RT overnight. Flash column chromatography with 20% ethyl 
acetate in hexanes afforded the corresponding alcohol. 
(E)-10-(trimethylsilyl)dec-8-en-5-ol R: n-Bu: 82% yield. 1H NMR (400 MHz, CDCl3) δ 5.40 (dt, 
J = 15.0, 7.5 Hz, 1H), 5.24 (dt, J = 15.0, 7.0 Hz, 1H), 3.58 (br, 1H), 1.99-2.14 (m, 2H), 1.65 (t, J 
= 12.0, 1H), 1.26-1.48 (m, 6H), 0.88 (t, J = 6.8 Hz, 3H), -0.04 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 128.3, 126.6, 71.4, 37.5, 37.1, 29.1, 27.8, 22.7, 22.6, 14.0, -2.1. 
(E)-2-methyl-8-(trimethylsilyl)oct-6-en-3-ol R: i-pro: 95% yield. 1H NMR (500 MHz, CDCl3) δ 
5.42 (dtt, J = 15.5, 7.5, 1.3 Hz, 1H), 5.26 (dt, J = 15.0, 7.0 Hz, 1H), 3.36-3.39 (m, 1H), 2.11-
2.15 (m, 1H), 2.01-2.08 (m, 1H), 1.61-1.67 (m, 1H), 1.47-1.53 (m, 1H), 1.38 (d, J = 8.5 Hz, 2H), 
0.90 (d, J = 7.0 Hz, 3H), 0.89 (d, J = 7.0 Hz, 3H), -0.03 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 
128.4, 126.8, 76.2, 34.2, 33.4, 29.4, 22.6, 18.8, 17.1, -2.0. 
 
(E)-S-(10-(trimethylsilyl)dec-8-en-5-yl) ethanethioate (2.44) and (E)-S-(2-methyl-8-
(trimethylsilyl)oct-6-en-3-yl) ethanethioate (2.45) 
The above alcohol was reacted with mesyl chloride (2 equiv) and Et3N (3 
equiv) in dichloromethane (~0.5 M solution) from -40 °C to RT over two 
hours. The reaction mixture was acidified with 1N hydrochloric acid, washed twice with water, 
dried with MgSO4 and concentrated under vacuum. The resulting crude product (100% yield) 
R OH
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was reacted with HSAc (2.7 equiv) and Cs2CO3 (2.4 equiv) according to the general protocol E2. 
Flash column chromatography with 5% ethyl acetate in hexanes afforded the desired thioacetate. 
(E)-S-(10-(trimethylsilyl)dec-8-en-5-yl) ethanethioate (2.44) R: n-Bu: 66% yield. 1H NMR (500 
MHz, CDCl3) δ 5.37 (dt, J = 15.0, 8.0 Hz, 1H), 5.19 (dt, J = 15.0, 7.0 Hz, 1H), 3.47-3.53 (m, 
1H), 2.29 (s, 3H), 1.95-2.09 (m, 2H), 1.47-1.64 (m, 4H), 1.38 (d, J = 8.0 Hz, 2H), 1.23-1.33 (m, 
4H), 0.86 (t, J = 7.0 Hz, 3H), -0.04 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 195.8, 127.6, 126.9, 
44.1, 35.1, 34.5, 30.8, 30.1, 28.8, 22.6, 22.5, 13.9, -2.1. 
(E)-S-(2-methyl-8-(trimethylsilyl)oct-6-en-3-yl) ethanethioate (2.45) R: i-pro: 47% yield. 1H 
NMR (400 MHz, CDCl3) δ 5.39 (dt, J = 14.8, 8.0 Hz, 1H), 5.21 (dt, J = 14.8, 6.8 Hz, 1H), 3.51 
(dt, J = 9.6, 4.4 Hz, 1H), 2.33 (s, 3H), 2.04-2.14 (m, 1H), 1.95-2.03 (m, 1H), 1.87-1.95 (m, 1H), 
1.47-1.65 (m, 2H), 1.39 (d, J = 8.0 Hz, 2H), 0.91 (d, J = 6.8 Hz, 3H), 0.89 (d, J = 6.8 Hz, 3H), -
0.02 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 195.4, 127.6, 126.9, 50.4, 32.8, 31.9, 30.7, 30.3, 
22.6, 19.9, 18.5, -2.1. 
 
(E)-10-(trimethylsilyl)dec-8-ene-5-thiol and (E)-2-methyl-8-(trimethylsilyl)oct-6-ene-3-thiol 
The above thioacetate was reacted with lithium aluminum hydride (2 
equiv) in diethyl ether (~0.15 M solution) from 0 °C to RT for 30 
minutes. The resulting slurry was treated successively with water (1 mL per mol of LAH), 10% 
NaOH solution (1 mL per mol of LAH) and saturated Na2SO4 solution (3 mL per mol of LAH), 
and extracted with ether to concentrated under vacuum. Flash column chromatography with 5% 
diethyl ether in hexanes afforded the desired thiol. 
(E)-10-(trimethylsilyl)dec-8-ene-5-thiol R: n-Bu: 92% yield. 1H NMR (500 MHz, CDCl3) δ 5.42 
(dt, J = 15.0, 7.5 Hz, 1H), 5.19 (dt, J = 15.0, 6.5 Hz, 1H), 2.74-2.81 (m, 1H), 2.13-2.20 (m, 1H), 
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2.05-2.13(m, 1H), 1.61-1.72 (m, 2H), 1.42-1.52 (m, 3H), 1.40 (d, J = 8.0 Hz, 2H), 1.26-1.33 (m, 
2H), 0.90 (t, J = 7.0 Hz, 3H), -0.02 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 127.5, 127.0, 40.4, 
39.2, 38.6, 30.3, 29.2, 22.6, 22.5, 14.0, -2.0. 
(E)-2-methyl-8-(trimethylsilyl)oct-6-ene-3-thiol R: i-pro: 89% yield. 1H NMR (500 MHz, 
CDCl3) δ 5.43 (dt, J = 15.0, 8.0 Hz, 1H), 5.19 (dt, J = 15.0, 7.0 Hz, 1H), 2.71-2.77(m, 1H), 2.18-
2.25 (m, 1H), 2.04-2.12 (m, 1H), 1.81-1.87 (m, 1H), 1.59-1.67 (m, 1H), 1.45-1.54 (m, 1H), 1.40 
(d, J = 8.0 Hz, 2H), 0.00 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 127.6, 127.1, 47.1, 36.5, 33.4, 
30.7, 22.6, 20.4, 17.2, -2.0. 
 
((E)-6-((E)-hex-1-en-1-ylthio)dec-2-en-1-yl)trimethylsilane (2.46) and ((E)-6-((E)-hex-1-en-
1-ylthio)-7-methyloct-2-en-1-yl)trimethylsilane (2.47) 
General protocol F2 was followed, starting from the above thiols, (E)-1-
iodohex-1-ene (1.5 equiv), Pd(dppf)Cl2·CH2Cl2 complex (0.1 equiv) and 
distilled Et3N (2.5 equiv). Flash column chromatography with 1% diethyl ether in hexanes 
afforded the desired vinyl sulfides. 
((E)-6-((E)-hex-1-en-1-ylthio)dec-2-en-1-yl)trimethylsilane (2.46) (R = n-Bu): 63% yield. 1H 
NMR (500 MHz, CDCl3) δ 5.89 (d, J = 15.0 Hz, 1H), 5.74 (dt, J = 15.0, 7.0 Hz, 1H), 5.41 (dt, J 
= 15.0, 7.5 Hz, 1H), 5.21 (dt, J = 15.0, 7.0 Hz, 1H), 2.66-2.71 (m, 1H), 2.12 (dt, J = 7.5, 7.5 Hz, 
2H), 2.07 (dt, J = 7.0, 7.0 Hz, 2H), 1.52-1.60 (m, 4H), 1.41 (d, J = 8.5 Hz, 2H), 1.28-1.37 (m, 
6H), 0.90 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 7.0 Hz, 3H), -0.02 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 133.8, 127.9, 126.8, 121.2, 46.6, 35.1, 34.5, 32.9, 31.4, 30.0, 29.0, 22.6, 22.1, 14.0, 
13.9, -2.0; IR (film) 3583, 3063, 1455, 1247, 1155, 964, 848 cm-1; HRMS (ESI) m/z calcd. for 
C19H39SSi [M+H]+ 327.2542, found 327.2522. 
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((E)-6-((E)-hex-1-en-1-ylthio)-7-methyloct-2-en-1-yl)trimethylsilane (2.47) (R = i-pro): 77% 
yield. 1H NMR (300 MHz, CDCl3) δ 5.88 (d, J = 15.0 Hz, 1H), 5.70 (dt, J = 15.0, 7.0 Hz, 1H), 
5.41 (dt, J = 15.5, 8.0 Hz, 1H), 5.20 (dt, J = 15.0, 7.0 Hz, 1H), 2.61 (dt, J = 9.5, 4.5 Hz, 1H), 
2.16-2.23 (m, 1H), 2.08-2.13 (m, 1H), 2.05 (dt, J = 7.0, 7.0 Hz, 2H), 1.89-1.96(m, 1H), 1.56-
1.63 (m, 1H), 1.46-1.53 (m, 1H), 1.41 (d, J = 8.0 Hz, 2H), 1.27- 1.36 (m, 4H), 0.97 (d, J = 7.0 
Hz, 3H), 0.93 (d, J = 7.0 Hz, 3H), 0.88 (t, J = 7.0 Hz, 3H), -0.02 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 132.3, 128.0, 127.0, 123.2, 54.3, 32.9, 32.3, 32.1, 31.4, 30.6, 22.7, 22.1, 19.7, 18.9, 
13.0, -2.0; IR (film) 3336, 2872, 1715, 1464, 1385, 1368, 1247, 1156, 1013,841 cm-1; HRMS 
(EI) m/z calcd. for C18H36SSi [M] 312.2307 , found 312.2349. 
 
tert-Butyldimethyl((10-(trimethylsilyl)dec-8-yn-5-yl)oxy)silane and tert-butyldimethyl((2-
methyl-8-(trimethylsilyl)oct-6-yn-3-yl)oxy)silane 
To a solution of the corresponding alkyne in THF (~0.5 M solution) 
cooled at -40 °C was added drop wise 1.6 M n-BuLi solution (1.3 
equiv). The reaction mixture was allowed to 0 °C, stirred for 15 minutes, and trimethylsilyl 
methyl iodide (1.5 equiv) was added dropwise. The reaction was heated at 50 °C for 6 hours to 
complete the conversion. After cooling to 0 °C, the reaction was quenched saturated NH4Cl 
solution, extracted twice with diethyl ether and concentrated under vacuum. Flash column 
chromatography with 10% dichloromethane in hexanes afforded the corresponding propargyl 
silane. 
tert-Butyldimethyl((10-(trimethylsilyl)dec-8-yn-5-yl)oxy)silane R: n-Bu intermediate: 68% 
yield. 1H NMR (300 MHz, CDCl3) δ 3.77-3.72 (m, 1H), 2.24-2.16 (m, 2H), 1.57 (dt, J = 6.9, 6.9 
Hz, 2H), 1.42-1.41 (m, 4H), 0.91-0.87 (m, 12H), 0.03 (s, 6H), 0.00 (s, 9H). 
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tert-Butyldimethyl((2-methyl-8-(trimethylsilyl)oct-6-yn-3-yl)oxy)silane R: i-pro intermediate: 
68% yield. 1H NMR (300 MHz, CDCl3) δ 3.58 (dd, J = 11.1, 5.7 Hz, 1H), 2.13-2.21 (m, 2H), 
1.67-1.78 (m, 1H), 1.50-1.57 (m, 2H), 1.42 (t, J = 2.6 Hz, 2H), 0.89 (s, 9H), 0.86 (d, J = 7.2 Hz, 
3H), 0.83 (d, J = 7.2 Hz, 3H), 0.09 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H). 
 
(Z)-tert-butyldimethyl((10-(trimethylsilyl)dec-8-en-5-yl)oxy)silane (2.50) and (Z)-tert-
butyldimethyl((2-methyl-8-(trimethylsilyl)oct-6-en-3-yl)oxy)silane (2.51) 
To a 25 mL round bottom flask was charged nickel acetate tetra hydrate 
(0.4 equiv) and 95% ethanol, and hydrogen atmosphere was applied. Then a 
freshly prepared 1M NaBH4 solution (0.5 equiv) in 95% ethanol (with 0.1M 
NaOH) was added to the flask with vigorous stirring within 10 seconds. After three minutes 
ethylenediamine (0.8 equiv) was added, followed by another three minutes of stirring. The above 
propargyl silane was added, and the reaction mixture was stirred for 1 hours at RT. After 
completion of the reaction, the mixture was partitioned between diethyl ether and water. The 
organic phase was dried with sodium sulfate, filtered and concentrated under vacuum. Flash 
column chromatography with 10% dichloromethane in hexanes afforded the desired cis-ally 
silane. 
(Z)-tert-butyldimethyl((10-(trimethylsilyl)dec-8-en-5-yl)oxy)silane (2.50) R: n-Bu: 92% yield. 
1H NMR (500 MHz, CDCl3) δ 5.38 (dt, J = 10.5, 8.7 Hz, 1H), 5.26 (dt, J =10.5, 7.1 Hz, 1H), 
3.68-3.62 (m, 1H), 2.10-2.04 (m, 1H), 1.98-1.90 (m, 1H), 1.48-1.42 (m, 6H), 1.32-1.28 (m, 2H), 
0.90-0.87 (m, 12H), 0.05 (s, 6H), 0.00 (s, 9H). 
(Z)-tert-butyldimethyl((2-methyl-8-(trimethylsilyl)oct-6-en-3-yl)oxy)silane (2.51) R: i-pro: 91% 
yield. 1H NMR (500 MHz, CDCl3) δ 5.38 (dtt, J = 10.5, 8.5, 1.5 Hz, 1H), 5.26 (dtt, J = 10.5, 7.0, 
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1.5 Hz, 1H), 3.45 (apq, J = 5.5 Hz, 1H), 2.08 (dddd, J = 15.0, 7.5, 7.5, 7.5 Hz, 1H), 1.89 (dddd, 
J = 15.0, 7.5, 7.5, 7.5 Hz, 1H), 1.68-1.77 (m, 1H), 1.46 (d, J = 8.0 Hz, 2H), 1.39-1.43 (m, 2H), 
0.90 (s, 9H), 0.86 (d, J = 7.0 Hz, 3H), 0.84 (d, J = 7.0 Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H), 0.00 
(s, 9H). 
 
(Z)-10-(trimethylsilyl)dec-8-en-5-ol and (Z)-2-methyl-8-(trimethylsilyl)oct-6-en-3-ol 
The above allylsilane was stirred with 9-CSA (0.1 equiv) in methanol (~0.4 
M) at RT overnight. Flash column chromatography with 20% ethyl acetate 
in hexanes afforded the corresponding alcohol. 
(Z)-10-(trimethylsilyl)dec-8-en-5-ol R: n-Bu intermediate: 98% yield. 1H NMR (300 MHz, 
CDCl3) δ 5.44 (dt, J = 10.7, 8.4 Hz, 1H), 5.27 (dt, J = 10.7, 7.0 Hz, 1H), 3.58-3.62 (m, 1H), 
2.02-2.18 (m, 2H), 1.55-1.28(m, 10H), 0.88 (t, J = 7.2 Hz, 3H), 0.02 (s, 9H). 
(Z)-2-methyl-8-(trimethylsilyl)oct-6-en-3-ol R: i-pro intermediate: 94% yield. 1H NMR (500 
MHz, CDCl3) δ 5.42 (dtt, J = 10.5, 8.5, 1.5 Hz, 1H), 5.28 (dtt, J = 10.5, 7.0, 1.3 Hz, 1H), 3.36-
3.40 (m, 1H), 2.13-2.20 (m, 1H), 2.06 (dddd, J = 14.5, 7.0, 7.0, 7.0 Hz, 1H), 1.68-1.78 (m, 1H), 
1.39-1.55 (m, 5H), 0.91 (d, J = 7.0 Hz, 3H), 0.90 (d, J = 7.0 Hz, 3H), 0.00 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 127.5, 125.4, 77.7, 33.0, 32.8, 25.6, 23.3, 18.4, 18.2, 17.9, 17.7, -1.8, -4.3, -4.4. 
 
(Z)-S-(10-(trimethylsilyl)dec-8-en-5-yl) ethanethioate (2.52) and (Z)-S-(2-methyl-8-
(trimethylsilyl)oct-6-en-3-yl) ethanethioate (2.53) 
The above alcohol was reacted with mesyl chloride (2 equiv) and Et3N (3 
equiv) in dichloromethane (~0.5 M solution) from -40 °C to RT over two 
hours. The reaction mixture was acidified with 1N hydrochloric acid, 
SiMe3
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washed twice with water, dried with MgSO4 and concentrated under vacuum. The resulting 
crude product (100% yield) was reacted with HSAc (2.7 equiv) and Cs2CO3 (2.4 equiv) 
according to the general protocol E2. Flash column chromatography with 5% ethyl acetate in 
hexanes afforded the desired thioacetate. 
(Z)-S-(10-(trimethylsilyl)dec-8-en-5-yl) ethanethioate (2.52) R: n-Bu intermediate: 76% yield. 1H 
NMR (300 MHz, CDCl3) δ 5.41 (dt, J = 10.7, 8.4 Hz, 1H), 5.22 (dt, J = 10.7, 7.0 Hz, 1H), 3.55-
3.49 (m, 1H), 2.31 (s, 3H), 2.02-2.18 (m, 2H), 1.55-1.28(m, 10H), 0.89 (t, J = 6.7 Hz, 3H), 0.00 
(s, 9H). 
(Z)-S-(2-methyl-8-(trimethylsilyl)oct-6-en-3-yl) ethanethioate (2.53) R: i-pro intermediate: 47% 
yield. 1H NMR (500 MHz, CDCl3) δ 5.40 (dtt, J = 10.5, 9.0, 1.5 Hz, 1H), 5.23 (dtt, J = 10.5, 7.0, 
1.3 Hz, 1H), 3.36-3.40 (dt, J = 9.5, 4.5 Hz, 1H), 2.33(s, 3H), 1.98-2.09 (m, 2H), 1.89-1.97 (m, 
1H), 1.58-1.65 (m, 1H), 1.45-1.55 (m, 1H), 1.45 (d, J = 7.5 Hz, 2H), 0.92 (d, J = 7.0 Hz, 3H), 
0.90 (d, J = 7.0 Hz, 3H), 0.00 (s, 9H);; 13C NMR (75 MHz, CDCl3) δ 196.0, 126.3, 126.2, 50.9, 
32.4, 32.0, 30.8, 24.8, 19.9, 18.9, 18.5, -1.8. 
 
(Z)-10-(trimethylsilyl)dec-8-ene-5-thiol and (Z)-2-methyl-8-(trimethylsilyl)oct-6-ene-3-thiol 
The above thioacetate was reacted with lithium aluminum hydride (2 equiv) 
in diethyl ether (~0.15 M solution) from 0 °C to RT for 30 minutes. The 
resulting slurry was treated successively with water (1 mL per mol of 
LAH), 10% NaOH solution (1 mL per mol of LAH) and saturated Na2SO4 solution (3 mL per 
mol of LAH), and extracted with ether to concentrated under vacuum. Flash column 
chromatography with 5% diethyl ether in hexanes afforded the desired thiol. 
SiMe3
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(Z)-10-(trimethylsilyl)dec-8-ene-5-thiol R: n-Bu thiol: 79% yield. 1H NMR (300 MHz, CDCl3) δ 
5.41 (dt, J = 11.0, 7.0 Hz, 1H), 5.22 (dt, J = 11.0, 6.8 Hz, 1H), 2.85-2.76 (m, 1H), 2.20-2.05 (m, 
2H), 1.75-1.60 (m, 2H), 1.55-1.25 (m, 6H), 0.91 (t, J = 7.6 Hz, 3H), 0.01 (s, 9H); IR (film) 3005, 
2858, 1721, 1463, 1379, 1247, 1137, 1017, 855 cm-1. 
(Z)-2-methyl-8-(trimethylsilyl)oct-6-ene-3-thiol R: i-pro thiol: 100% yield. 1H NMR (400 MHz, 
CDCl3) δ 5.42 (apq, J = 9.2 Hz, 1H), 5.22 (dt, J = 10.8, 7.2 Hz, 1H), 2.73 (ddd, J = 13.2, 8.0, 
4.0), 2.16-2.26(m, 1H), 2.09 (dddd, J = 13.6, 6.8, 6.8, 6.8 Hz, 1H), 1.79-1.91 (m, 1H), 1.61-
1.70(m, 1H), 1.43-1.55(m, 3H), 1.13 (d, J = 6.8 Hz, 1H), 0.97 (d, J = 6.8 Hz, 3H), 0.91 (d, J = 
6.8 Hz, 3H), 0.00 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 126.4, 126.3, 47.6, 36.4, 33.6, 25.1, 
20.3, 18.5, 17.3, -1.8. 
 
((Z)-6-((E)-hex-1-en-1-ylthio)dec-2-en-1-yl)trimethylsilane (2.54) and ((Z)-6-((E)-hex-1-en-
1-ylthio)-7-methyloct-2-en-1-yl)trimethylsilane (2.55) 
General protocol F2 was followed, starting from the corresponding thiol, 
(E)-1-iodohex-1-ene (1.5 equiv), Pd(dppf)Cl2·CH2Cl2 complex (0.1 equiv) 
and distilled Et3N (2.5 equiv). Flash column chromatography with 1% 
diethyl ether in hexanes afforded the desired vinyl sulfide. 
((Z)-6-((E)-hex-1-en-1-ylthio)dec-2-en-1-yl)trimethylsilane (2.54): R: n-butyl substrate: 52% 
yield. 1H NMR (300 MHz, CDCl3) δ δ 5.90 (dt, J = 15.0, 1.2 Hz, 1H), 5.75 (dt, J = 14.9, 6.9 Hz, 
1H), 5.46-5.37 (m, 1H), 5.27-5.20 (m, 1H), 2.73-2.65 (m, 1H), 2.17-2.02 (m, 4H), 1.61-1.54 (m, 
4H), 1.51-1.28 (m, 9H), 0.89 (t, J = 7.1 Hz, 3H), 0.88 (t, J = 7.1 Hz, 3H), 0.00 (s, 9H); 13C NMR 
(125 MHz, CDCl3) δ 133.7, 126.6, 126.0, 121.2, 46.9, 34.8, 34.5, 32.9, 31.4, 29.0, 24.3, 22.6, 
SiMe3
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22.0, 18.4, 14.0, 13.8, -1.8.; IR (film) 3399, 2927, 1721, 1463, 1247, 1137, 1017, 855 cm-1; 
HRMS (ESI) m/z calcd. for C19H39SSi [M+H]+ 327.2542, found 327.2515. 
((Z)-6-((E)-hex-1-en-1-ylthio)-7-methyloct-2-en-1-yl)trimethylsilane (2.55): R: i-propyl 
substrate: 46% yield. 1H NMR (400 MHz, CDCl3) δ 5.89 (d, J = 14.8 Hz, 1H), 5.71 (dt, J = 14.8, 
6.8 Hz, 1H), 5.42 (dt, J = 10.4, 8.8 Hz, 1H), 5.23 (dt, J = 10.8, 7.2 Hz, 1H), 2.60 (dt, J =9.2, 4.4 
Hz, 1H), 2.09-2.05 (m, 2H), 2.05(dt, J = 6.8, 6.8 Hz, 2H), 1.89-1.97 (m, 1H), 1.57-1.66 (m, 1H), 
1.42-1.56 (m, 3H), 1.26-1.37 (m, 4H), 0.98 (d, J = 6.8 Hz, 3H), 0.95(d, J = 6.8 Hz, 3H), 0.88(t, J 
= 7.2 Hz, 3H), 0.00 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 132.3, 126.7, 126.2, 123.3, 54.7, 
32.9, 32.2, 32.1, 31.4, 25.0, 22.1, 19.6, 19.0, 18.5, 13.9, -1.8; IR (film) 3582, 2927, 1713, 1464, 
1384, 1247, 1150, 1104, 856 cm-1; HRMS (ESI) m/z calcd. for C18H36SSiNa [M+Na]+ 335.2205, 
found 335.2194.  
 
The cyclization of n-butyl substituted trans-allylsilane 
General protocol G2 was followed, starting from the n-butyl substituted 
trans-allylsilane 2.46 (123 mg, 0.38 mmol) in MeNO2. The reaction 
afforded 64.2 mg (68% yield) of the cyclization products with a o-trans-m-cis : o-trans-m-trans : 
o-cis-m-cis : o-cis-m-trans 1: 0.18:0.09:0.05. 
(2R,3R,6S)-6-butyl-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran (2.56): n-butyl o-
trans-m-cis : 1H NMR (600 MHz, CDCl3) δ 5.1 (ddd, J = 17.5, 10.5, 8.0 Hz, 1H), 5.59 (dt, J = 
15.5, 7.0 Hz, 1H), 5.24 (ddt, J = 15.2, 8.9, 1.4 Hz, 1H), 4.98 (ddd, J = 17.0, 1.5, 1.0 Hz, 1H), 
4.96 (ddd, J = 10.5, 2.0, 0.6 Hz, 1H), 3.17 (dd, J = 9.6 Hz, 1H), 2.78 (dddd, J = 13.5, 7.2, 6.0, 
2.5, 1H), 2.10 (dtd, J = 11.0, 8.0, 3.0 Hz, 1H), 2.06-2.00 (m, 1H), 1.97 (dtt, J = 7.5, 7.5, 1.7 , 
2H), 1.89 (ddd, J = 13.7, 6.9, 3.2 Hz, 1H), 1.53-1.18 (m, 13H), 0.89 (t, J = 7.5 Hz, 3H, 0.88 (t, J 
n-Bu S n-Pr
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= 7.3 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 141.7, 133.6, 129.5, 114.5, 48.9, 48.0, 43.6, 35.7, 
34.5, 34.4, 33.0, 29.0, 22.7, 22.2, 14.0, 13.6; IR (film) 3077, 2859, 1638, 1461, 1263, 1153, 963, 
912 cm-1; HRMS (ESI) m/z calcd. for C16H29S [M+H]+ 253.1990, found 253.2009. 
(2R,3R,6R)-6-butyl-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran: n-butyl o-trans-m-
trans : 1H NMR (500 MHz, CDCl3) δ 5.81 (ddd, J = 17.8, 10.5, 7.7 Hz, 1H), 5.60 (dt, 15.0, 7.0 
Hz, 1H), 5.33 (ddt, J = 15.0, 8.5, 1.0 Hz, 1H), 5.03-4.98 (m, 2H), 3.23 (dd, J = 8.5, 8.5 Hz, 1H), 
2.73-2.64 (m, 1H), 2.22 (dddd, J = 9.7, 8.7, 8.7, 3.5 Hz, 1H), 2.03-1.95 (m, 2H), 1.94-1.80 (m, 
2H), 1.75-1.65 (m, 2H), 1.64-1.27 (m, 4H), 0.89 (dt, J = 14.8, 7.2 Hz, 6H); 13C NMR (150 MHz, 
CDCl3) δ 141.8, 133.0, 129.9, 114.3, 46.6, 44.2, 39.9, 34.4, 34.0, 30.6, 30.1, 26.6, 22.5, 22.3, 
14.1, 13.6; IR (film) 3076, 2954, 1638, 1460, 1186, 991, 963, 912 cm-1; HRMS (ESI) m/z calcd. 
for C16H29S [M+H]+ 253.1990, found 253.1991. 
(2S,3R,6R)-6-butyl-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran: n-butyl o-cis-m-cis : 
1H NMR (500 MHz, CDCl3) δ 6.34 (ddd, J = 17.3, 10.4, 8.3 Hz, 1H), 5.62 (dtd, J = 15.3, 6.8, 0.8 
Hz, 1H), 5.32 (ddt, J = 15.3, 8.0, 1.2 Hz, 1H), 5.18-5.02 (m, 2H), 3.61 (dd, J = 8.1, 2.8 Hz, 1H), 
2.82 (dddd, J = 13.5, 7.2, 6.0, 3.6 Hz, 1H), 2.45-2.55 (m, 1H), 1.96 (dtd, J = 7.2, 7.2, 1.2 Hz, 
2H), 1.91-1.84 (m, 1H), 1.73-1.62 (m, 3H), 1.57-1.45 (m, 6H), 1.39-1.26 (m, 2H), 0.88 (t, J = 7.2 
Hz, 3H), 0.87 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 137.7, 132.7, 129.4, 116.0, 
48.7, 44.2, 42.9, 37.4, 35.9, 34.4, 33.4, 28.9, 28.5, 22.7, 22.3, 14.0, 13.6; IR (film) 3023, 2854, 
1614, 1434, 1342,1149, 984 cm-1; HRMS (ESI) m/z calcd. for C16H29S [M+H]+ 253.1990, found 
253.1998. 
(2R,3S,6R)-6-butyl-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran: n-butyl o-cis-m-
trans: 1H NMR (500 MHz, CDCl3) δ 5.72 (ddd, J = 17.2, 10.4, 6.0 Hz, 1H), 5.66 (dd, J = 15.1, 
7.9 Hz, 1H), 5.58 (dt, J = 15.1, 6.6 Hz, 1H), 5.01-4.96 (m, 2H), 3.28 (dd, J = 8.2, 3.8 Hz, 1H), 
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2.87 (dddd, J = 10.0, 7.0, 7.0, 2.7 Hz, 1H), 2.60 (dddd, J = 11.2, 7.4, 3.7, 3.7 Hz, 1H), 2.11-1.97 
(m, 3H), 1.70-1.66 (m, 1H), 1.52-1.24 (m, 6H), 0.95-0.83 (m, 6H); 13C NMR (150 MHz, CDCl3) 
δ 142.0, 132.9, 126.6, 114.0, 46.1, 45.6, 37.7, 35.5, 34.5, 29.1 ,26.9, 22.6, 22.5, 14.1, 14.0, 13.7; 
IR (film) 2941, 2859, 1643, 1431, 1382, 1198, 913 cm-1; HRMS (ESI) m/z calcd. for C16H29S 
[M+H]+ 253.1990, found 253.1981. 
 
The cyclization of 6-iso-propyl substituted trans-allylsilane 
General protocol G2 was followed, starting from the iso-propyl 
substituted trans-allylsilane 2.47 (75.6 mg, 0.24 mmol), DDQ (57.2 mg, 
0.25 mmol), 2,6-dichloropyridine (74.0 mg, 0.50 mmol) and 4Å M.S. (230 mg) in MeNO2. The 
reaction afforded 45.7 mg (79% yield) of the cyclization products with a o-trans-m-cis : o-trans-
m-trans : o-cis-m-cis : o-cis-m-trans ratio of 1.00 : 0.14 : 0.09 : 0.04. 
(2R,3R,6R)-6-isopropyl-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran (2.57): 6-iso-
propyl o-trans-m-cis: 1H NMR (500 MHz, CDCl3) δ 5.63 (ddt, J = 17.5, 10.5, 8.0 Hz, 1H), 5.60 
(dt, J = 15.5, 7.0 Hz, 1H), 5.25 (dd, J = 15.3, 9.0 Hz, 1H), 4.99-4.95 (m, 2H), 3.16 (dd, J = 9.7, 
9.7 Hz, 1H), 2.70 (ddd, J = 11.7, 5.5, 2.3 Hz, 1H), 2.14-2.04 (m, 1H), 2.03-1.88 (m, 4H), 1.79-
1.68 (m, 1H), 1.52-1.44 (m, 1H), 1.43-1.31 (m, 2H), 1.25 (qd, J = 13.5, 2.9 Hz, 1H), 0.99 (dd, J 
= 6.8, 1.6 Hz, 6H), 0.87 (t, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 141.7, 133.6, 129.7, 
114.5, 50.7, 49.0, 48.0, 34.4, 33.3, 32.8, 31.0, 22.2, 19.9, 19.7, 13.6; IR (film) 3061, 2923, 2868, 
1532, 1422, 1261, 931 cm-1; HRMS (ESI) m/z calcd. for C15H27S[M+H]+ 239.1833, found 
239.1845. 
(2R,3R,6S)-6-isopropyl-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran : 6-iso-propyl o-
trans-m-trans: 1H NMR (500 MHz, CDCl3) δ 5.88 (ddd, J = 17.8, 10.5, 7.7 Hz, 1H), 5.61 (dtd, J 
i-Pr S n-Pr
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= 15.2, 6.8, 0.8 Hz, 1H), 5.39 (ddt, J = 15.2, 8.1, 1.4 Hz, 1H), 5.04-4.97 (m, 2H), 3.22 (t, J = 8.0 
Hz, 1H), 2.44-2.36 (m, 1H), 2.23-2.29 (m, 1H), 2.05-1.94 (m, 2H), 1.87-1.93(m, 1H), 1.88-1.80 
(m, 1H), 1.77-1.59 (m, 2H), 1.55-1.45 (m, 1H), 1.41-1.28 (m, 2H), 1.00 (d, J = 6.8 Hz, 3H), 0.96 
(d, J = 6.7 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 141.8, 133.6, 129.7, 
114.5, 48.2, 47.7, 34.3, 32.4, 29.6, 27.0, 22.2, 19.9, 19.7, 13.5; IR (film) 3051, 2943, 2859, 1621, 
1482, 1431, 1153, 1091, 923 cm-1; HRMS (ESI) m/z calcd. for C15H27S[M+H]+ 239.1833, found 
239.1839. 
(2R,3S,6R)-6-isopropyl-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran: 6-iso-propyl o-
cis-m-cis: 1H NMR (500 MHz, CDCl3) δ 6.35 (ddd, J = 17.3, 10.4, 8.4 Hz, 1H), 5.61 (dtd, J = 
15.2, 6.8, 0.8 Hz, 1H), 5.32 (ddt, J = 15.3, 8.3, 1.4 Hz, 1H), 5.18-5.05 (m, 2H), 3.61 (dd, J = 8.2, 
2.8 Hz, 1H), 2.73 (ddd, J = 11.3, 5.5, 2.6 Hz, 1H), 2.46-2.51 (m, 1H), 2.05-1.94 (m, 2H), 1.77-
1.59 (m, 2H), 1.55-1.45 (m, 3H), 1.41-1.28 (m, 2H), 1.09 (d, J = 6.6 Hz, 6H), 0.88 (t, J = 7.4 Hz, 
3H); 13C NMR (100 MHz, CDCl3) δ 141.7, 133.6, 129.4, 116.0, 49.7, 46.2, 44.0, 34.5, 33.1, 
31.0, 22.2, 20.0, 19.7, 13.6; IR (film) 3076, 2871, 1638, 1462, 1384, 1286, 992, 962, 914 cm-1; 
HRMS (ESI) m/z calcd. for C15H27S[M+H]+ 239.1833, found 239.1848. 
(2R,3S,6S)-6-isopropyl-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydro-2H-thiopyran: 6-iso-propyl o-
cis-m-trans: 1H NMR (400 MHz, CDCl3) δ 5.75-5.63 (m, 2H), 5.58 (dt, J = 15.1, 6.5 Hz, 1H), 
5.05-4.91 (m, 2H), 3.30 (dd, J = 8.1, 3.9 Hz, 1H), 2.78 (ddd, J = 11.2, 5.6, 2.4 Hz, 1H), 2.59 
(dddd, J = 11.6, 7.2, 3.7, 3.7 Hz, 1H), 2.17-1.95 (m, 3H), 1.72 (m, 2H), 1.61-1.49 (m, 2H), 1.45-
1.35 (m, 2H), 0.98 (dd, J = 6.8, 4.3 Hz, 6H), 0.90 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 142.1, 132.8, 126.5, 113.9, 77.3, 77.0, 76.6, 46.2, 45.5, 44.4, 34.5, 32.4, 31.0, 27.0, 
22.4, 20.0, 19.7, 13.6; IR (film) 2971, 2863, 1641, 1502, 1333, 1187, 961, 913cm-1; HRMS (ESI) 
m/z calcd. for C15H27S[M+H]+ 239.1833, found 239.1844. 
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The cyclization of n-butyl substituted cis-allylsilane 
General protocol G2 was followed, starting from the n-butyl substituted cis-allylsilane 2.54 (50.0 
mg, 0.15 mmol), DDQ (35.7 mg, 0.15 mmol), 2,6-dichloropyridine (44.4 mg, 0.30 mmol) and 
4Å M.S. (150 mg) in MeNO2. The reaction afforded 33.5 mg (87% yield) of the cyclization 
products with a o-trans-m-cis : o-trans-m-trans : o-cis-m-cis : o-cis-m-trans ratio of 1: 0.17 : 
0.17 : 0.80. 
 
The cyclization of 6-iso-propyl substituted cis-allylsilane 
General protocol G2 was followed, starting from the iso-propyl substituted cis-allylsilane 2.55 
(82.8 mg, 0.26 mmol), DDQ (62.0 mg, 0.27 mmol), 2,6-dichloropyridine (77.0 mg, 0.52 mmol) 
and 4Å M.S. (240 mg) in MeNO2. The reaction afforded 45.5 mg (72% yield) of the cyclization 
product with a o-trans-m-cis : o-trans-m-trans : o-cis-m-cis : o-cis-m-trans 1 : 0.14 : 0.12 : 1.0. 
 
 
Cyclization of trisubstituted allylsilane 
((E)-6-((E)-hex-1-en-1-ylthio)-2-methylhex-2-en-1-yl)trimethylsilane (2.63) 
General protocol H for the synthesis of vinyl iodide was followed, starting 
from the corresponding alkyne 2.62 (224 mg, 1.0 mmol), ZrCp2Cl2(323 
mg, 1.1 mmol) and 1M DIBAL-H (1.1 mL, 1.1 mmol). Flash column 
chromatography with 5% dichloromethane in hexanes afforded the corresponding vinyl iodide. 
This intermediate was reacted with (E)-1-iodohex-1-ene (315 mg, 1.5 mmol), 
Pd(dppf)Cl2·CH2Cl2 complex (40.8 mg, 0.05 mmol) and distilled Et3N (0.42 mL, 3.0 
S n-Pr
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mmol).according to general protocol I to afford 128 mg (45% in two steps) of the desired 
allylsilane substrate 2.63. 1H NMR (400 MHz, CDCl3) δ 5.90 (dt, J = 15.0, 1.3 Hz, 1H), 5.62 (dt, 
J = 15.0, 7.0 Hz, 1H), 4.91 (t, J = 7.2 Hz, 1H), 2.62 (t, J = 7.5 Hz, 2H), 2.07 (m, 4H), 1.76-1.55 
(m, 9H), 1.47 (s, 2H), 0.89 (t, J = 7.1 Hz, 3H), 0.00 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 
145.5, 131.0, 122.5, 110.0, 39.0, 37.3, 32.9, 31.5, 29.0, 26.6, 22.3, 22.1, 13.9, -1.1; IR (film) 
3068, 2927, 1715, 1650, 1454, 1376, 1247, 1025, 842 cm-1; HRMS (ESI) m/z calcd. for 
C16H33SSi [M+H]+ 285.2072, found 285.2070. 
 
(2S,3S)-2-((E)-pent-1-en-1-yl)-3-(prop-1-en-2-yl)tetrahydro-2H-thiopyran (2.64) (trans-
product) 
 General protocol G2 was followed, starting from the above trans-allylsilane 
2.63 (72.1 mg, 0.25 mmol), DDQ (59.0 mg, 0.26 mmol), 2,6-dichloropyridine 
(74.0 mg, 0.50 mmol) and 4Å M.S. (220 mg) in MeNO2. The reaction afforded 38.3 mg (72%) of 
the desired cyclization products 2.64 with a trans: cis ratio of 1:0.53. 1H NMR (400 MHz, 
CDCl3) δ 5.62-5.53 (dt, J = 15.2, 7.2 Hz, 1H), 5.22 (ddt, J = 15.2, 8.9, 1.4 Hz, 1H), 4.69 (m, 
2H), 3.30 (dd, J = 9.8, 9.8 Hz, 1H), 2.78 (ddd, J = 13.2, 13.2, 2.8 Hz, 1H), 2.53 (dtd, J = 13.4, 
3.4, 1.5 Hz, 1H), 2.22 (ddd, J = 12.1, 10.5, 2.9 Hz, 1H), 2.09-2.00 (m, 2H), 1.99-1.89 (m, 2H), 
1.83-1.64 (m, 3H), 1.61 (s, 3H), 1.38 (dt, J = 14.6, 4.1 Hz, 2H), 0.87 (t, J =7.2 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 148.2, 133.1, 129.2, 111.4, 53.4, 52.6, 47.0, 34.3, 32.3, 29.9, 27.7, 
22.3, 19.4, 13.4; IR (film) 3072, 2958, 1643, 1438, 1451, 1374, 1287, 962, 889 cm-1; HRMS 
(ESI) m/z calcd. for C13H23S [M+H]+ 211.1520, found 211.1523. 
(2R,3S)-2-((E)-pent-1-en-1-yl)-3-(prop-1-en-2-yl)tetrahydro-2H-thiopyran (cis-product of 2.64): 
1H NMR (400 MHz, CDCl3) δ 5.67-5.1 (m, 2H), 4.83-4.74 (m, 1H), 4.65-4.59 (m, 1H), 3.45-
S n-Pr
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3.38 (m, 1H), 2.87-2.79 (m, 1H), 2.59-2.50 (m, 1H), 2.38 (dt, J = 13.6, 3.6 Hz, 1H), 2.16-2.09 
(m, 1H), 2.04-1.98 (m, 2H), 1.85-1.75 (m, 1H), 1.72 (dd, J = 3.3, 2.7 Hz, 3H), 1.69-1.61 (m, 1H), 
1.49-1.42 (m, 2H), 1.04 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 148.1, 133.4, 129.0, 
111.3, 52.4, 52.1, 47.0, 34.4, 32.0, 29.5, 28.1, 22.6, 19.6, 13.9, 13.2; IR (film) 3008, 2858, 1726, 
1642, 1451, 1376, 1133, 891 cm-1; HRMS (ESI) m/z calcd. for C13H23S [M+H]+ 211.1520, found 
211.1527. 
 
Synthesis of tetrahydrothiophenes 
 (Z)-5-(trimethylsilyl)pent-3-en-1-ol (2.66) 
To a solution of the alkyne 2.65 in THF (~0.5 M solution) cooled at -40 °C was added 
drop wise 1.6 M BuLi solution (10.0 mL, 16.0 mmol). The reaction mixture was 
allowed to 0 °C, stirred for 15 minutes, and trimethylsilyl methyl iodide (3.93 g, 18.3 
mmol) was added dropwise. The reaction was heated at 50 °C for 6 hours to complete the 
conversion. After cooling to 0 °C, the reaction was quenched saturated NH4Cl solution, extracted 
twice with diethyl ether and concentrated under vacuum. Flash column chromatography with 
10% dichloromethane in hexanes afforded 2.0 g (62%) of the corresponding propargyl silane. 1H 
NMR (400 MHz, CDCl3) δ 3.68 (t, J = 7.4 Hz, 2H), 2.36 (tt, J = 7.3, 2.7 Hz, 2H), 0.89 (s, 9H), 
0.08 (s, 9H), 0.06 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 78.7, 75.4, 62.7, 25.9, 23.3, 18.3, 6.9, -
2.1, -5.2. 
To a 25 mL round bottom flask was charged nickel acetate tetrahydrate (386 mg, 1.55 mmol) and 
95% ethanol (3 mL), and hydrogen atmosphere was applied. Then a freshly prepared 1M NaBH4 
solution (1.94 mL) in 95% ethanol (with 0.1M NaOH) was added to the flask with vigorous 
stirring within 10 seconds. After three minutes ethylenediamine (0.21 mL, 3.10 mmol) was 
OH
SiMe3
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added, followed by another three minutes of stirring. The above propargyl silane (1.05 g, 3.88 
mmol) was added, and the reaction mixture was stirred for 1 hours at RT. After completion of 
the reaction, the mixture was partitioned between diethyl ether and water. The organic phase was 
dried with sodium sulfate, filtered and concentrated under vacuum, and then the crude product 
was treated with 2-CSA (85.8 mg, 0.4 mmol) in methanol (9 mL) at RT overnight. Flash column 
chromatography with 20% ethyl acetate in hexanes afforded 519 mg (85% for two steps) of the 
desired alcohol 2.66. 1H NMR (400 MHz, CDCl3) δ 5.58 (dtt, J = 10.3, 8.7, 1.5 Hz, 1H), 5.26 
(dtt, J = 10.3, 7.3, 1.5 Hz, 1H), 3.63 (t, J = 6.4 Hz, 2H), 2.27 (dt, J = 6.7, 6.7 Hz, 2H), 1.57-1.40 
(m, 3H), 0.00 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 129.0, 122.5, 62.4, 30.5, 18.6, -1.8. 
 
((Z)-5-((E)-hex-1-en-1-ylthio)pent-2-en-1-yl)trimethylsilane (2.67) 
The above alcohol 2.66 (498 mg, 3.1 mmol) and Et3N (1.31 mL, 9.3 mmol) 
were mixed in dichloromethane (9 mL) and cooled to -50 °C. Mesyl 
chloride (0.72 g, 6.3 mmol) was added drop wise, white precipitates were 
formed in a few minutes, and the resulting suspension was slowly allowed to 0 °C over 1 hour. 
The reaction mixture was acidified with 1N hydrochloric acid, washed twice with water, dried 
with MgSO4 and concentrated under vacuum. The resulting crude product (803 mg, 100% yield) 
was reacted with HSAc (0.27 mL, 3.78 mmol) and Cs2CO3 (1.23 g, 3.78 mmol) according to the 
general protocol E2. Flash column chromatography with 3% diethyl ether in hexanes afforded 
the desired thioacetate (607 mg, 89% yield). 1H NMR (300 MHz, CDCl3) δ 5.48 (dtt, J = 10.1, 
8.7, 1.4 Hz, 1H), 5.22 (dtt, J = 10.1, 7.1, 1.4 Hz, 1H), 2.87 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 2.26 
(dt, J = 7.1, 7.1 Hz, 2H), 1.47 (d, J = 8.7 Hz, 2H), 0.00 (d, J = 3.0 Hz, 9H); 13C NMR (100 MHz, 
CDCl3) δ 196.0, 127.9, 124.4, 30.6, 29.1, 27.0, 18.6, -1.8. 
S
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The above thioacetate (585 mg, 2.71 mmol) was reacted with lithium aluminum hydride (205 
mg, 5.42 mmol) in diethyl ether (10 mL) from 0 °C to RT for 30 minutes. The resulting slurry 
was treated successively with water (5.0 mL), 10% NaOH solution (5.0 mL) and saturated 
Na2SO4 solution (15.0 mL), and extracted with ether to concentrated under vacuum. Flash 
column chromatography with 5% diethyl ether in pentane afforded 407 mg (86%) of the desired 
thiol. 1H NMR (300 MHz, CDCl3) δ 5.54 (dtt, J = 10.6, 8.7, 1.6 1H), 5.25 (dtt, J = 10.6, 7.1, 1.4 
1H), 2.54 (dt, J = 7.5, 7.5 Hz, 2H), 2.31 (dt, J = 7.0, 7.0 Hz, 2H), 1.49 (d, J = 8.6 Hz, 2H), 1.43 
(t, J = 7.7 Hz, 1H), 0.02 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 129.0, 122.5, 62.4, 30.5, 18.6, -
1.8. 
General protocol F2 was followed, starting from the above thiol (391 mg, 2.25 mmol), (E)-1-
iodohex-1-ene (790 mg, 3.75 mmol), Pd(dppf)Cl2·CH2Cl2 complex (102mg, 0.125 mmol) and 
distilled Et3N (1.05 mL, 7.5 mmol). Flash column chromatography with 10% DCM in hexanes 
afforded 308 mg (53%) of the desired vinyl sulfide 2.67. 1H NMR (400 MHz, CDCl3) δ 5.91 (dt, 
J = 15.0, 1.3 Hz, 1H), 5.65 (15.0, 11.0 Hz, 1H), 5.54-5.41 (m, 1H), 5.37-5.19 (m, 1H), 2.64 (t, J 
= 7.4 Hz, 2H), 2.30 (dt, J = 8.1, 8.1 Hz, 2H), 2.08 (dtd, J = 7.1, 7.1, 1.3 Hz, 2H), 1.51-1.46 (m, 
3H), 1.41-1.17 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H), 0.01 (d, J = 3.0 Hz, 9H); 13C NMR (100 MHz, 
CDCl3) δ 131.2, 127.3, 124.8, 122.4, 38.6, 32.8, 31.4, 27.2, 22.0, 18.6, 13.8, -1.8; IR (film) 3009, 
2955, 1643, 1419, 1248, 1150, 851 cm-1; HRMS (ESI) m/z calcd. For C14H29SiS [M+H]+ 
257.1759, found 257.1743. 
 
(2R,3S)-2-((E)-pent-1-en-1-yl)-3-vinyltetrahydrothiophene (2.68) 
General protocol G2 was followed, starting from the above ally silane 34 (100 
mg, 0.39 mmol), DDQ (93.3 mg, 0.41 mmol), 2,6-dichloropyridine (121.5 
S
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mg, 0.82 mmol) and 4Å M.S. (300 mg) in MeNO2 (4 mL). The reaction afforded 54.8 mg (77% 
yield) of the desired tetrahydrothiophene 2.68 with a cis: trans ratio of 20:1. 1H NMR (400 MHz, 
CDCl3) δ 5.81 (ddd, J = 17.3, 10.3, 8.1 Hz, 1H), 5.47 (dt, J = 14.9, 6.4 Hz, 1H), 5.38 (dd, J = 
15.0, 9.2 Hz, 1H), 5.14-4.96 (m, 2H), 3.90 (dd, J = 9.1, 6.3 Hz, 1H), 2.99 (ddd, J = 10.3, 7.2, 4.9 
Hz, 1H), 2.93-2.85 (m, 1H), 2.85-2.74 (m, 1H), 2.11 (ddt, J = 11.9, 6.8, 5.0 Hz, 1H), 2.01-1.89 
(m, 3H), 1.45-1.32 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 137.2, 
131.8, 129.3, 115.8, 53.2, 52.0, 34.9, 34.2, 30.6, 22.3, 13.5; IR (film) 2963, 2931, 1754, 1718, 
1648, 1554, 1370, 1196, 1019, 798 cm-1; HRMS (ESI) m/z calcd. For C11H19S [M+H]+ 183.1207, 
found 183.1248. 
 
(2R,3R)-3-ethyl-2-pentyltetrahydrothiophene (2.69) 
A mixture of 2.68 (30 mg, 0.16 mmol) and 10% Pd/C (30 mg) in methanol (1 
mL) was stirred under a hydrogen atmosphere overnight. The mixture was 
purified by flash column chromatography (10% DCM in pentane) to give 22.1 mg (74%) of the 
product 2.69. 1H NMR (400 MHz, CDCl3) δ 3.26 (dt, J = 9.6, 4.7 Hz, 1H), 2.85-2.76 (m, 2H), 
2.09-1.92 (m, 2H), 1.84-1.69 (m, 1H), 1.69-1.57 (m, 2H), 1.52-1.43 (m, 2H), 1.38-1.21 (m, 6H), 
0.94 (t, J = 7.4 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 51.5, 49.0, 33.2, 
31.8, 29.6, 28.3, 22.6, 21.3, 14.1, 12.9; IR (film) 2957, 2928, 2859, 1460, 1378, 1261 cm-1; 
HRMS (EI) m/z calcd. for C11H22S [M] 186.1442, found 186.1418. 
S
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APPENDIX C 
ASYMMETRIC BIMOLECULAR COUPLING REACTIONS THROUGH 
OXIDATIVELY GENERATED AROMATIC CATIONS: SCOPE AND LIMIT 
Experimental 
General Experimental  
Proton (1H NMR) and carbon (13C NMR) nuclear magnetic resonance spectra were recorded at 
300/400 MHz and 75/100MHz, respectively. The chemical shifts are given in parts per million 
(ppm) on the delta (δ) scale. Solvent peaks were used as a reference value, for 1H NMR: CDCl3 
= 7.26, CD2Cl2 = 5.32, for 13C NMR: CDCl3 = 77.0, CD2Cl2 = 54.0. Data are reported as 
follows: (s = singlet; d = doublet; t = triplet; q = quartet; dd = doublet of doublets; dt = doublet of 
triplets; br = broad). Samples for IR were prepared as a thin film on a NaCl plate by dissolving 
the compound in CH2Cl2 and then evaporating the CH2Cl2. Analytical TLC was performed on 
pre-coated (25 mm) silica gel 60F-254 plates. Flash column chromatography was done using 32-
63 60 Å silica gel. Chiral HPLC analysis was performed on a Shimadzu LC-20AD instrument 
with a Lux Cellulose 3 column. 
Methylene chloride was distilled under N2 from CaH2. Toluene was dried with 4Å molecular 
sieves. Anhydrous α,α,α-trifluorotoluene was purchased from Sigma-Aldrich. 2H-chromene and 
related derivatives were prepared following the Stratakis protocol.67 Chiral phosphate derivatives 
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were prepared following Yamamoto, Akiyama and Terada protocol, respectively.68 The 4Å 
molecular sieves powder is activated at 110 °C at least for 24 hours before use. Other reagents 
were obtained from commercial sources without further purification. All reactions were 
performed in oven or flame-dried glassware with magnetic stirring under nitrogen unless 
otherwise noted. 
 
Representative procedure 
To a solution of 2H-chromene (1.0 equiv) in a corresponding solvent (0.1 M concentration) at 0 
°C were added 4Å molecular sieves powder (60 mg/mL) and the corresponding catalyst (0.05 to 
1 equiv). DDQ (1.4 equiv) was added to the reaction mixture, and it was stirred until TLC 
analysis showed complete consumption of the substrate. After cooling to the corresponding 
specified temperature, the nucleophile (2~3 equiv) was added, and the reaction was stirred until 
TLC analysis showed complete consumption of the oxidized intermediate. The reaction was 
quenched with 10% aqueous NaHCO3 solution, extracted three times with diethyl ether (10 mL), 
and carefully concentrated under reduced pressure. Flash column chromatography with 3% 
Et2O/pentane afforded the desired product. An aliquot was taken and analyzed by chiral HPLC 
for enantiomeric excess. 
 
Allyl phenyl dimethylsilane 
To a round bottom flask was charged magnesium turnings (1.94 g, 81 mmol, 3.75 equiv) and 
diethyl ether (5 mL). Allyl bromide (2.8 mL, 32.3 mmol, 1.5 equiv) in diethyl ether (30 mL) was 
added dropwise over 50 min with external water bath at room temperature. After an additional 30 
min stirring at room temperature, the reaction mixture was cooled to 0 °C, and 
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phenyldimethylsilyl chloride (3.68 g, 21.5 mmol, 1.0 equiv) was added dropwise. The reaction 
was stirred overnight at room temperature, quenched with saturated NH4Cl solution, extracted 
two times with diethyl ether (20 mL), dried and concentrated under reduced pressure. Flash 
column chromatography with 3% Et2O/pentane afforded at least 3.02 g (80%) of the desired 
product. 1H NMR (300 MHz, CDCl3) δ7.41-7.44 (m, 2H), 7.25-7.29 (m, 3H), 5.68 (ddt,  J = 16.5, 
10.2, 8.1 Hz, 1H), 4.75-4.81 (m, 2H), 1.66 (dt,   J = 8.1, 1.0 Hz, 2H), 0.19 (s, 6H); 13C NMR (75 
MHz, CDCl3) δ 138.6, 134.5, 133.6, 129.0, 127.7, 113.4, 23.7, -3.5. 
 
Reaction Optimization: Solvent screening 
To investigate the background reaction rate in the absence of LiClO4, three common solvents, 
dichloromethane, acetonitrile and toluene were used to perform the reaction. Thus, the 
representative procedure was followed in each corresponding solvent on a 50 mg scale of 2H-
chromene but without using LiClO4 or chiral catalyst, and TLC observation was performed. The 
oxidized intermediate disappeared at 1.5 hours in acetonitrile and 2 hours in DCM. At two hours 
in toluene there was a significant amount of oxidized intermediate present, and after 12 hours the 
oxidized intermediate completely disappeared. No actual separation of the addition product was 
performed.  
 
Reaction Optimization: Catalyst Screening 
Stoichiometic reaction with triisopropyl-substituted (TRIP) phosphoric acid (3.9): The 
reaction was performed at 0 °C for 45 min, using 2H-chromene 3.3 (5.3 mg, 40 µmol, 1.0 equiv), 
TRIP phosphoric acid (3.9) (30 mg, 40 µmol, 1.0 equiv), 4Åmolecular sieves (30 mg), DDQ 
(12.7 mg, 56µmol, 1.4 equiv), allyltrimethylsilane (14 mg, 120 µmol, 3.0 equiv) and toluene (0.4 
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mL). The enantiomeric excess was determined to be 26% by chiral HPLC (1% i-PrOH:hexanes, 
1.0 mL/min). Characterization data were in agreement with previously reported values. 
Stoichiometic reaction with ditrifluoromethylphenyl-substituted phosphoric acid (3.10): 
The reaction was performed at 0 °C for 45 min, using 2H-chromene 3.3 (11.9 mg, 90 µmol, 1.0 
equiv), ditrifluoromethylphenyl-substituted phosphoric acid (3.10) (70 mg, 90 µmol, 1.0 equiv), 
4Å molecular sieves (30 mg), DDQ (28.7 mg, 126µmol, 1.4 equiv), allyltrimethylsilane (31 mg, 
270 µmol, 3.0 equiv) and toluene (0.4 mL). The enantiomeric excess was determined to be 4% 
by chiral HPLC (1% i-PrOH:hexanes, 1.0 mL/min). Characterization data were in agreement 
with previously reported values. 
Stoichiometic reaction with TRIP phosphoramide (3.11): The reaction was performed at 0 °C 
for 45 min, using 2H-chromene 3.3 (7.1 mg, 54 µmol, 1.0 equiv), TRIP phosphoramide (3.11) 
(48.5 mg, 54 µmol, 1.0 equiv), 4Å molecular sieves (30 mg), DDQ (17.2 mg, 76µmol, 1.4 equiv), 
allyltrimethylsilane (19 mg, 160 µmol, 3.0 equiv) and toluene (0.4 mL). Thick precipitates were 
observed during the oxidation step, and additional solvent (0.3 mL) was used to facilitate 
stirring. The precipitates disappeared soon after the addition of the nucleophile. The 
enantiomeric excess was determined to be 62% by chiral HPLC (1% i-PrOH:hexanes, 1.0 
mL/min). Characterization data were in agreement with previously reported values. 
Stoichiometic reaction with 4-(anthracen-9-yl)-2,6-diisopropylpheny substituted 
phosphoramide (3.12): The reaction was performed at 0 °C for 45 min, using 2H-chromene 3.3 
(5.3 mg, 40 µmol, 1.0 equiv), 4-(anthracen-9-yl)-2,6-diisopropylphenyl-substituted 
phosphoramide (3.12) (46 mg, 40 µmol, 1.0 equiv), 4Å molecular sieves (30 mg), 
allyltrimethylsilane (14 mg, 120 µmol, 3.0 equiv) and toluene (0.4 mL).. The enantiomeric 
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excess was determined to be 31% by chiral HPLC (1% i-PrOH:hexanes, 1.0 mL/min). 
Characterization data were in agreement with previously reported values. 
Stoichiometic reaction with TRIP thiophosphoric acid (3.13): The reaction was performed at 
0 °C for 45 min, using 2H-chromene 3.3 (6.8 mg, 52 µmol, 1.0 equiv), TRIP thiophosphoric acid 
(3.13) (40 mg, 52 µmol, 1.0 equiv), 4Å molecular sieves (30 mg), DDQ (16.5 mg, 73µmol, 1.4 
equiv), allyltrimethylsilane (18 mg, 160 µmol, 3.0 equiv) and toluene (0.4 mL). The 
enantiomeric excess was determined to be 4% by chiral HPLC (1% i-PrOH:hexanes, 1.0 
mL/min). Characterization data were in agreement with previously reported values. 
Stoichiometic reaction with TRIP thiophosphoramide (3.14): The reaction was at 0 °C for 45 
min, using 2H-chromene 3.3 (5.3 mg, 40 µmol, 1.0 equiv), TRIP thiophosphoramide (3.14) (36 
mg, 40 µmol, 1.0 equiv), 4Å molecular sieves (30 mg), DDQ (12.7 mg, 56µmol, 1.4 equiv), 
allyltrimethylsilane (14 mg, 120 µmol, 3.0 equiv) and toluene (0.4 mL). The enantiomeric excess 
was determined to be 13% by chiral HPLC (1% i-PrOH:hexanes, 1.0 mL/min). Characterization 
data were in agreement with previously reported values. 
 
Reaction Optimization: Solvent Refinement 
Stoichiometic TRIP phosphoramide (3.11) reaction in DCM: The reaction was performed in 
dichloromethane (0.3 mL) at 0 °C for 45 min, using 2H-chromene 3.3 (4.4 mg, 33 µmol), 100% 
loading of TRIP phosphoramide (3.11) (29.5 mg, 33 µmol) and allyltrimethylsilane (12 mg, 100 
µmol). Thick precipitates were observed during the oxidation step, and additional solvent (0.3 
mL) was used to facilitate stirring. The precipitates disappeared soon after the addition of the 
nucleophile. The enantiomeric excess was determined to be 34% by chiral HPLC (1% i-
PrOH:hexanes, 1.0 mL/min). 
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Stoichiometic TRIP phosphoramide (3.11) reaction in α,α,α-trifluorotoluene: The reaction 
was performed in α,α,α-trifluorotoluene (0.3 mL) at 0 °C for 45 min, using 2H-chromene 3.3 (4.7 
mg, 36 µmol), 100% loading of TRIP phosphoramide (3.11) (32.4 mg, 36 µmol) and 
allyltrimethylsilane (13 mg, 110 µmol). Thick precipitates were observed during the oxidation 
step, and additional solvent (0.3 mL) was used to facilitate stirring. The precipitates disappeared 
soon after the addition of the nucleophile. The enantiomeric excess was determined to be 77% by 
chiral HPLC (1% i-PrOH:hexanes, 1.0 mL/min). 
 
Reaction Optimization: Influence of nucleophile 
Stoichiometic TRIP-phosphoramide reaction with allylphenyldimethylsilane: The reaction 
was performed at 0 °C for 45 min, using 2H-chromene 3.3 (4.4 mg, 33 µmol), 100% loading of 
TRIP phosphoramide (3.11) (29.5 mg, 33 µmol), DDQ (10.5 mg, 46 µmol), 
allylphenyldimethylsilane (18 mg, 100 µmol) and α,α,α-trifluorotoluene (0.3 mL). The 
enantiomeric excess was determined to be 92% by chiral HPLC (1% i-PrOH:hexanes, 1.0 
mL/min). Characterization data were in agreement with previously reported values.  
Stoichiometic TRIP-phosphoramide reaction with allyltributyltin: The reaction was 
performed at 0 °C for 45 min, using 2H-chromene 3.3 (4.4 mg, 33 µmol), 100% loading of TRIP 
phosphoramide (3.11) (29.5 mg, 33 µmol), DDQ (10.5 mg, 46µmol), allyltributyltin (33 mg, 100 
µmol) and α,α,α-trifluorotoluene (0.3 mL). The enantiomeric excess was determined to be 48% 
by chiral HPLC (1% i-PrOH:hexanes, 1.0 mL/min). Characterization data were in agreement 
with previously reported values. 
Stoichiometic TRIP-phosphoramide reaction with allyltriphenyltin: The reaction was 
performed at 0 °C for 45 min, using 2H-chromene 3.3 (5.0 mg, 38 µmol, 1.0 equiv), 100% 
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loading of TRIP phosphoramide (3.11) (34.5 mg, 38 µmol), DDQ (12 mg, 53µmol, 1.4 equiv), 
allyltriphenyltin (27 mg, 69 µmol, 1.8 equiv) and α,α,α-trifluorotoluene (0.3 mL). The 
enantiomeric excess was determined to be 89% by chiral HPLC (1% i-PrOH:hexanes, 1.0 
mL/min). Characterization data were in agreement with previously reported values. 
 
Figure S3.1 HPLC of Racemic mixture 
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Figure S3.2  HPLC from allyphenyldimethylsilane at 0 °C 
Stoichiometric TRIP-phosphoramide reaction with allylphenyldimethylsilane at low 
temperature: The reaction was performed at -25 °C for 3 hours, using 2H-chromene 3.3 (37.2 
mg, 0.28 mmol), TRIP phosphoramide (3.11) (249 mg, 0.028 mmol, 1.0 equiv), 4Å molecular 
sieves powder (200 mg), DDQ (89 mg, 0.39 mmol, 1.4 equiv), allylphenyldimethylsilane (148 
mg, 0.84 mmol, 3 equiv) and anhydrous α,α,α-trifluorotoluene (3 mL). Normal workup and flash 
column chromatography with 3% Et2O/pentane afforded 28.9 mg (60%) of the desired product 
3.15. The enantiomeric excess was determined to be 89% by chiral HPLC (1% i-PrOH:hexanes, 
1.0 mL/min). 1H NMR (300 MHz, CDCl3) δ7.06-7.12 (m, 1H), 6.98 (dd,   J = 7.5, 1.5 Hz, 1H), 
6.84 (ddd,   J = 7.5, 7.5, 0.9 Hz, 1H), 6.74 (d,  J = 8.1 Hz, 1H), 6.42 (d,  J = 9.9 Hz, 1H), 5.84-
5.96 (m, 1H), 5.71 (dd,  J = 9.9, 3.3 Hz, 1H), 5.10-5.19 (m, 2H), 4.87-4.93 (m, 1H), 2.44-2.56 
(m, 2H); 13C NMR (100 MHz, CD2Cl2) δ154.0, 134.1, 129.7,127.0, 125.9, 124.6, 122.6, 121.6, 
118.1, 116.4, 75.2, 40.3; IR (film) 2926, 1640, 1605, 1486, 1457, 1230, 1204, 1111, 1038, 917, 
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769, 753cm-1; HRMS (ESI) m/z calcd. for C12H11O [M − H]+ 171.0810, found 171.0813; [α]25D = 
-174.2 (c = 1.24, CH2Cl2). 
 
Figure S3.3 HPLC from allyphenyldimethylsilane 100% cat at -25 °C 
 
Reaction Optimization: substoichiometric amount of catalyst 
Allyltriphenyltin with 20% of 3.11 at zero degree: The reaction was performed at 0 °C for 45 
min, using 2H-chromene 3.3 (6.6 mg, 0.05 mmol), 20 mol% loading of TRIP phosphoramide 
(3.11) (8.8 mg, 0.01 mmol), DDQ (15.9 mg, 0.07 mmol), allyltriphenyltin (39.1 mg, 0.1 mmol, 2 
equiv) and anhydrous α,α,α-trifluorotoluene (0.4 mL). The enantiomeric excess was determined 
to be 62% by chiral HPLC (1% i-PrOH:hexanes, 1.0 mL/min). Characterization data were in 
agreement with previously reported values. 
Allyltriphenyltin with 20% of 3.11 at low temperature: The reaction was performed at -25 °C for 
3 hours, using 2H-chromene 3.3 (46.7 mg, 0.35 mmol, 1.0 equiv), TRIP phosphoramide (3.11) 
(62.5 mg, 0.07 mmol, 20% equiv), 4Å molecular sieves powder (200 mg), DDQ (112 mg, 0.50 
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mmol, 1.4 equiv), allyltriphenyltin (547 mg, 1.4 mmol, 4 equiv) and anhydrous α,α,α-
trifluorotoluene (3 mL). The workup procedure is according to Curran’s paper.69 Upon 
consumption of the oxidized intermediate the reaction mixture was filtered through silica gel and 
eluted with 10% Et2O/pentane to give a light yellow filtrate. The filtrate was cooled to 0 °C, and 
DBU (234 mg, 1.54 mmol) was added. Then a solution of I2 in diethyl ether was added dropwise 
until the color of I2 persisted, during which precipitates were formed. The mixture was filtered 
through silica gel again using 10% Et2O/pentane as the eluent and carefully concentrated under 
reduced pressure. Flash column chromatography with 3% Et2O/pentane afforded 39.6 mg (66%) 
of the desired product. The enantiomeric excess was determined to be 81% by chiral HPLC (1% 
i-PrOH:hexanes, 1.0 mL/min). Characterization data were in agreement with previously reported 
values. 
 
Figure S3.4 HPLC from allyltriphenyltin 20% cat at -25 °C 
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Allyltriphenyltin with 10% of 3.11 at low temperature: The reaction was performed at -25 °C 
for 3 hours, using 2H-chromene 3.3 (45.1 mg, 0.34 mmol), TRIP phosphoramide (3.11) (31.7 
mg, 0.034 mmol, 10% equiv), 4Å molecular sieves powder (200 mg), DDQ (108.7 mg, 0.48 
mmol, 1.4 equiv), allyltriphenyltin (334 mg, 0.86 mmol, 2.5 equiv) and anhydrous α,α,α-
trifluorotoluene (3 mL). DBU/I2 workup and flash column chromatography with 3% 
Et2O/pentane afforded 35 mg (66%) of the desired product. The enantiomeric excess was 
determined to be 68% by chiral HPLC (1% i-PrOH:hexanes, 1.0 mL/min). Characterization data 
were in agreement with previously reported values. 
Allyltriphenyltin with 5% of 3.11 at low temperature: The reaction was performed at -25 °C 
for 3 hours, using 2H-chromene 3.3 (47.5 mg, 0.36 mmol), TRIP phosphoramide (3.11) (16.0 
mg, 0.018 mmol, 5% equiv), 4Å molecular sieves powder (200 mg), DDQ (115 mg, 0.51 mmol, 
1.4 equiv), allyltriphenyltin (352 mg, 0.90 mmol, 2.5 equiv) and anhydrous α,α,α-
trifluorotoluene (3 mL). DBU/I2 workup and flash column chromatography with 3% 
Et2O/pentane afforded 35 mg (57%) of the desired product. The enantiomeric excess was 
determined to be 31% by chiral HPLC (1% i-PrOH:hexanes, 1.0 mL/min). Characterization data 
were in agreement with previously reported values. 
Allylphenyldimethylsilane with 20% of 3.11 at zero degree: The reaction was performed at 0 
°C for 45 min, using 2H-chromene 3.3 (6.6 mg, 0.05 mmol), 20 mol% loading of TRIP 
phosphoramide (3.11) (8.8 mg, 0.01 mmol), DDQ (15.9 mg, 0.07 mmol), 
allylphenyldimethylsilane (26 mg, 0.15 mmol, 3 equiv) and anhydrous α,α,α-trifluorotoluene 
(0.4 mL). The enantiomeric excess was determined to be 62% by chiral HPLC (1% i-
PrOH:hexanes, 1.0 mL/min). Characterization data were in agreement with previously reported 
values. 
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Allylphenyldimethylsilane with 20% of 3.11 at low temperature: The reaction was performed 
at -25 °C for 3 hours, using 2H-chromene 3.3 (41.5 mg, 0.32 mmol, 1.0 equiv), TRIP 
phosphoramide (3.11) (55.7 mg, 0.063 mmol, 20% equiv), 4Å molecular sieves powder (200 
mg), DDQ (100 mg, 0.44 mmol, 1.4 equiv), allylphenyldimethylsilane(169 mg, 0.96 mmol, 3 
equiv) and anhydrous α,α,α-trifluorotoluene (3 mL). Normal workup and flash column 
chromatography with 3% Et2O/pentane afforded 30.4 mg (56%) of the desired product. The 
enantiomeric excess was determined to be 86% by chiral HPLC (1% i-PrOH:hexanes, 1.0 
mL/min). Characterization data were in agreement with previously reported values. 
 
Figure S3.5 HPLC from allyphenyldimethylsilane 20% at -25 °C 
Allylphenyldimethylsilane with 10% of 3.11 at low temperature: The reaction was performed 
at -25 °C for 3 hours, using 2H-chromene 3.3 (46.5 mg, 0.35 mmol, 1.0 equiv), TRIP 
phosphoramide (3.11) (31.2 mg, 0.035 mmol, 10% equiv), 4Å molecular sieves powder (200 
mg), DDQ (109.5 mg, 0.48 mmol, 1.4 equiv), allylphenyldimethylsilane(185 mg, 1.05 mmol, 3 
equiv) and anhydrous α,α,α-trifluorotoluene (3 mL). Normal workup and flash column 
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chromatography with 3% Et2O/pentane afforded 31.6 mg (52%) of the desired product. The 
enantiomeric excess was determined to be 79% by chiral HPLC (1% i-PrOH:hexanes, 1.0 
mL/min). Characterization data were in agreement with previously reported values. 
 
Allylphenyldimethylsilane with 5% of 3.11 at low temperature: The reaction was performed 
at -25 °C for 4 hours, using 2H-chromene 3.3 (48.4 mg, 0.37mmol, 1.0 equiv), TRIP 
phosphoramide (3.11) (16.2 mg, 0.018mmol, 5% equiv), 4Å molecular sieves powder (200 mg), 
DDQ (117 mg, 0.51 mmol, 1.4 equiv), allylphenyldimethylsilane(194 mg, 1.1mmol, 3 equiv) and 
anhydrous α,α,α-trifluorotoluene (3 mL). Normal workup and flash column chromatography with 
3% Et2O/pentane afforded 35.4 mg (56%) of the desired product. The enantiomeric excess was 
determined to be 17% by chiral HPLC (1% i-PrOH:hexanes, 1.0 mL/min). Characterization data 
were in agreement with previously reported values. 
 
Determination of absolute configuration  
A mixture of the chiral 2-allyl-2H-chromene 3.15 (30 mg, 0.22 mmol, 73% ee by HPLC, 
prepared by the representative procedure in this paper) and 10% Pd/C (10 mg) in 
dichloromethane (3 mL) was stirred under a hydrogen atmosphere for 4 hours. Flash column 
chromatography with 3% Et2O/pentane afforded 19.6 mg (64%) of the hydrogenated chiral ether 
3.19. 1H NMR (300 MHz, CDCl3) δ 7.03-7.10 (m, 2H), 6.78-6.84 (m, 2H), 3.94-4.04 (m, 1H), 
2.72-2.90 (m, 2H), 1.95-2.03 (m, 1H), 1.72-2.02 (m, 2H), 1.45-1.62 (m, 3H), 0.98 (t,  J = 7.1 Hz, 
3H); 13C NMR (100 MHz, CDCl3) δ 155.1, 129.5, 127.1, 122.1, 119.8, 116.7, 75.6, 37.6, 34.1, 
27.4, 24.8, 22.3, 18.6, 14.1, 14.0; IR (film) 2957, 2872, 1582, 1488, 1457, 1302, 1232, 1119, 
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984, 885, 752 m-1; HRMS (EI) m/z calcd for C12H16O [M]+ 176.1201, found 176.1219; [α]25D = 
+73.0 (c = 1.96, CH2Cl2). 
 
Independent Synthesis With Known Absolute Configuration 
3-(2-Bromophenyl)propanal (3.17) 
 To a solution of o-bromohydrocinnamic acid (3.16) (2.29 g, 10.0 mmol) in 
methanol (20 mL) stirred at 0 °C, thionyl chloride (1.47 mL, 20.0 mmol) was 
added dropwise, and then the reaction was stirred at room temperature overnight. The reaction 
was carefully quenched with saturated aqueous NaHCO3 solution (10 mL), neutralized with 
powder NaHCO3, and extracted three times with 20 mL of diethyl ether. The organic layer was 
dried over Na2SO4, filtered and concentrated under reduced pressure. Flash column 
chromatography with 10% ethyl acetate in hexanes afforded 2.19 g (90%) of the desired ester. 1H 
NMR (400 MHz, CDCl3) δ 7.51 (d,  J = 8.0 Hz, 1H), 7.20-7.26 (m, 2H), 7.06 (dd,  J = 7.2 Hz, 
1H), 3.67 (s, 3H), 3.07 (t,  J = 7.8 Hz, 2H), 2.65 (t,  J = 7.8 Hz, 2H); 13C NMR (100 MHz, 
CDCl3) δ 172.7, 139.5, 132.7, 130.2, 127.9, 124.1, 51.4, 33.7, 31.2.  
To the solution of methyl 3-(2-bromophenyl)propanoate (1.22 g, 5.0 mmol) in dichloromethane 
(20 mL) at -78 °C, 1M DIBAL-H solution in hexanes (6 mL, 6.0 mmol) was added dropwise. 
The reaction was stirred at -78 °C for 1 hour, quenched with methanol (2 mL), and concentrated 
under reduced pressure. Flash column chromatography with 10% ethyl acetate in hexanes 
afforded 0.81 g (76%) of the desired aldehyde 3.17. 1H NMR (300 MHz, CDCl3) δ 9.85 (d,  J = 
0.9 Hz, 1H), 7.55 (d,  J = 8.1 Hz, 1H), 7.24-7.28 (m, 2H), 7.07-7.13 (m, 1H), 3.09 (t,  J = 7.5 
Hz, 2H), 2.82 (t,  J = 7.5 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 200.9, 139.6, 132.9, 130.4, 
128.0, 127.6, 124.2, 43.6, 28.6. 
Br
CHO
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(S)-1-(2-Bromophenyl)hex-5-en-3-ol (3.18) 
To a solution of (+)-IPC-Cl (1.80 g, 5.6 mmol, 1.87 equiv) in diethyl 
ether (3 mL) stirred at 0 °C, freshly prepared 0.5M allylmagnesium 
bromide solution in diethyl ether (10.5 mmol, 5.25 mmol, 1.75 equiv) 
was added dropwise over 20 min. The reaction was stirred at 0 °C for an additional 30 min, 
decanted, extracted two times with diethyl ether (5 mL), and concentrated under reduced 
pressure. The residual oil was dissolved in dry pentane (10 mL), filtered through Millex syringe 
filter, and added dropwise into a solution of 3-(2-Bromophenyl)propanal 3.17 (640 mg, 3.0 
mmol, 1.0 equiv) in diethyl ether (5 mL) at -100 °C over 45 min. The addition was in such a 
pattern that the allylmagnesium bromide solution touched the inner wall of the reaction flask 
before entering the solution. After one additional hour at -100 °C, the reaction was quenched 
with methanol (2 mL) and concentrated under reduced pressure. The residual oil was dissolved 
in THF (3 mL), cooled to 0 °C, and treated with saturated aqueous NaHCO3 solution (7.0 mL) 
and 30% H2O2 (5.6 mL). After 3 hours at room temperature, the reaction mixture was extracted 
three time with diethyl ether (10 mL), dried over Na2SO4 and concentrated under reduced 
pressure. Flash column chromatography with 15% ethyl acetate in hexanes afforded 510 mg 
(67%) of the chiral alcohol (3.18). 1H NMR (400 MHz, CDCl3) δ 7.54 (d,  J = 8.1 Hz, 1H), 7.11-
7.17 (m, 2H), 6.93-6.99 (m, 1H), 5.58-5.82 (m, 1H), 5.07 (d, J = 15.6 Hz, 1H), 5.06 (d, J = 11.7 
Hz, 1H), 3.58-3.66 (m, 1H), 2.80-2.90 (m, 1H), 2.67-2.77 (m, 1H), 2.22-2.30 (m, 1H), 2.07-2.17 
(m, 1H); 13C NMR (75 MHz, CDCl3) δ 141.3, 134.5, 132.8, 130.4, 127.6, 127.4, 124.4, 118.3, 
70.0, 41.9, 36.8, 32.4; IR (film) 3371, 3072, 2927, 1640, 1567, 1471, 1439, 1045, 1022, 994, 
916, 749cm-1; HRMS (ESI) calc. for C12H15BrONa ([M+Na]+): 277.0204, found 277.0197; [α]25D 
= -9.7 (c = 2.56, CH2Cl2). 
Br
OH
 169 
(R)-3,4-dihydro-2-propyl-2H-1-benzopyran (3.19) 
An round bottom flask was charged with Pd(OAc)2 (11.2 mg, 0.05 mmol, 5 
mol%), (2-biphenyl)di-tert-butylphosphine (18.6 mg, 0.063 mmol, 6.3 
mol%), and Cs2CO3 (652 mg, 2.0 mmol, 2.0 equiv). The flask was evacuated and back-filled 
with argon, and (S)-1-(2-Bromophenyl)hex-5-en-3-ol 3.18 (255 mg, 1.0 mmol, 1.0 equiv) in 
toluene (2 mL) was added via syringe. The flask was then placed into an oil bath pre-heated at 65 
°C and stirred overnight. The reaction mixture was then cooled to room temperature, quenched 
with water (10 mL), and extracted two times with diethyl ether (10 mL). The combined organic 
layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. Flash column 
chromatography with 3% Et2O/pentane afforded 100 mg (75%) of the chiral allyl ether. 1H NMR 
(300 MHz, CDCl3) δ 7.07 (d,  J = 7.4 Hz, 1H), 7.04 (d,  J = 7.4 Hz, 1H), 6.80-6.86 (m, 2H), 
5.86-6.00 (m, 1H), 5.10-5.20 (m, 2H), 4.02-4.09 (m, 1H), 2.71-2.85 (m, 2H), 2.54-2.61 (m, 1H), 
2.37-2.45 (m, 1H), 1.98-2.06 (m, 1H), 1.70-1.79 (m, 1H).  
A mixture of (S)-3,4-dihydro-2-allyl-2H-1-benzopyran (83 mg, 0.62 mmol) and 10% Pd/C (20 
mg) in dichloromethane (3 mL) was stirred under a hydrogen atmosphere for 4 hours. . Flash 
column chromatography with 3% Et2O/pentane afforded 67.4 mg (81%) of the hydrogenated 
chiral ether 3.19. [α]25D = +99.1 (c = 1.96, CH2Cl2). 
O
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Figure S3.6 HPLC from hydrogenated racemic mixture  
(1.0 mL/min, 80% Methanol in water) 
 
 
Figure S3.7 Hydrogenation product from independent route (Brown’s reaction) 
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Figure S3.8 HPLC from hydrogenated product from the present methodology 
 
3.4 Attempts To Expand The Scope 
 
(R)-2-(2-methylallyl)-2H-benzopyran （3.20） 
The reaction was performed at -25 °C for 3 hours, using 2H-chromene 3.3 
(38 mg, 0.29 mmol, 1.0 equiv), TRIP phosphoramide (3.11) (50.9 mg, 
0.058mmol, 20% equiv), 4Å molecular sieves powder (200 mg), DDQ (92 mg, 0.41 mmol, 1.4 
equiv), methylallylphenyldimethylsilane (162 mg, 0.87 mmol, 3 equiv) and anhydrous α,α,α-
trifluorotoluene (3 mL). Normal workup and flash column chromatography with 3% 
Et2O/pentane afforded 36.4 mg (68%) of the desired product 3.20. The enantiomeric excess was 
determined to be 33% by chiral HPLC (1% i-PrOH:hexanes, 1.0 mL/min). Characterization data 
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were in agreement with previously reported values. 1H NMR (300 MHz, CD2Cl2) δ 7.12 (ddd,  J 
= 7.8, 7.8, 1.8 Hz, 1H), 6.98 (dd,  J = 7.5, 1.5 Hz, 1H), 6.85 (ddd,  J = 7.5, 7.5, 1.5 Hz, 1H), 6.75 
(d,  J = 7.8 Hz, 1H), 6.43 (d,  J = 9.9 Hz, 1H), 5.74 (dd,  J = 9.9, 3.6 Hz, 1H), 4.96-5.03 (m, 
1H), 4.89 (aps, 1H), 4.79 (d,  J = 0.9 Hz, 1H), 2.56 (dd,  J = 13.8, 7.8 Hz, 1H), 2.35 (dd,  J = 
13.8, 6.0 Hz, 1H), 1.82 (s, 3H); 13C NMR (75 MHz, CD2Cl2) δ 153.8, 142.2, 129.7, 127.0, 126.3, 
124.4, 122.7, 121.6, 116.7, 113.6, 74.2, 43.8, 23.1; IR (film) 3075, 2936, 1640, 1606, 1486, 
1457, 1229, 1208, 1113, 1055, 1034, 891, 767, 753 m-1; HRMS (ESI) m/z calcd. for C13H13O [M 
− H]+ 185.0966, found 185.0971; [α]25D = +55.7 (c = 2.51, CH2Cl2). 
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Figure S3.9 HPLC from Racemic mixture of 3.20 
 
 
Figure S3.10 HPLC from enantiomerically enriched 3.20 
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(S)-2-allyl-6-methoxychroman （3.22） 
 The reaction was performed at -25 °C for 3 hours, using 6-methoxy-
2H-chromene 3.21 (48 mg, 0.30 mmol, 1.0 equiv), TRIP 
phosphoramide (3.11) (53 mg, 0.06 mmol, 20% equiv), 4Å molecular sieves powder (200 mg), 
DDQ (95.3 mg, 0.42 mmol, 1.4 equiv), allylphenyldimethylsilane(158 mg, 0.9 mmol, 3 equiv) 
and anhydrous α,α,α-trifluorotoluene (3 mL). Normal workup and flash column chromatography 
with 5% Et2O/pentane afforded 32.4 mg (53%) of the desired product 3.22. The enantiomeric 
excess was determined to be 9% by chiral HPLC (1% i-PrOH:hexanes, 1.0 mL/min). 
Characterization data were in agreement with previously reported values. 
 
1H NMR (400 MHz, CDCl3) δ6.72 (d,  J = 8.4 Hz, 1H), 6.66 (dd,  J = 8.8, 2.1 Hz, 1H), 6.54 (d,  
J = 2.8 Hz, 1H), 6.38 (d,  J = 9.6 Hz, 1H), 5.88 (ddt,  J = 18.0, 10.4, 7.2 Hz, 1H), 5.74 (dd,  J = 
9.6, 3.2 Hz, 1H), 5.15 (d,  J = 8.8 Hz, 1H), 5.12 (s, 1H), 4.84 (brs, 1H), 3.75 (s, 3H), 2.53−2.60 
(m, 1H), 2.40−2.47 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ 153.9, 147.1, 133.4, 126.1, 124.3, 
122.5, 117.8, 116.5, 114.2, 111.6, 74.3, 55.6, 39.4. [α]25D = -8.7 (c = 0.33, CH2Cl2). 
 
O
MeO
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Figure S3.11 HPLC from racemic 3.22 
 
 
Figure S3.12 HPLC from enantiomerically enriched 3.22 
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Background reaction with methallylphenyldimethylsilane: The reaction was performed at -25 
°C for 1 hour, using 2H-chromene 3.3 (48.8 mg, 0.37 mmol, 1.0 equiv), 4Å molecular sieves 
powder (200 mg), DDQ (120 mg, 0.53 mmol, 1.4 equiv), methallylphenyldimethylsilane (206 
mg, 1.1 mmol, 3 equiv) and anhydrous α,α,α-trifluorotoluene (3 mL), but without using LiClO4 
or chiral catalysts. Normal workup and flash column chromatography with 3% Et2O/pentane 
afforded 42 mg (61%) of the desired racemic product.  
Background reaction of 6-Methoxy--2H-chromene 3.21: The reaction was performed at -25 
°C for 2 hours, using 6-methoxy-2H-chromene 3.21 (101 mg, 0.62 mmol, 1.0 equiv), 4Å 
molecular sieves powder (200 mg), DDQ (198 mg, 0.87 mmol, 1.4 equiv), 
allylphenyldimethylsilane(334 mg, 1.9 mmol, 3 equiv) and anhydrous α,α,α-trifluorotoluene (3 
mL), but without using LiClO4 or chiral catalysts. Normal workup and flash column 
chromatography with 5% Et2O/pentane afforded 53.1 mg (42%) of the desired racemic product.  
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